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The most important mechanism of trimethoprim resistance is the plasmid-encoded
production of an additional trimethoprim resistant dihydrofolate reductase. The
epidemiology of plasmid-mediated resistance to trimethoprim has been studied
by biochemical typing of the enzymes responsible. In recent years several new
trimethoprim resistant dihydrofolate reductases have been identified. The type
III enzyme, considered the rarest of the plasmid-mediated dihydrofolate reduc¬
tases was isolated once in New Zealand in 1979 and never subsequently detected.
However the biochemical properties of a trimethoprim resistant dihydrofolate
reductase isolated in Nottingham were examined as DNA gene probing had sug¬
gested that the enzyme was a type III and the biochemical properties confirmed
this.
The enzymes responsible for trimethoprim resistance in two outbreaks of Shigella
in the United States were examined. Detailed biochemical analysis suggested
that the two enzymes were different from each other but similar to the type III.
Therefore the three enzymes were subsequently renamed types Ilia, Illb and IIIc.
The properties of the type Illb enzyme were very similar to the original type Ilia;
however, sequence analysis of the N-terminal of this protein showed that it was
quite distinct from the type Ilia.
The type IV dihydrofolate reductase was isolated in South India in 1984 and
is the only inducible plasmid-mediated dihydrofolate reductase. Examination of
the induction process suggested that the resistance mechanism of the enzyme was
similar to chromosomal hyperproduction where resistance is achieved not because
l
of the insensitivity of the dihydrofolate reductase, but because it is produced
in such an amount that it "swamps" the inhibiting trimethoprim. Purification
and sequence analysis of the type IV dihydrofolate reductase revealed that the
enzyme was similar to the chromosomal dihydrofolate reductase and that it was
complexed with NSl an Escherichia coli DNA binding protein.
The biochemical properties of the type V dihydrofolate reductase, which was
isolated in Sri Lanka in 1985, were similar to those of the type I enzyme, with
the exception that the type V has an unusually low molecular mass when mea¬
sured on Sephadex. On native polyacrylamide gel electrophoresis however the
two enzymes co-migrate, this biochemical similarity suggests the two enzymes
are closely related.
The efficiency of plasmid-mediated resistance to trimethoprim has compromised
the use of this drug in many parts of the world, from biochemical studies it is
clear that plasmid-mediated enzymes continue to evolve.
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FPLC fast protein liquid chromatography
FUdR 5-fluoro-2 '-deoxyuridine
gly glycine
HPLC high-performance liquid chromatography










NADP nicotinamide adenine dinucleotide phosphate
NADPH nicotinamide adenine dinucleotide phosphate (reduced form)
OD optical density
PABA para-amino benzoic acid
PAGE polyacrylamide gel electrophoresis
pi isoelectric point
psi pounds per square inch
R resistance
RNA ribonucleic acid
SDS sodium dodecyl sulphate




Amino acids in sequence figures are represented by the standard one or three
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The amino acid sequences reported in this thesis have been registered in the pro¬
tein database of the National Biomedical Research Foundation (NBRF), Wash¬







As soon as it was proposed by Koch and Henle (Henle, 1840; Koch, 1884) in the
last century that diseases were caused by specific microorganisms, attempts were
made to control them with the use of chemicals. The first stage in the development
of chemotherapy really involves disinfection and antisepsis; the chemical agents
used, chlorine phenol and detergents, being too toxic for systemic use (Lister,
1867a, 1867b). These chemicals were used largely for the sterilisation of surgical
equipment and at low concentrations for the treatment of water.
If chemical agents were to be used successfully to treat human infections it was
realised that they must exhibit selective toxicity i.e. be toxic to the bacteria
but not to the host (Ehrlich, 1913). Ehrlich in 1907 had discovered salvarsan
a synthetic arsenic compound effective against Treponema pallidum the syphilis
pathogen, this had been introduced to clinical medicine in 1910 and therefore the
search for further chemicals or magic bullets active against bacteria continued.
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This search however appeared fruitless and it was not until 1935 when Domagk
discovered the selective antibacterial activity of prontisil (Domagk, 1935) and
the active constituent identified as sulphanilamide (Trefouel et al., 1935) that
antibacterial chemotherapy became a practical proposition and the antibacterial
activities of sulphonamides were quickly exploited (White and Reeves, 1989).
In the light of the discovery of sulphanilamide the search continued for other novel
chemicals with antibacterial activity. This approach however has so far produced
relatively few new antibacterials with the exception of trimethoprim, nalidixic
acid and very recently the fluorinated 4-quinolones. Arguably the most important
result of Domagk's work was that it revived interest in the subject of antimicrobial
chemotherapy, and led to a re-evaluation of the work by Fleming, who in 1929
had discovered that microorganisms themselves produce antimicrobial agents or
antibiotics (Fleming, 1929).
Fleming had described an antibiotic produced by the fungus Penicillium notatum,
however little work had been carried out on the compound. Chain et al. purified
the antibiotic in 1940 and it was not until this point that it became clear that
penicillin was a far more effective chemotherapeutic agent than anything that
had previously been discovered.
This heralded the golden age of antibiotics as it was realised that effective an¬
tibiotics were naturally produced by soil organisms. Rather than the search for
novel chemicals which had been going on the switch was made to mass screening
of soil organisms for new antibiotics.
With hindsight it is perhaps not surprising that if some organisms were producing
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antibiotics others must be producing compounds which overcame the inhibitory
effects of the antimicrobials, as the range of different antimicrobials was devel¬
oped so did the variety of resistance mechanisms (Goldstein et al., 1974). More
importantly resistance did not always develop by stepwise mutational events as
had been predicted, but could exist on stable extrachromosomal pieces of DNA,
known as plasmids, which could be transferred between bacteria (Akiba et al.,
1960; Mitsuhashi, 1969). The most common plasmid resistance mechanism is
drug inactivation and the best studied system is the /^-lactamase hydrolysis of
penicillins (Philippon et al., 1989; Medeiros, 1989).
The growing realisation that naturally occurring antibiotics had naturally oc¬
curring antagonists renewed interest in the development of completely synthetic
antibacterials. It was argued that as there would be no naturally occurring en¬
zymes that could break down these drugs resistance would be less of a problem.
It was against this background that trimethoprim was launched in 1969. A com¬
pletely synthetic antibacterial agent it offered new hope in the fight against bac¬
terial resistance, but also offered the microbiologist a unique "model" system for
studying the development of resistance from day one.
1.2 Trimethoprim
Trimethoprim (2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine) (figure 1) is
one of a series of compounds first fully described by Roth in 1962. It had been
observed that many 5-benzyl-2,4-diaminopyrimidines possessed a high degree of
antimalarial activity (Falco et al., 1951a, 1951b) and that this was highest in
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compounds which contained a methyl group in the pyrimidine 6 position (Falco
et al., 1951a). When the 6-alkyl group was removed antimalarial activity was de¬
creased, however, the antibacterial action of the compound was increased (Roth
et al., 1962). A series of 5-benzyl-2,4-diaminopyrimidines were synthesised and
tested for antibacterial activity. Trimethoprim was selected for further study
on the basis of the magnitude and breadth of its antibacterial activities. The
first clinical use of trimethoprim was in the treatment of a Proteus septicemia
in combination with polymixin and sulphonamides in 1962 (Noall et al., 1962).
Apparent synergy between trimethoprim and sulphonamide meant that trimetho¬
prim when it was launched in 1969 was marketed as a sulphonamide potentiator,
and only available in combination with sulphamethoxazole (Bushby and Hitch-
ings, 1968; Darrell et al., 1968; Bushby, 1969, 1973). It was claimed that the
combination had several advantages, sequential blockade in the same pathway
would confer clinical advantage, the combination of the two drugs was synergistic
and the combination would delay the emergence of resistance (Hitchings, 1973).
In order to understand the rationale for this and the subsequent resistance mech¬
anism, it is necessary to examine the pathway of folate metabolism and the action
of trimethoprim.
Both sulphamethoxazole and trimethoprim act on the pathway producing tetrahy-
drofolate an essential co-factor in the biosynthesis of several amino acids, purines
and pyrimidines (Huennekens and Osborn, 1959; Blakely, 1969). The biochem¬
ical pathway for folate biosynthesis was described by Brown in 1971 (figure 2).
The enzyme dihydropteroate synthetase catalyses the condensation of P-amino
benzoic acid and dihydropteridine to form dihydropteroate. Dihydrofolate syn-
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thetase then catalyses the addition of one or more glutamic acid residues to form
dihydrofolate. This is then reduced by the action of dihydrofolate reductase to
form tetrahydrofolate.
Sulphamethoxazole and trimethoprim both act as competitive inhibitors of en¬
zymes in this pathway, sulphamethoxazole inhibits dihydropteroate synthetase
(Brown, 1962), whilst trimethoprim acts by inhibiting dihydrofolate reductase
(Burchall and Hitchings, 1965). The basis for their selective toxicity is dif¬
ferent however. The dihydropteroate synthetase reaction inhibited by sulphur
compounds does not occur in mammalian cells which utilise preformed folates.
Although the reduction of dihydrofolate to tetrahydrofolate catalysed by dihydro¬
folate reductase does occur in both microbial and eukaryotic cells trimethoprim
is a much more potent inhibitor of microbial dihydrofolate reductase than of the
mammalian enzyme (Burchall, 1969). Although trimethoprim has been known
to be selective because it binds less readily to mammalian dihydrofolate reduc-
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tase than bacterial dihydrofolate reductase, the exact method of this specificity
has only recently been elucidated. X-ray crystallography studies demonstrating
that trimethoprim can fit well into the substrate binding site of Escherichia coli
dihydrofolate reductase but not the mammalian enzyme (Matthews et al., 1985b).
1.2.1 Trimethoprim in Combination
As with any new antibacterial agent, when trimethoprim was launched several
claims were made about its efficacy and long term prospects. In the case of
trimethoprim however the most contentious issue revolved not about the drug it¬
self but the decision to use it in combination with sulphamethoxazole and whether
or not the advantages proposed for the combination were valid.
In terms of the first two claims (namely that the synergism of the 2 drugs caused
by sequential blockade in the same pathway conferred clinical advantage) while
there is little doubt that a synergistic effect can be observed in vitro (Bushby and
Hitchings, 1968; Darrell et al., 1968; Bushby, 1969), the reason for this synergism
has been questioned, Poe (1976) arguing that it was not because trimethoprim
and sulphonamide inhibit reactions in the same pathway but owing to the fact
that sulphonamides may also bind to bacterial dihydrofolate reductase.
The situation in vivo is much less clear cut, and synergy in vivo has never been
adequately demonstrated although the two drugs appear synergistic in experi¬
mental infections in mice (Bohni, 1969; Grunberg, 1973). It can be argued that
if Poe's theory of blockade at the same site was correct it would be difficult to
imagine how potentiation would occur in vivo. Trimethoprim is such a potent an-
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tibacterial in its own right that synergy would only occur if it was in subinhibitory
levels and the sulphonamide was present in adequate amounts, an unlikely sce¬
nario (Lacey, 1979). Studies comparing the clinical efficacy of trimethoprim alone
and in combination with sulphamethoxazole have shown no difference between
the two (Lacey et al., 1980; Mabeck and Vejlsgaard, 1980). Furthermore models
of urinary tract infection have demonstrated that the presence of sulphamethox¬
azole contributed nothing to the dominant activity of trimethoprim (Greenwood
and O'Grady, 1976; Greenwood, 1979).
Since 1972 in Finland, and 1979 in the United Kingdom trimethoprim has been
available as a single agent (Lacey, 1982). The monotherapy appears to be as
successful as the combination in the treatment of urinary and respiratory tract
infections (Brumfitt and Pursell, 1972; Kasanen et al., 1978; Lacey et al. 1980;
Brumfitt et al. 1985). The use of trimethoprim alone also has the advantage of
fewer side effects which were associated with sulphamethoxazole (Lacey et al.,
1980).
One area in which trimethoprim and sulphamethoxazole do appear to be synergis¬
tic in vivo is in the case of Pneumocystis carinii pneumonia. Pneumocystis carinii
is the most common infection in patients with acquired immuno-deficiency syn¬
drome and the combination is an effective treatment (Fischl et al., 1988; Shafer
et al., 1989). Because of the high incidence of side effects associated with sul¬
phamethoxazole trimethoprim has also been used in combination with dapsone
to treat pneumonia caused by Pneumocystis carinii (Leoung et al., 1986).
The question of whether the combination prevented the emergence of resistance is
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much harder to assess. Studies in vitro showed that exposure of laboratory bac¬
teria to trimethoprim alone produced a significantly larger increase in resistance
amongst Escherichia coli than exposure to the combination (Darrell et al., 1968).
The relevance to this in vivo however appears doubtful and a number of studies
have found no difference in the emergence of resistant organisms in groups treated
with trimethoprim alone or in combination with sulphamethoxazole. Lacey et al.
in 1980 demonstrated no difference in cure rates and emergence of resistance in
a randomised double blind trial of 279 patients suffering from respiratory and
urinary tract infections. A later study specifically looking at respiratory tract
infection also failed to find any difference in the emergence of resistance between
trimethoprim and cotrimoxazole (Amyes et al., 1986a). Other studies have also
suggested the combination did not delay resistance (Kasanen and Sundquist,
1982; Brumfitt et al., 1983) and that the rise in resistance after the introduction
of trimethoprim alone was caused by increased use of the drug (Huovinen et al.,
1986).
It is now generally accepted that the use of the combination did not delay the
emergence of resistance nor did it give an improved clinical response (Lacey, 1982)
and trimethoprim monotherapy has now been used successfully for a number
of years (Turnridge, 1988). Levels of resistance are similar in countries where
trimethoprim is predominantly administered alone and in those which use the
combination (Kasanen and Sundquist, 1982). However the argument is by no
means over (Maskell and Pead, 1989).
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1.3 Epidemiology of Trimethoprim Resistance
Resistance to trimethoprim was detected shortly after its introduction in the
United Kingdom in 1969 (Lacey et al., 1972; Griineberg, 1976) and France in
1971 (Acar and Goldstein, 1982), indeed some strains of Klebsiella isolated before
the introduction of trimethoprim have been found to be trimethoprim resistant
(Hamilton-Miller and Grey, 1975). The most important resistance mechanism
has been plasmid-mediated, following the first report of transferable resistance in
1972 (Fleming et al., 1972). Initially it was difficult to gain accurate figures on
trimethoprim resistance because wide variations existed between hospitals in the
same area (Huovinen et al., 1982; Amyes, 1986), and inappropriate testing meth¬
ods were often employed (Amyes and Smith, 1974a). However a detailed picture
of trimethoprim resistance worldwide has now been built up (Huovinen, 1987;
Turnridge, 1988; Elwell and Fling, 1989). One clear pattern that has emerged is
that there is now a distinct difference between resistance levels in developed and
Third World countries (Murray et al., 1982; Farrar, 1985). Considering first the
developed countries:
1.3.1 United Kingdom
Trimethoprim resistance levels (MIC > 8 or 10 mg/L) in United Kingdom urinary
isolates have generally remained around 10 - 15%. Brumfitt et al. (1983) reported
13% of hospital isolates resistant in 1981, this is similar to a 12 year follow-up
survey at the Whitington hospital which showed that the percentage of trimetho¬
prim resistant isolates remained fairly constant around 9.8% - 13% (Chirnside et
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al., 1985). Resistance levels in general practice have generally been lower than in
hospital, with the proportion of resistant strains ranging from around 5% to 11%
(Brumfitt et al., 1983; Griineberg, 1984; Amyes, 1987). There have been higher
incidences of resistance in the United Kingdom. In one Edinburgh long stay hos¬
pital, 64% of urinary bacteria were found to be trimethoprim resistant (MIC > 10
mg/L) (Young and Amyes, 1983). This appears to have been an isolated example
as the resistance in urinary bacteria in the Edinburgh general hospital popula¬
tion over a three year period was only 16.5% (Amyes et al., 1986b). In common
with other countries trimethoprim resistance is a particular problem in geriatric
hospitals (Bendall et al., 1989).
Although overall resistance to trimethoprim has remained fairly constant there
have been changes in the nature of resistance. In some areas the percentage
of resistant strains that can transfer resistance has increased (Chirnside et al.,
1985) as has the proportion of high level resistant strains (Brumfitt et al., 1983).
Whilst in others there has been a shift from plasmid to chromosomal carriage of
high level resistance genes (Towner et al., 1982; Amyes et al., 1986b; Kraft et al.,
1986).
1.3.2 Finland and Sweden
Finland was the first country in the world to register clinical use of trimethoprim
alone for urinary tract infection in 1973, and consequently the levels of trimetho¬
prim resistance have been monitored closely. In hospital strains, resistance to
trimethoprim-sulphamethoxazole rose from 8% in 1971 to 35% in 1983 (Huovi-
nen et al., 1986). Two distinct increases in trimethoprim resistance were observed;
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the first after the wider use of trimethoprim-sulphamethoxazole, the second re¬
sulting from the dramatic increase in the consumption of trimethoprim alone in
1977. Most importantly resistance has been shown to be primarily related to
the total use of trimethoprim, regardless of whether it is in combination or alone
(Huovinen et al., 1986). As in the United Kingdom, wide variations in resistance
levels have been reported between hospitals (Huovinen et al., 1982, 1983). It was
realised that it was important to define hospital type in these studies as resistance
was considerably lower in an oncology hospital (22%) than a geriatric hospital
(71%) despite approximately the same trimethoprim consumption in each (Dorn-
busch and Toivanen, 1981). In outpatients trimethoprim resistance has increased
from 3% to 19% in the ten years 1978 - 1988 (Heikkila et al., 1990). Although
trimethoprim alone represented 25% of all drug usage for urinary tract infec¬
tion, the proportion of trimethoprim resistant strains in Finland was the same
as in countries where only the combination was used (Kasanen and Sundquist,
1982). Much higher levels of trimethoprim resistance have been found in Finland
than Sweden 31-49% as opposed to 1.6-3.6% (Dornbusch and Toivanen, 1981;
Dornbusch and Hagelberg, 1983). This probably reflects much higher usage of
trimethoprim in Finland at this time.
However, usage in Sweden has increased and in 1984 3% of the population of
Jamtland had received trimethoprim. Among older age groups, one third received
trimethoprim in a six year period (Skold et al., 1986). One result of this increased
usage was that one third of patients with resistant organisms had never been
treated with trimethoprim and Rydberg and Cederberg (1986) demonstrated that
trimethoprim resistance was capable of spreading among families of outpatients
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being treated with trimethoprim.
1.3.3 United States
Levels of trimethoprim resistance in the United States have remained relatively
low with 3 - 8% of Escherichia coli being resistant (Murray et al., 1985).
1.3.4 France
Resistance to trimethoprim in hospitals in Paris was 17.9% as far back as 1972 and
this had risen to 24.8% in 1979 (Acar and Goldstein, 1982). By 1984 resistance
had only increased slightly to 25.5%. However the proportion of strains with high
level resistance increased markedly from 40.2% of strains in 1972 to 95.4% in 1984
(Goldstein et al., 1986b). From 1983 to 1988 resistance decreased in all groups
of isolates (Goldstein and Acar, 1990).
1.3.5 Developing Countries
Generally speaking much higher levels of trimethoprim resistance are found here
than in the developed countries. The introduction of trimethoprim-sulphamethox-
azole into these countries has largely replaced ampicillin because of its longer shelf
life, low cost and b.d. dosage (Farrar, 1985). In India in 1984, 64% of urinary
bacteria have been reported to be resistant to trimethoprim (Young et al., 1986a).
In contrast in Sri Lanka, a trimethoprim resistance level of only 3.9% has been
reported but this included sampling normal healthy members of the population
(Sundstrom et al., 1987). This is an important point as it is becoming apparent
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that carriage of resistant organisms in the normal commensal population may
be an important factor contributing to the high level of resistance found in the
Third World. Strains capable of transferring low level trimethoprim resistance
have been isolated from apparently healthy students in Nigeria (Lamikanra et al.,
1989) and in the Sudan 76% of children have been shown to harbour commensal
gut flora with high level trimethoprim resistance (Shears et al., 1988).
In hospitalised patients in Nigeria 63.3% resistance has been reported for Gram-
negative bacilli causing urinary tract infection (Lamikanra and Ndep, 1989).
Trimethoprim resistance in Tanzania was lower than this, 36% of the enterobacte-
ria and 27% of the urinary bacteria being resistant (Amyes, 1986). In South Africa
48.5% of enterobacteria have been found to be trimethoprim resistant (Wylie and
Koornhof, 1989). High incidences have been found in Chile where 44% of the Es¬
cherichia coli in a paediatric hospital in Santiago were resistant (Murray et al.,
1985) and 34% resistance to trimethoprim was found in enterobacteria from a
range of hospitals (Urbina et al., 1989). In Bangkok 40% resistance has been
reported in a general teaching hospital (Murray et al., 1985).
Perhaps the major difference between developed and underdeveloped countries is
seen with resistance among Shigella spp.. Resistance among Shigella was initially
very rare (Gordon et al., 1975; Nelson et al., 1976; Barada and Guerrant, 1980;
Macaden and Bhat, 1985); however, increasing use of trimethoprim as the drug of
choice for Shigellosis (Salter, 1982) and for travellers' diarrhoea (Ericsson et al.,
1990), has meant that trimethoprim resistant Shigella are now a major problem
in many parts of the world (Elwell and Fling, 1989).
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The emergence of trimethoprim-sulphamethoxazole resistance in Shigella was first
reported by Bannatyne et al. (1980). It was found that 3% of Shigella strains
isolated in Ontario, Canada in 1978 were resistant to cotrimoxazole (Tonin and
Grant, 1987). Since then alarming increases in resistance to trimethoprim have
been reported for many countries. In Bangladesh resistance has risen from 17%
in 1982 to 64% in 1984 (Shahid et al., 1985). In another study in Bangladesh,
within one family, resistance rose from 5% to 83% between 1979 and 1983, in this
case inadequate dosing with cotrimoxazole before admission may have accounted
for the high resistance, and in general this is a common problem in the Third
World (Zaman et al., 1983). In Vellore, South India, where Shigella spp. have
been the commonest etiological agent of gastroenteritis for many years 84% of
Shigella flexneri and 88% of Shigella shigae have been found to be resistant to
trimethoprim. Of the resistant strains, 84% had MICs > 1000 mg/L (Jesudason
et al., 1989). Large numbers of Shigella which could freely transfer trimethoprim
resistance have been isolated in Korea (Chun et al., 1981), and cotrimoxazole
resistant Shigella emerged in Brazil in 1983 when it was discovered that 3 out
of 4 Shigella flexneri isolates could transfer trimethoprim-sulphamethoxazole re¬
sistance to Escherichia coli K12 (Tiemens et al., 1984). In common with many
developing countries trimethoprim-sulphamethoxazole is freely available in Brazil
and is a constituent in many antidiarrhoeal medicines. In Thailand resistance
among Shigella spp. has risen from 3% in 1982 to 29% in 1986 in one paediatric
hospital (Chatkaeomorakot et al., 1987). Although mainly a problem of the Third
World one European country, which has a serious problem with cotrimoxazole re¬
sistant Shigella, is Spain with up to 96.9% resistant by 1982 (Lopez-Brea et al.,
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1983).
One unusual feature of trimethoprim resistance in Shigella is that resistance may
be disseminated by the epidemic spread of one or two bacterial clones. Studies on
an epidemic of Shigella dysenteriae in central Africa suggested that a single clone
was responsible and that the plasmid content changed in response to antibiotic
selective pressure (Frost et al., 1982, 1985). A fifteen year study of Shigella
sonnei in Bulgaria has shown that resistance was associated with the spread of
two distinct bacterial clones (Bratoeva and John, 1989).
This is not always the case though as reports from Spain have shown a high
prevalence of non epidemic Shigella sonnei resistant to cotrimoxazole (Palenque
et al., 1983). The most likely reason for this is that Shigella in this area acquire
resistance from faecal flora in which R-plasmids are abundant.
Trimethoprim resistant Shigella spp. have also increased in the United Kingdom
from 1.3% in 1979 to 16.8% in 1983 (Gross et al., 1984). This was an alarm¬
ing increase; however, it should be borne in mind that 61% of cases were from
patients recently returned from abroad or who had been in contact with recent
travellers. Interestingly, there have been occasional reports of trimethoprim resis¬
tant Shigella among specific groups, in countries where Shigella resistance is not
normally a problem. One such example was a rapid rise in trimethoprim resis¬
tance on a Navajo reservation in the United States (Griffin et al., 1989), Shigella
infections are relatively uncommon in the United States but are a recognised
problem on Indian reservations (Blaser et al., 1983).
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1.3.6 Trimethoprim Resistance in Salmonella and Staphy¬
lococcus
The two other areas which have been of great interest in the epidemiology of
trimethoprim resistance have been the development of resistance in Salmonella
and in the Gram-positive bacteria, in particular, Staphylococci. These two areas
will be considered in turn:
There has been a lot of interest in antibiotic resistance in Salmonella, as it is
one area in which there has been a clear spread of genes between animal and
man. Initially trimethoprim resistance was rare, the first example was in 1975
when there was a Salmonella typhimurium outbreak in cattle (Richards et al.,
1978) and in 1976 there were four such outbreaks. However, overall plasmid
determined resistance in strains of Salmonella 1976 to 1977 remained low at only
0.3% (Richards et al., 1978).
In 1978 the incidence of resistance began to increase and by 1981 was 6.7% (Ward
et al., 1982). The source of the resistance genes was bovine and associated with
specific phage-types. Multiresistant Salmonella typhimurium of phage-types 204
and 193 appeared in 1977 and spread epidemically in cattle. By 1979 there were
290 cases of these resistant phage-types causing infections in humans (Threlfall
et al., 1980). A new phage-type 204C appeared in 1979 and was associated
with trimethoprim resistance (Threlfall et al., 1980). By 1985 59% of Salmonella
typhimurium from cattle and 4% of strains from humans were of phage-type
204C (Threlfall et al., 1986). Almost all trimethoprim resistance in Salmonella
typhimurium and the majority in other serotypes was plasmid-encoded (Threlfall
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et al., 1983). Trimethoprim resistant phage-types of Salmonella tymphimurium
have spread from Britain to the continent by the export of infected calves (Rowe
et al, 1979).
The pattern of trimethoprim resistance in Salmonella typhi has been watched
closely as it was quickly realised that trimethoprim-sulphamethoxazole was an
effective treatment for typhoid (Akinugbe et al., 1968; Pugsley et al., 1969) and
trimethoprim was regarded as the drug of choice in chloramphenicol resistant
Salmonella typhi (Butler et al., 1977, 1982). Resistance has been slower to develop
than in Salmonella typhimurium and only three cases were documented between
1970 and 1982 (Ward et al., 1982). It was first reported in 1981 when a patient
with enteric fever acquired resistance to cotrimoxazole during therapy (Datta et
al., 1981). Studies in India have shown Salmonella typhi to be highly sensitive
to cotrimoxazole (Paramasivan et al., 1977). However a study in Peru in 1981 to
1983 has shown 14% of Salmonella typhi to be resistant to trimethoprim (Taylor
et al., 1985) and in Mexico 16% resistance has been found (Solorzano et al., 1987).
Considering Gram-positive organisms: trimethoprim has been advocated for use
in Staphylococcal infections of the respiratory tract (Garrod, 1969) and for cases
of Staphylococcal osteomyelitis caused by penicillin resistant organisms (Craven
et al., 1970). Trimethoprim has also been used successfully in combination with
rifampicin to treat life threatening Staphylococcal infections (Griineberg et al.,
1984) where it was recognised to have great potential in patients with penicillin
hypersensitivity.
In the early 1970s resistance to trimethoprim or cotrimoxazole was relatively low,
25
1.6% among hospital isolates although 18.5% were resistant to sulphamethoxazole
(Nakhla, 1972). Lewis and Lacey (1973) found that the increase in multiresistant
strains of Staphylococcus aureus was low at around 1.0%, moreover this resistance
appeared intrinsic and there was no evidence of it being plasmid-mediated. At
this time, methicillin resistant Staphylococcus aureus from Europe and the United
Kingdom were uniformly sensitive to trimethoprim-sulphamethoxazole (Seligmow\
1973). However by 1977 cotrimoxazole resistance among hospital Staphylococcus
aureus in one London hospital had risen to 12.6% (Chattopadhyay, 1977), the
reason for this sharp rise was that cotrimoxazole usage had, by this time, risen
so much that it was second only to ampicillin. By 1981 the level of resistance
among hospital isolates of Staphylococcus aureus was only 6% (Brumfitt et al.,
1983). There are very few reports of the incidence of trimethoprim resistance in
the rest of the world but in the United States the level of trimethoprim resistance
in Staphylococcus aureus is around 10% (Archer et al., 1986) while in coagulase
negative species is around 42% (Galetto et al., 1987).
Trimethoprim resistance has also been found in other Staphylococcal species in
the United Kingdom, 38.7% of Staphylococcus epidermidis from infected urines in
hospital in London and 11.5% in general practice have been found to be resistant
to trimethoprim (Brumfitt et al., 1983). Resistance in Staphylococcus saprophyti¬
cs was lower 0% in hospital and 1.7% from general practice, overall resistance
in Gram-positives was 15.2% in hospital and 3.8% in general practice (Brumfitt
et al., 1983).
These results are in agreement with those of Richardson (1983) who reported 30%
of clinically significant Staphylococcus epidermidis from a wide range of hospitals
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from the United Kingdom and abroad resistant to trimethoprim whilst Staphy¬
lococcus saprophyticus was uniformly sensitive. Interestingly the proportion of
resistance in Staphylococcus epidermidis was 12.6% in strains responsible for the
normal skin flora in schoolchildren. The incidence of trimethoprim resistance
among methicillin resistant Staphylococcus aureus has increased markedly from
the 0% reported in 1973 (Seliga\cuyl973) to 69% from a more recent worldwide
selection of strains (Maple et al., 1989). A further survey of Staphylococcus au¬
reus and Staphylococcus epidermidis isolates from university hospitals throughout
Europe found 26% Staphylococcus aureus and 77% of Staphylococcus epidermidis
resistant to trimethoprim. As well as the higher incidence of resistance among
Staphylococcus epidermidis these strains were more frequently connected to me¬
thicillin resistance (Burdeska and Then, 1990).
1.4 Mechanisms of Resistance
A number of mechanisms conferring resistance to trimethoprim have been re¬
ported. There are four well characterised resistance mechanisms 1) Thymineless
strains, 2) Impermeability, 3) Alterations in the chromosomal dihydrofolate re¬
ductase, 4) Plasmid-encoded production of an additional trimethoprim insensitive
dihydrofolate reductase.




Thymineless mutants lack the enzyme thymidylate synthetase required for the
synthesis of thymidine and utilise exogenous thymine or thymidine (Barner and
Cohen, 1959). Provided thymine or thymidine is present, these mutants are
highly resistant to trimethoprim (Amyes and Smith, 1975). Indeed trimethoprim
can be used to select for thymineless mutants in vitro by growing bacteria in the
presence of both trimethoprim and thymine (Stacey and Simson, 1965; Bertino
and Stacey, 1966). As levels of thymine are very low in urine, blood and body
tissue it was felt that the emergence of thymineless mutants was unlikely in
vivo (Maskell et al., 1978). However, the emergence of trimethoprim resistant
thymineless mutants associated with cotrimoxazole therapy has been reported
on a number of occasions (Barker et al., 1972; Maskell et al., 1976; King et al.,
1983). In urinary tract infection, a thymine like compound has been detected
in sufficient concentration to support the growth of thymine requiring organisms
(Maskell et al., 1978). In one study between 1972 and 1979 thymineless bacteria
accounted for 1.5% of trimethoprim resistant strains isolated per year (Acar and
Goldstein, 1982).
One area where thymineless strains have an important role in determining trimetho¬
prim resistance is cystic fibrosis, where trimethoprim-sulphamethoxazole is widely
used prophylactically to suppress Staphylococcal infection (Marks, 1989). The
levels of resistance have consequently been studied closely and in one study 21%
of patients with Staphylococcus aureus contained thymine dependent Staphylo¬
coccus aureus as their predominant Staphylococcal isolate. All had received
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trimethoprim-sulphamethoxazole prophylactically for an average of 30.9 months
(Gillagan et al., 1987). In the case of cystic fibrosis thymine dependent organ¬
isms can survive because the bronchial secretions in these patients contain many
deteriorating cells which act as a source of thymine. The importance of thymine
dependent Staphylococcus aureus in cystic fibrosis may be greater than realised
as the organisms cannot grow on the media routinely used for the isolation of
Staphylococcus aureus (Gillagan et al., 1987).
1.4.2 Impermeability
Impermeability is often cited as a mechanism of resistance to antibiotics and
there are two distinct areas to be considered. Firstly organisms which are intrin¬
sically resistant to trimethoprim because of a natural generalised permeability
barrier and secondly those that undergo changes in permeability as a response to
antibiotic challenge.
Impermeability as a mechanism of intrinsic resistance is thought to be the reason
why Pseudomonas aeruginosa is resistant to trimethoprim (Werner and Goeth,
1984). As the dihydrofolate reductase from Pseudomonas aeruginosa is sensi¬
tive to trimethoprim (Burchall, 1973) it was argued that resistance must result
from the impermeability of the outer membrane although this view has been
challenged (Scudamore and Goldner, 1982). Lack of permeability is thought to
account for the resistance of Pseudcmonas cepacia to a range of antibiotics in¬
cluding trimethoprim; however, it may not be the only resistance mechanism as
an altered dihydrofolate reductase with decreased sensitivity for trimethoprim
has been isolated from resistant Pseudomonas cepacia (Parr, et al. 1987; Burns
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et al. 1989).
Acquired impermeability giving resistance appears to be common; however this
is often concluded without any positive evidence and rather results from failure
to detect any other resistance mechanism (Hamilton-Miller, 1979; Burchall et al.,
1982). There have been some cases though where impermeability is clearly im¬
portant in determining resistance. Amyes and Smith (1977) reported resistance
to trimethoprim caused by the presence of plasmid R388s, which promoted the
host strain to become mucoid. Simultaneous resistance to trimethoprim, chloram¬
phenicol and nalidixic acid has been reported in Klebsiella pneumoniae (Smith,
1976). This pattern of resistance has also been reported among clinical isolates
of Klebsiella, Enterobacter and Serratia spp. (Acar and Goldstein, 1982). These
mutants can be selected in vitro at high frequency with the use of only one of the
antibiotics (Gutmann et al., 1985). In these strains binding of chloramphenicol
to ribosomes was normal and dihydrofolate reductase levels were the same in the
mutant and wild type. The resistant mutants showed a lower uptake of glucose
and chloramphenicol and examination of the outer membrane revealed decreased
levels of a 40 kilodalton protein in the mutants (Gutmann et al., 1985). In this
case the sole resistance mechanism appears to be decreased permeability but the
overall significance of impermeability in the epidemiology of trimethoprim resis¬
tance has not been clear.
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1.4.3 Alterations in Chromosomal Dihydrofolate Reduc¬
tase
Trimethoprim resistance resulting from alterations in the chromosomal dihydro¬
folate reductase can be manifested by a) increased production of the enzyme,
thereby swamping the inhibiting trimethoprim, or b) by changes in the structure
of the enzyme giving increased resistance to trimethoprim inhibition (Grey et al.,
1979; Smith and Calvo, 1982).
Considering strains resistant by mechanism a), increased levels of dihydrofolate
reductase have been reported in Str&ptacaccuc, pneumoniae (McCuen and Sirotnak,
1974) and in Escherichia coli (Sheldon and Brenner, 1976; Smith and Calvo,
1979). Baccanari et al. (1975) reported elevated levels of dihydrofolate reductase
from Escherichia coli RT 500 which was resistant to 500 mg/L trimethoprim.
This strain produced a 300 fold increase in enzyme activity over the wild type
and 10 fold more than a corresponding strain resistant to 128 mg/L trimetho¬
prim. Increased synthesis of chromosomal dihydrofolate reductase appears not to
result from gene amplification but from increased efficiences of RNA polymerase
and ribosome sites (Flensburg and Skold, 1987). A recent clinical isolate of Es¬
cherichia coli resistant to > 1000 mg/L expresses chromosomal dihydrofolate
reductase 200 times more than the sensitive Escherichia coli I\12. Interestingly
the dihydrofolate reductase activity increased when the strain was cultivated in
the presence of trimethoprim and this induction was dependent on drug concen¬
tration (Tennhammar-Ekman et al., 1986). Overproduction of the chromosomal
enzyme may be an important mechanism of resistance in Haemophilus influenzae
(Degroot et al., 1988).
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Alterations in the structural gene resulting in a dihydrofolate reductase with de¬
creased affinity for trimethoprim (mechanism b) have been detected in a number
of Escherichia coli strains (Sheldon, 1977; Baccanari et al., 1981; Smith and
Calvo, 1982) and recently in Pseudomonas cepacia (Burns et al., 1989). These
altered dihydrofolate reductases are usually not the sole resistance mechanism
but are often more highly expressed than the wild-type enzyme (Baccanari et al.,
1981; Flensburg and Skold, 1987). Indeed changes in the structural gene may
not only increase resistance to trimethoprim but affect the level of expression
simultaneously (Sheldon, 1977).
Although alterations in chromosomal dihydrofolate reductases can give high level
resistance to trimethoprim , their occurrence is not often clinically significant
and are much less common than plasmid-mediated resistance (Steen and Skold,
1985).
1.4.4 Plasmid-Mediated Resistance
By far the most important mechanism of trimethoprim resistance has been the
plasmid-encoded production of an additional trimethoprim resistant dihydrofolate
reductase enabling the blocked chromosomal enzyme to be bypassed (Amyes and
Smith, 1974b; Skold and Widh, 1974). Plasmid-encoded resistance to trimetho¬
prim was first reported by Fleming et al. (1972) and is now widespread. The
trimethoprim resistant dihydrofolate reductases found in Gram-negative bacteria
have been divided into a number of classes based on their biochemical profiles
(Huovinen, 1987; Amyes, 1989).
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Table 1. Biochemical properties of the plasmid-mediated dihydrofolate reduc¬
tases.
Enzyme Tp ID50* Mtx ID50 TDS0 DHF Km Tp K, Size
fiM mins pM //M daltons
la 57 4.4 0.5 5.6 7.4 35000
lb 32 2.8 1.2 11 41 24500
Ila 70000 1100 > 12 4.6 6100 35000
lib 80000 750 > 12 8.3 150 35000
lie 20000 1000 > 12 4.2 400 34000
III 2.0 — — 0.4 0.019 16900
IV 0.2 0.02 > 12 37 0.063 46700
V 10 — > 5 — — —
VI 200 7.25 0.4 31.25 75 10000
VII 30 3.0 1.5 20.0 7.0 11500
SI 50 0.002 > 12 10.8 11.6 19700
* o.WoV-ejoi.o-fcvows, p6
Initially resistance was dominated by the spread of two genes encoding dihy¬
drofolate reductase types I and II, the type I was particularly common probably
because the gene was located on a transposon (Barth et al., 1976). However more
recently a number of new enzymes have been identified and now seven main types
have been distinguished in Gram-negative bacteria, and one type in Staphylococci
(table 1).
Type I dihydrofolate reductase
The early plasmid-mediated dihydrofolate reductases fell into two types, both of
which confer high level trimethoprim resistance (Pattishall et al., 1977). The type
I enzyme encoded by plasmid R483 has a molecular mass of 35,000 and could
33
be separated from the host enzyme on the basis of gel-filtration. The enzyme
is produced to a level about 10-times that of the chromosomal dihydrofolate
reductase. The dose required for 50% inhibition (ID50) of the type I enzyme for
trimethoprim and methotrexate was 57 //M and 4.4 yuM respectively and these
figures are several thousand fold higher than the chromosomal enzyme (Pattishall
et al., 1977). The type I enzyme is markedly heat sensitive losing half its activity
after 30 seconds at 45°C.
The type I dihydrofolate reductase consists of a dimer with a subunit size of
18,000 (Fling and Elwell, 1980; Novak et al., 1983). It has been purified and its
N-terminal amino acid sequence determined (Novak et al., 1983). However, be¬
cause of its lability, the complete sequence could only be elucidated by nucleotide
sequencing (Fling and Richards, 1983). The sequence of the type I shows no ho¬
mology with the type II enzymes but significant homology with the Escherichia
coli chromosomal enzyme.
The gene coding for the type I dihydrofolate reductase resides on a transposon
Tn7 (Barth et al., 1976) and this has proved to be an important factor in de¬
termining the spread of the type I enzyme. The type I enzyme is ubiquitous
and has proved to be the most commonly detected plasmid-mediated dihydrofo¬
late reductase (Pulkkinen et al., 1984; Steen and Skold, 1985; Huovinen et al.,
1986; Delgado and Otera, 1988). Indeed it has been shown that a rapid rise in
trimethoprim resistance in one area can be attributed to the appearance of Tn7
as opposed to other resistance genes (Huovinen et al., 1985).
Although originally plasmid-mediated the type I dihydrofolate reductase has been
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found with increasing frequency on the bacterial chromosome (Towner et al.,
1978, 1980; Towner, 1981; Fling et al., 1982; Steen and Skold, 1985; Amyes et al.,
1986b). In one study of trimethoprim resistant Escherichia coli from hospital and
community, the proportion of strains which had chromosomal carriage of Tn7 rose
from 38 to 70% (Kraft et al., 1986). It is not clear as yet if this movement of Tn7
from plasmid to chromosome will lead to changes in the incidence of resistance.
The type I enzyme has been found integrated into the chromosome of Vibrio
cholerae on the transposon Tnl527 which is closely related to Tn7 (Goldstein et
al., 1986a) and has also been found in the same clinical strains as the type II
dihydrofolate reductase (Fling et al., 1982; Burchall et al., 1982; Papadopoulou
et al., 1986).
A second transposon mediated type I like dihydrofolate reductase has been char¬
acterised (Young and Amyes, 1985). This enzyme encoded by Tn4132 has very
similar properties to the type I enzyme but a lower molecular mass of 24,500. It
is probably closely related to the type I and has been named the type lb, and the
type I renamed type la (Young and Amyes, 1985).
Type II Dihydrofolate Reductase
The type II enzyme encoded by plasmid R67 has a much lower specific activity
than the type I. It is produced in amounts the same or less than the chromosomal
enzyme (Pattishall et al., 1977). However it is able to confer high level resistance
as the enzyme is practically insensitive to trimethoprim and methotrexate (ID50
Tp 70,000 ID50 Mtx 1100 ^M). The molecular mass of the type II enzyme
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is 36,000 when measured by gel filtration and polyacrylamide gel electrophoresis
(Smith et al., 1979). The enzyme was thought to consist of four subunits each
9000 in size (Fling and Elwell, 1980) and amino acid sequencing of the purified
enzyme suggested that all the subunits were identical (Smith et al., 1979). How¬
ever more recently X-ray crystallography studies have revealed that, in common
with the type I enzyme, the type II may be a dimeric molecule (Matthews et al.,
1986), and it is likely therefore that the four subunits interact as dimers. Com¬
plete amino acid sequencing of the type II enzyme from R67 showed that it had
no homology with any of the other dihydrofolate reductases (Stone and Smith,
1979). This sequence has been confirmed by the nucleotide sequence of the type
II gene from R67 (Brisson and Hohn, 1984).
The type II enzymes have now been split into three classes all of which are
biochemically similar but are distinguishable by sequence analysis (Stone and
Smith, 1979; Zolg and Hanggi, 1981; Flensburg and Steen, 1986). The original
type II enzyme encoded by plasmid R67 is termed the Ha and the lib and lie are
encoded by plasmids R388 and R751 respectively. Comparison of the amino acid
composition of the three enzymes has shown that they are almost identical. There
are only 11 (out of 78) amino acid differences between the enzymes encoded by
plasmids R751 and R388 and only 17 differences when either enzyme is compared
with the R67 enzyme (Flensburg and Steen, 1986).
The epidemiology of the type II enzyme has been studied extensively, it is widespread
though not as common as the type I, despite the fact that the lie is found on a
transposon (Fling and Elwell, 1980). The incidence of the type II dihydrofolate
reductase genes has been studied with radiolabeled DNA probes and the propor-
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tion of trimethoprim resistant strains carrying type II genes has been found to
be 26% in a worldwide selection of clinical bacteria (Fling et al., 1982) and 60%
in Chile (Murray et al., 1985). In one hospital in the United States trimethoprim
resistance was shown to be the result of the spread of a single conjugative plas-
mid, with a wide host range, which contained the type II dihydrofolate reductase
gene (Mayer et al., 1985). This situation has not been seen in Europe. The
type II enzyme has recently been identified in Vibrio cholerae (Tabtieng et al.,
1989). Unlike the type I enzyme there is no evidence as yet that a transposon
carrying the type II dihydrofolate reductase gene has migrated into the bacterial
chromosome.
Type III Dihydrofolate Reductase
The type III enzyme was reported in a single bacterial species Salmonella ty-
phimurium, and was detected because of its lack of hybridisation with radiola¬
beled DNA probes for the type I and II enzymes (Fling et al., 1982). The type
III dihydrofolate reductase differs markedly from the types I and II. It has a lower
molecular mass 16,900, is monomeric and only confers low level resistance (MIC
Tp 64 mg/L) (Joyner et al., 1984). The type III enzyme is much more sensitive to
trimethoprim inhibition than either of the other two enzymes (ID50 Tp 2 pM, K;
19 nM). However, it is able to confer resistance as it has a very strong affinity for
the substrate dihydrofolate (Km 0.4 //M). Amino acid sequencing of the first 20
amino acids of the protein showed it to have 50% homology with the Escherichia
coli chromosomal enzyme (Joyner et al., 1984).
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The complete DNA sequence for the type III gene has recently been elucidated
(Fling et al., 1988) and shows it to be much more closely related to Gram-negative
bacterial chromosomal dihydrofolate reductases than to the other plasmid-mediated
enzymes. The type III enzyme shows 51% homology with the Escherichia coli
and 44% homology with the Neisseria gonorrhoeae chromosomal enzymes (Fling
et al., 1988).
The type III enzyme was found originally on a broad host range plasmid (incQ)
but appears not to have spread. However, as the enzyme only confers low level
resistance, this apparent rarity may actually be attributed to a lack of detec¬
tion as isolates with low level trimethoprim resistance are not normally screened
for transferability of resistance. Towner and Pinn (1981) detected a transfer¬
able plasmid conferring only a moderate level of resistance to trimethoprim and
stressed the need in all plasmid surveys to test all trimethoprim resistant isolates,
regardless of their MIC, for their ability to transfer.
Type IV Dihydrofolate Reductase
The type IV enzyme was identified during a survey of antibiotic resistance in
South India in 1984 (Young et al., 1986b). Subsequent biochemical analysis
revealed the type IV was unusual in a number of ways 1) It is an inducible enzyme
which is rare for plasmid-encoded resistance enzymes in Gram-negative bacteria,
2) It has a large molecular mass (46,700) and 3) It is only partially resistant to
trimethoprim (ID50 Tp 0.2 /«M) (Young and Amyes, 1986a). Furthermore, the
expression of the enzyme depends on the presence of methionine adenine and
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glycine in the media (Young et al., 1986b).
The Type V Dihydrofolate Reductase
This novel enzyme was identified in Sri Lanka and was detected because of a lack
of hybridisation with DNA probes for the types I and II enzymes. This evidence
along with a partial biochemical profile suggested that it may be a novel enzyme
(Sundstrom et al., 1987).
Type VI Dihydrofolate Reductase
A high-level trimethoprim resistant Proteus mirabI lis strain isolated in South
Africa contained a 79 kb plasmid (pUK 672) which encoded trimethoprim resis¬
tance. The dihydrofolate reductase produced was biochemically different from
any of the other plasmid-mediated enzymes and was designated type VI (Wylie
et al., 1988). The type VI enzyme is the smallest of the plasmid-mediated di¬
hydrofolate reductases with a molecular mastb of 10,000, the enzyme is highly
resistant to inhibition by trimethoprim and methotrexate (ID50 Tp 200 pM ID50
Mtx 7.25 pM). The type VI enzyme is very heat labile losing half of its activity
after 24 seconds at 45°C (Wylie et al., 1988).
Type VII Dihydrofolate Reductase
Plasmid pUN835 from an Escherichia coli responsible for an outbreak of porcine
diarrhoea contained a dihydrofolate reductase gene which did not probe with di-
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hydrofolate reductase genes I - V (Amyes et al., 1989). Biochemical characterisa¬
tion has shown this enzyme to have similar properties to the type la dihydrofolate
reductase. However it has a much lower molecular rrvxss of 11,500 (Amyes et
al., 1989).
SI Dihydrofolate Reductase
Until 1983, trimethoprim resistance in Gram-positive organisms was not plasmid-
mediated. However, in 1983 a trimethoprim resistance gene was identified on plas-
mid pSKl from mult i-resistant Staphylococcus aureus from Australia (Lyon et al.,
1986). The plasmid confers high level trimethoprim resistance and encodes a di¬
hydrofolate reductase which is unlike any of the enzymes found in Gram-negative
bacteria and it has been designated Si (Young et al., 1987). The Si enzyme is
produced in large amounts, has a molecular mass of 19,700, is monomeric and
is resistant to trimethoprim (ID50 50 ^M) but sensitive to methotrexate (ID50
0.002 //M) (Young et al., 1987). A plasmid-mediated dihydrofolate reductase
conferring trimethoprim resistance has also been isolated in the United States
(Coughter et al., 1987) but the enzyme has also been shown to be type Si (Tait
and Amyes, 1989). The SI dihydrofolate reductase has been detected on both
the chromosome and on plasmids and the position of the gene appears to affect
the level of resistance conferred (Galetto et al., 1987).
The gene encoding the SI dihydrofolate reductase has now been sequenced (Rouch
et al., 1989) and shows most homology with the Staphylococcus aureus chromoso¬
mal enzyme (Hartman et al., 1988; Amyes and Tait, 1990). At present it appears
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that the Si dominates trimethoprim resistance in staphylococci, whether this
remains the situation has yet to be seen.
The efficiency of plasmid-mediated resistance to trimethoprim has compromised
the use of this drug in many parts of the world. Recently there has been a
rapid increase in the number of plasmid-mediated dihydrofolate reductases. This
increase in numbers may not be as rapid as it appears but partly due to more
sophisticated techniques for detection and distinguishing between enzyme types.
Biotin labelled DNA probing has proved a useful tool for the screening of isolates
(Carter et al., 1987; Towner et al., 1988; Towner, 1990). Probing has shown
that whilst the type I and II enzymes are still common a significant proportion
of resistance is caused by other enzyme types. Chatkaeomorakot et al. (1987)
for instance have shown that 58% of enterotoxigenic Escherichia coli did not
contain genes for the types I, II or III dihydrofolate reductases. It is clear that
plasmid-mediated resistance to trimethoprim is still evolving.
1.5 Other Antifolate Drugs
There are a number of other drugs which act on the pathway of folate metabolism.
These are not all antibacterial, methotrexate is an inhibitor of mammalian dihy¬
drofolate reductase and is an important anticancer treatment and pyri methamine
has marked antimalarial activity (Burchall, 1979; Sandler and Smith, 1989).
In terms of antibacterial antifolates a number of trimethoprim-like compounds
have been developed. It was realised that minor alterations in the benzyl moiety
of trimethoprim could lead to impressive biological changes and this led to the de-
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velopment of 2,4-diamino-5-(3,5-dimethoxy-4-methoxyethoxy-benzyl)-pyrimidine
better known as tetroxsprim (Liebenow and Prikryl, 1979). Like trimethoprim
this compound strongly inhibits prokaryotic dihydrofolate reductase but only
weakly inhibits the eukaryotic enzyme (Aschhoff and Vergin, 1979). A combi¬
nation of tetroxcprim and sulphadiazine has been shown to be synergistic in
vitro (Grimm, 1979; Wiedemann, 1979) and has been used successfully clinically
in the treatment of urinary and respiratory tract infections (Ferber and Ahrens,
1979; Pust et al., 1979). However tetroxaprim is not resistant to the enzymes
conferring resistance to trimethoprim and therefore offers no real advantage over
trimethoprim (Bywater et al., 1979).
Lipophilic analogues of trimethoprim bearing 3,5-dialkyl-4-hydroxy substituents
in the benzyne ring have been developed which are much more active in vitro
against Neisseria gonorrhoeae than is trimethoprim (Roth et al., 1988). However
in vivo studies showed that these drugs were extensively metabolised and their
development was discontinued (Roth et al., 1988). Similarly 3,4-dimethoxy-5-
alkenyl, -5-alkyl and -5-alkoxy analogues of trimethoprim which had high in vitro
activity against anaerobic organisms had a short half life and were disappoint¬
ing in vivo (Roth et al., 1989). However one of a series of 2,4-diamino-5-[(l,2-
dihydro-6-quinolyl)methyl] pyrimidines containing gem-dimethyl or fluoromethyl
substituents at the 2- position of the dihydroquinoline ring, (2,4-diamino-5-[[l,2-
dihydro-2,4-dimethyl-3-fluoro-2-(fluoromethyl)-8-methoxy- 6(lhI)quinolyl]methyl]-
pyrimidine), has outstanding activity against Gram-positive organisms. The com¬
pound has as broad a spectrum of antibacterial activity as trimethoprim and the





The bacterial strains used were as follows:
Escherichia coli HB101 (pUN972) transformant containing the type Ilia, dihydro-
folate reductase gene (located on a 0.85 kb Pst 1 fragment) cloned into pUClS,
from Kevin Towner.
Escherichia coli C600 (pBH600), transconjugant containing the original clinical
plasmid responsible for trimethoprim resistance in a Shigella sonnei outbreak in
a nursing home in Tennessee, from Neil Barg.
Escherichia coli JM101 (pBH7001a) an E. coli clone consisting of a 1.8 kb Pst 1
fragment encoding the trimethoprim resistance gene from an outbreak of Shigella
sonnei in a National Park cloned into pUC9, from Neil Barg.
Escherichia coli JM83 (pFE1242), strain containing a recombinant plasmid formed
by inserting partial Tag 1 fragments encoding the type Ilia dihydrofolate reduc-
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tase from pAZl cloned into pUC9, from Lynn Elwell.
Escherichia coli J62_2 (pUK1123), an E. coli transconjugant containing the orig¬
inal clinical trimethoprim R-plasmid specifying the type IV dihydrofolate reduc¬
tase, from Hilary Young.
Escherichia coli C600 (pUK1150), an E. coli clone containing plasmid pBR322
with a 2.6 kb Hind III fragment of pUK1123 encoding the type IV dihydrofolate
reductase, from Hilary Young.
Escherichia coli C600 (pUK1152), an E. coli clone containing a 4.1 kb EcoRl
fragment of pUK1123 containing the type IV dihydrofolate reductase gene ligated
into pACYC184, from Hilary Young.
Escherichia coli C600 (pUK1140), an E. coli clone containing a 4.1 kb EcoR1
fragment of pUK1123 containing the type IV dihydrofolate reductase gene in¬
serted into pBR322, from Hilary Young.
Escherichia coli C600 (pUK1148), contains the recombinant plasmid formed by
inserting a 1.7 kb Cla 1 fragment of pUK1123 encoding the type IV dihydrofolate
reductase into pBR322, from Hilary Young.
Escherichia coli HB101 (pLK09) transconjugant containing the recombinant plas¬
mid pLK09. This contained a 1.25 kb insert which included the type V dihydro¬
folate reductase from plasmid pLM020, from Ola Skold.
Escherichia coli HB101 (pUK2000) an E. coli clone containing plasmid pUC18
with a 0.48 kb Hpa 1 fragment encoding the type V dihydrofolate reductase, from
Ola Skold.
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Escherichia coli C600 (pFE872) an E. coli clone containing plasmid pBR322 with




Escherichia coli K12 met"
Escherichia coli C met"
all from Sebastian Amyes.
2.2 Media
2.2.1 Complex Media
The complex media used were Nutrient Broth No. 2 (CM67), Diagnostic Sensi¬
tivity Test Agar (CM261), Isosensitest Broth (CM473) and Columbia agar base
(CM331B), (Oxoid, Basingstoke, Hants).
2.2.2 Minimal Media
Double strength minimal salts medium (DM) was prepared as described by Davis
and Mingioli (1950) (table 2). Single strength minimal medium DM base was
prepared by diluting double strength DM base with an equal volume of distilled
water prior to autoclaving. For the preparation of diluents, single strength DM
base was distributed in 9.9 ml and 4.5 ml aliquots which were autoclaved at 15
psi for 15 minutes. Supplement solutions: for incorporation into minimal medium
are shown in table 3.
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These ingredients were dissolved in a litre
of distilled water in the order given.
50 ml quantities were distributed and
autoclaved at 15 psi for 15 minutes.
Table 3. Supplement solutions.
Solution Source Strength Final Mode of
prepared concentration sterilisation
D-glucose BDH 200mg/ml 2.8mg/ml Autoclaving
L-proline BDH 5mg/ml 50pg/ml Steaming
L-histidine BDH 5mg/ml 50pg/ml Steaming
L-tryptophan BDH 2mg/ml 50pg/ml Steaming
L-methionine BDH 5mg/ml 50pg/ml Filtration
adenine BDH 5mg/ml 50pg/ml Steaming
glycine BDH 5mg/ml 50pg/ml Steaming
thymidine* Sigma 5mg/ml varied Steaming
Autoclaving was performed for 15 minutes at 15 psi. Steaming was for 30 minutes,
filtration was through a Millipore filter with pore size 0.2pm.
"Thymidine solution was also added to complex media as described in the Results.
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2.2.3 Preparation of Plates
Complex Media
All laboratory media were made up according to the manufacturer's instructions
and were autoclaved at 15 psi for 15 minutes. The plates were poured while the
agar was still molten, each containing approximately 15 ml. With antimicrobial
drug sensitivity plates, the agar was allowed to cool to 50°C before the appropriate
antimicrobial drugs were added and the plates poured. After setting, the plates
were dried, inverted at 50°C for 20 - 30 minutes.
Minimal Media
To 50 ml of double strength DM media were added, aseptically, the required
amino acid supplements (to give a final concentration of 50 /ig/ml), 1.4 ml of
20% D-glucose and the appropriate antimicrobial drugs. Sterile distilled water
was added to bring the volume to 60 ml. This mixture was added to 40 ml of
molten bacteriological agar No. 1 (Lll Oxoid) and mixed gently before pouring.
2.3 Materials
2.3.1 Chemotherapeutic Drugs
The chemotherapeutic drugs used are listed in table 4. All were supplied sterile
and prepared as indicated.
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Table 4. Chemotherapeutic drugs.






















NADPH tetrasodium salt was purchased from the Sigma Chemical Company and
was stored desiccated at -20°C. Solutions of NADPH were prepared and used on
the same day.
Dihydrofolic acid (DHF) (Sigma) was prepared by dissolving 25 mg of DHF in
0.05M sodium phosphate buffer pH 7.4 containing 0.05M /2-mercaptoethanol.
This solution was distributed into aliquots which were stored in total darkness at
-20°C. No aliquot was refrozen after use. Preparation of DHF for zymographic
staining is described later.
5-fluoro-2'-deoxyuridine (FUdR) and 2'-deoxyadenosine were purchased from
Sigma and stored at room temperature prior to use. FUdR was added directly to
culture media to give the required concentration except when final concentrations
below 1.0 //g/ml were required. In these cases the FUdR was diluted in sterile
distilled water and the required volume added. 2'-deoxyadenosine was made up
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to 5 mg/ml in distilled water and sterilised by steaming for 30 minutes. The
required amount was then added to cultures.
EDTA, Folic acid and /Tmercaptoethanol were all purchased from Sigma and
stored at room temperature.
MTT (Sigma) was stored at +4°C in darkness. A fresh solution ofMTT dissolved
in distilled water was used for each zymographic stain.
Methotrexate agarose from Sigma was stored in the dark at +4°C until use.
2.3.3 Standard Markers
The standard molecular weight proteins used to calibrate Sephadex gel filtration
columns and native polyacrylamide gels are shown in table 5. For SDS polyacry-
lamide gels a Sigma molecular weight kit (MW-SDS-70L kit) was used. Isoelectric
focusing gels were calibrated with an Electran pi calibration kit 4.7 - 10.6 (44270
2G) from BDH.
2.3.4 Buffers
Sodium phosphate buffers were made according to the Data for Biochemical Re¬
search, (Oxford University Press). The buffer used routinely for dihydrofolate
reductase extraction and purification was 50 mM sodium phosphate buffer pH 7.4
containing 10 mM /3-mercaptoethanol and 1 mM EDTA (buffer A).
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Bovine serum albumin 66000 Sigma
Ovalbumin 45000 Sigma
Chymotrypsinogen 25500 Sigma
Trypsin inhibitor 20100 Sigma
Cytochrome C 12384 Sigma
A protinin 6500 Sigma
Chain B insulin 3878 Sigma
2.4 Methods
2.4.1 Plasmid Transfer
Donor and recipient strains were grown overnight in 4.5 ml of nutrient broth at
37°C. After overnight growth 0.1 ml of the donor culture and 1 ml of the recipient
culture were mixed in 4.5 ml of prewarmed nutrient broth and incubated statically
for 18 hours. At the end of this time the mating mixture was vortexed to separate
donor and recipient cells. Cells were collected by centrifugation at 4000g for 15
minutes (Heraeus Christ Bactifuge) and resuspended in 5.6 ml basal DM medium
and further diluted to 10-1, 10-2 and 10-4 in DM medium. 0.1 ml of neat culture
and each dilution was spread on selective DM plates only allowing growth of a
plasmid containing recipient strain. Plates were incubated at 37°C for 48 hours
after which time the resultant single colonies were purified on selective plates.
Controls consisted of spreading donor and recipient strains on selective plates,
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after centrifugation and resuspension in 4.5 ml DM.
2.4.2 Viable Counts
Serial dilutions were made with 1 in 10 and 1 in 100 dilution steps in single
strength DM, i.e. 0.5 ml of culture and 4.5 ml diluent or 0.1 ml culture and
9.9 ml of diluent respectively. Suspensions were mixed on a rotomixer (Hook
and Tucker Ltd.) and 0.1 ml amounts spread with a sterile glass spreader onto
nutrient agar plates. The spread plates were incubated, inverted, at 37°C for 18
hours.
2.4.3 Minimum Inhibitory Concentration (MIC) Deter¬
minations on Solid Media
Oxoid No. 2 nutrient broth (4.5 ml amounts) were seeded with an inoculum from
a fresh nutrient agar plate and grown overnight at 37°C. A 1 in 104 dilution was
prepared by serial dilution in DM base and 2 /A of this suspension was spot¬
ted onto media containing varying concentrations of the drug with a multipoint
inoculator (Denley). All plates were incubated at 37°C for 18 hours with the
exception of DM plates which were incubated for 48 hours. Concentrations of
drug were usually increased by a factor of two and the MIC was taken as the first
concentration permitting no visible growth. A control plate lacking any drug was
used in each case.
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2.4.4 Enzyme Preparation
Enzyme was prepared from overnight cultures of bacteria grown in Oxoid Isosen-
sitest broth with vigorous agitation at 37°C. Bacteria were harvested by cen-
trifugation at 6000g for 15 minutes (RC-5B Sorval), washed in Davis Mingioli
minimal media and the final pellet resuspended in buffer A. After this point all
operations were performed at +4°C. The bacteria were disrupted by sonication
(2 x 30s, 8 /J,m MSE Soniprep) and the cell debris removed by centrifugation
(40,000g, lh).
The resulting crude enzyme preparation could be used to establish how much
dihydrofolate reductase the strain was producing (enzyme specific activity), for
example in induction studies. However to examine the biochemical properties the
crude extract had to be purified further.
Nucleic acids were precipitated by the gradual addition of 0.1 volume 10% strep¬
tomycin sulphate. The precipitate was removed by centrifugation at 12000g for
30 minutes in a Sorval RC-5B centrifuge. Dihydrofolate reductase was precipi¬
tated from the extract by the addition of ammonium sulphate to 50% and 80%,
after each precipitation the pellet was recovered by centrifugation at 12000g for
30 minutes in a Sorval RC-5B centrifuge. The 80% pellet was resuspended in a
minimum volume (about 2 ml) of buffer A and then assayed for dihydrofolate
reductase activity, resuspended pellets were stored frozen at -20°C until required.
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2.4.5 Concentrators
Where protein samples were required to be concentrated to suitable volumes, for
running on gel filtration columns, PAGE and IEF gels, Amicon Centriprep 10
and Centricon 10 concentrators were used. These provide fast efficient concen¬
tration of small volume macromolecular solutions by ultrafiltration through a low
adsorption hydrophobic membrane with a 10,000 dalton cut off. Concentrators
were used in accordance with manufacturer's instructions.
2.4.6 Enzyme Assays
Dihydrofolate reductase activity was assayed by the method of Osborn and Huen-
nekens 1958. Dihydrofolate was made up to 1 mM and stored as described in the
Materials, NADPH was made up to 1 mM in distilled water and used that day
only. The assays were performed in either a Pye Unicam Sp8000, Pye Unicam
Spl800 or Perkin Elmer Lambda 2 spectrophotometer at 37°C. 1 ml quartz cu¬
vettes were used and contained the following reagents:




distilled water to a volume of 0.95 ml
The blank cuvette contained all these constituents except NADPH. Both cuvettes
were placed in the spectrophotometer for four minutes to allow for temperature
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equilibration. To start the reaction 0.05 ml of 1 mM dihydrofolate was added
to both the blank and test cuvettes, and the decrease in absorbance at 340 nm
followed for ten minutes or until the absorbance fell to 0. When a decrease
in absorbance occurred before the addition of dihydrofolate, this was taken as
dihydrofolate-independent NADPH oxidase activity. This rate was subtracted
from the total rate observed in the presence of dihydrofolate, to give the level of
dihydrofolate reductase activity.
The decrease in absorbance at 340 nm is caused by reduced absorbancy both
by the oxidation of NADPH to NADP and by the reduction of dihydrofolate to
tetrahydrofolate. 52% of the combined decrease in absorbancy results from the
conversion of dihydrofolate to tetrahydrofolate when both substrates are being
consumed stoichiometrically (Mathews et al., 1963), and hence, with this proviso,
the rate of enzymic activity was expressed in molar terms of dihydrofolate being
converted to tetrahydrofolate. Controls were performed routinely in the absence
of enzyme to ensure that the addition of the two substrates together did not
result in a change of absorbance.
2.4.7 Protein Estimations
Protein estimations for establishing dihydrofolate reductase specific activity were
performed by the method of Waddell (1956). All samples to be tested were
suitably diluted in 50 mM sodium phosphate buffer pH 7.4 and the absorbance
measured at 215 and 225 nm. The protein concentration could then be calculated
with reference to a standard curve which had previously been prepared. This
method has been shown to be as precise and more sensitive than the protein
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estimation of Lowry et al. (1951).
2.4.8 Gel Filtration
Sephadex G50 or G75 fine grade (Pharmacia, Uppsala Sweden) was allowed to
swell for 3 hours at 100°C in buffer A, after being allowed to cool any "fines" were
carefully decanted and more buffer A added. The Sephadex slurry was poured
carefully into an Amicon acrylic column (2 cm2 x 90 cm) which was maintained
at 4°C in an LKB mini cold lab. When the column was fully packed the top was
connected and the flow changed to an upward direction with an LKB peristaltic
pump. The flow rate was adjusted to around 2 ml per 10 minutes and the column
washed continually with buffer A for 48 hours before use.
Samples for separation (1-2 ml) were applied to the bottom of the column and
eluted with buffer A. Two ml fractions were collected and maintained at 4°C
using an LKB Ultrorac fraction collector. Elution was continued until a volume
of buffer A, equivalent to the total volume (180 ml) of the column, had passed
through. The column was washed for twelve hours between each run with buffer
A.
2.4.9 Enzyme Molecular Weight Determinations
Calibration of Sephadex columns was based on the method of Andrews (1964).
Five mg of each of the 3 standards chosen were dissolved in buffer A and applied
to the Sephadex column. The standard proteins were eluted in buffer A and 2 ml
fractions were collected. The position of the protein peaks was determined by
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measuring the absorbance of the collected fractions at 280 nm.
2.4.10 Enzyme Kinetics
The biochemical properties of the dihydrofolate reductases being investigated
were examined after pooling those fractions, from gel filtration, which showed
peak activity. Inhibition of activity by trimethoprim and methotrexate was ex¬
amined by assaying the enzymes activity in increasing concentrations of the in¬
hibitor. The assays were performed as before with the exception that the required
amount of drug was added to both cuvettes and the volume of distilled water al¬
tered accordingly.
The temperature sensitivity of the enzymes were examined by incubating the
sample in a prewarmed container at 45°C for the requisite time. The sample was
then assayed for dihydrofolate reductase activity as normal.
To establish the Km for the enzymes the activity of each dihydrofolate reductase
was assayed under conditions of partial saturation with dihydrofolate and the
results analysed by the method of Lineweaver and Burk (1934). The reciprocal
of the substrate concentration 1 js was plotted against the reciprocal of the rate
of enzymic reaction 1/u. The intercept on the abscissa gives the negative of
the reciprocal of the Michaelis Constant (Km), the Km value being the substrate
concentration at which half the maximal velocity occurs (Dixon and Webb, 1958).
The inhibitor constants (K,) of the enzymes were calculated by repeating the as¬
says in limiting substrate dihydrofolate but this time in the presence of trimetho¬
prim. Again double reciprocal plots of \ /s against \/v were plotted, trimethoprim
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inhibition of dihydrofolate reductase is competitive and therefore this double re¬
ciprocal plot intercepts the ordinate at the same point as the Km line. However,
the plots in the presence of trimethoprim intercept the abscissa nearer the origin
than the lines obtained without inhibition. If the distance to the origin from the
intercept is —4- then:
where i is the concentration of the inhibitor (Dixon and Webb, 1958).
2.4.11 Zymography
Bands of dihydrofolate reductase activity were located on polyacrylamide gels by
zymographic staining (Tennhammar-Ekman and Skold, 1979; Broad and Smith,
1982). Immediately after the electrophoretic run, gels were flooded with pre-
warmed 1.2 mM NADPI1 in 0.2M sodium phosphate buffer pH 6.0. The gel
was then incubated for five minutes at 37°C after which time 0.15 ml of 50 mM
sodium phosphate buffer pH 7.4 containing 10 mM dihydrofolate and 50 mM
/3-mercaptoethanol was added. The gel was incubated for five minutes at 37°C
in a dark room, finally 6 mM MTT was added and the gel incubated at 37°C in
darkness until bands were visible, typically 5-10 minutes. Unspecific reduction




Isoelectric focusing was performed by a modification of the technique described
by Broad and Smith (1982). Dihydrofolate reductase which had been precipitated
by 80% ammonium sulphate was diluted 1 in 5 with buffer A containing 0.75 mM
NADPH and this was dialysed against buffer A (100 volumes) for 4 hours.
Aliquots of this (10 pi) were applied to the surface of standard polyacrylamide
plates containing ampholines capable of producing a gradient from pH 3.5 - 9.5
(LKB products No. 1804-101). Standard pi markers 4.7 - 10.6 (BDH 44270 2G)
were also applied to each gel. The samples were focused for six hours on a cooled
(9°C) Ultrophor-electrophoresis system (LKB No. 2217) at 500V and 20mA,
limited by constant power set at 1W. The gels were stained for dihydrofolate
reductase activity as described.
2.4.13 Affinity Chromatography
Affinity chromatography was performed with methotrexate agarose (Sigma) and
an Econo-Column (Bio-Rad) (0.375 cm2 x 20 cm) by a modification of the method
described by Kaufmann (1974). Prior to the application of the sample to the
methotrexate agarose column, the column was pretreated with the following so¬
lutions, 5 ml 1 M K2HPO4 containing 0.5g of folic acid, 100 ml 1M K2HPO4, and
200 ml 0.1M sodium phosphate buffer pH 5.6 containing 1M NaCl.
The column was then washed with 10 mM sodium phosphate buffer pH 5.6 until
the absorbance of the eluate at 280 nm was essentially 0. The column was then
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equilibrated with buffer A and the dihydrofolate reductase sample loaded. The
column was then washed with buffer A, the protein which did not bind was assayed
for dihydrofolate reductase activity to confirm that the enzyme was bound to the
column. Washing the column with buffer A was continued until the absorbance
at 280 nm was less than 0.01 OD units.
The dihydrofolate reductase activity was eluted by the addition of the following
solutions, 2 ml 1M K2HPO4, 2 ml 0.5M K2HPO4 containing 4 //moles of dihy¬
drofolate and finally 75 ml of 0.1M K2HP04 containing 1 //M dihydrofolate. Five
ml fractions were collected and assayed for dihydrofolate reductase activity. The
column was washed in buffer A and stored in the same buffer at +4°C in darkness
until further use.
2.4.14 Sequence Analysis
Sequence analysis was performed on an Applied Biosystems 477A instrument,
before each analysis the purity of the sample was checked by reverse phase HPLC
with an Applied Biosystems 130A microbore separation system. The procedure
is as described by Hayes et al. (1989).
2.4.15 Polyacrylamide Gel Electrophoresis
Polyacrylamide gel electrophoresis was carried out with a Pharmacia Phastsystem
(18-1601-01) according to manufacturer's instructions. For SDS polyacrylamide
gel electrophoresis PhastGels Gradient 10 - 15% (17-0540-01) and PhastGel SDS
Buffer Strips (17-0516-01) were used. Samples to be electrophoresised were di-
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luted in loading buffer to give a final concentration of approximately 0.5 ^g/^1
and /3-mercaptoethanol and SDS added to 5.0% and 2.5% respectively. This was
heated at 100°C for 5 minutes and bromophenol blue added to 0.01%.
Samples were loaded onto the gel and electrophoresised at 250V, 10mA and 3.0W
for approximately 60VH or until the bromophenol blue dye front reached the an¬
ode strip. The gel was then stained with coomassie blue in a Pharmacia Phast-
system development unit (18-1601-01) as described by the manufacturers.
For native electrophoresis PhastGel Homogenous 20 (17-0624-01) and PhastGel
Native Buffer strips (17-0517-01) were used. Sample preparation was as before,
except no SDS was added and samples were not boiled. The gels were run ac¬
cording to manufacturer's instructions until the tracking dye reached the anodic
buffer strip. Native gels were stained either by coomassie blue as above or by
zymography as described before.
2.4.16 Fast Protein Liquid Chromatography (FPLC)
FPLC was carried out with a Pharmacia FPLC system consisting of an LCC500
plus controller, UV-M Monitor, FRAC 100 with an HR5/5 Mono Q column.
The column was equilibrated with 50 mM Tris-HCl buffer (pH 8.0). Two ml
of concentrated dihydrofolate reductase sample (from the pooled peak fractions
obtained by gel filtration with a Sephadex G75 column) was added to the col¬
umn. Separation was achieved by elution with a linearly increasing concentration
of sodium chloride (in the above buffer) to a maximum concentration of 1M.






A. Type IV Dihydrofolate Reductase
3.1 Studies on the Induction Mechanism
The type IV dihydrofolate reductase differs from the other plasmid-mediated en¬
zymes in a number of ways, and perhaps the most important is that it is inducible
(Young and Amyes, 1986a). This is very unusual for a plasmid-encoded resistance
enzyme in Gram-negative bacteria, however it has been reported for E. coli chro¬
mosomal dihydrofolate reductase (Tennhammar-Ekman et al., 1986). The only
features of the induction mechanism of the type IV enzyme that had been found
were that induction could be achieved with increasing trimethoprim concentra¬
tions up to 160 mg/L (Young and Amyes, 1986a), and that the increase in specific
activity of the dihydrofolate reductase resulted from induction and did not result
from the selection of high production mutants (H-K. Young, unpublished results).
The induction mechanism was now studied in more detail to establish how it
operated. Induction was studied in E. coli J62_2 (pUK1123) an E. coli transcon-
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jugant containing the original clinical plasmid isolated in India in 1984 (Young
et al., 1986b). E. coli J62_2 lacking the plasmid shows no induction of dihydro-
folate reductase and dies rapidly when challenged with trimethoprim 10 mg/L in
complex media (H.-K. Young, unpublished results). Firstly, the induction of the
enzyme under various growth conditions was examined.
3.1.1 Minimum Time for Induction
The induction of the type IV dihydrofolate reductase was investigated by chal¬
lenging E. coli J62_2 (pUK1123) with different trimethoprim concentrations for
20 hours and then measuring the enzymes specific activity (Young and Amyes,
1986a). The speed at which the challenged bacteria responded on exposure to
trimethoprim should reveal the nature of the induction process. Therefore E. coli
J62_2 (pUK1123) was inoculated directly from a DSTA plate into five flasks con¬
taining 250 ml of Oxoid Isosensitest broth containing trimethoprim (40 mg/L).
This trimethoprim concentration was chosen for all induction studies as it pro¬
moted high levels of enzyme activity without diminishing the recovery of bacte¬
ria. The flasks were incubated shaking at 37°C. The contents of each flask were
allowed to grow for a set time before the bacteria were harvested and the spe¬
cific activity in the cleared lysates determined, the results are shown in table 6.
Clearly induction was not "switched on" immediately the cells were challenged
with trimethoprim but occurred at some time between 5 and 14 hours.
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Table 6. Minimum challenge time required for induction of the type IV dihydro-
folate reductase in E. coli J62_2 (pUK1123)
Length of challenge time with Tp Enzyme specific activity nmol












3.1.2 Viable Count and Gram-Stains over 24 hours
There was a considerable time lag between challenge of the bacteria with trimetho¬
prim and the production of elevated levels of dihydrofolate reductase and it was
not known what changes were taking place in the bacteria during this time. Pre¬
sumably if elevated levels of dihydrofolate reductase were not synthesised, to
enable the bacteria to overcome trimethoprim challenge, then no growth could
occur.
To test this theory the viable count of E. coli J62_2 (pUK1123) was followed
over 24 hours following challenge with 40 mg/L trimethoprim. E. coli J62_2
(pUK1123) was inoculated straight from a plate into two separate flasks con¬
taining 250 ml Isosensitest broth. One flask was challenged immediately with
trimethoprim (40 mg/L), the second had no trimethoprim added, the flasks were
incubated at 37°C and shaken vigorously for 24 hours. At time 0, and thereafter
every 4 hours, a viable count and Gram-stain was performed on the bacteria in
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each flask. The results are shown in figures 3 and 4.
Unchallenged E. coli J62_2 (pUK1123) followed a classic growth curve over the
24 hour period. When bacteria were challenged with trimethoprim, however,
a considerable initial drop in viable count was observed. At 8 hours this was
reversed and the cells began to grow. By the end of the 24 hour period there was
little difference in the viable count of the challenged and unchallenged cultures.
Gram-staining carried out in conjunction with the viable counts showed that as
the viable count of the challenged cells dropped, cell elongation occurred. After
8 hours, as the viable count increased, the cells shortened and at 24 hours, they
were indistinguishable from the unchallenged culture. These results supported the
findings of the previous experiment and they suggested that induction probably
took place around eight hours after trimethoprim challenge.
3.1.3 Growth before Challenge
The viable count of E. coli J62_2 (pUK1123) fell after it was challenged with
trimethoprim, until induction occurred and reversed the process. It was difficult
to establish whether the requirement for induction was that the cells were in a
certain growth phase. In the previous experiment challenged bacteria were in
lag phase and not actively growing when challenged. To observe the influence of
stage in the growthcurvej E. coli J62_2 (pUK1123) was inoculated from a DSTA
plate into 250 ml of Isosensitest broth and allowed to grow for various times until
challenged with trimethoprim (40 mg/L). After challenge, bacteria were allowed
to grow for 20 hours, then harvested and the specific activity in the cleared
lysates determined (table 7). After two hours pre-challenged growth, induction no
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Figure 3. Viable count of E. coli J62_2 (pUKll23) over 24 hours in the presence
and absence of trimethoprim 40 mg/L.
Time (hours)
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Figure 4. Gram-stains of E. coli J62_2 (pUK1123) grown over 24 hours in the
presence and absence of trimethoprim 40 mg/L
initial inoculum
control 8 hours Tp 8 hours
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Figure 4 (continued).
control 12 hours Tp 12 hours





control 20 hours Tp 20 hours
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Figure 4 (continued).
control 24 hours Tp 24 hours
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longer occurred on addition of trimethoprim even though the bacteria continued
to grow. The experiment was repeated employing shorter time intervals in the
pre-challenge growth stage (table 8). Clearly a factor was present which affected
induction and it appeared at around two hours growth following inoculation. This
was probably linked to growth
In order to establish exactly where in the growth & induction took place
E. coli J62_2 (pUK1123) was inoculated into a series of flasks each containing
250 ml of Isosensitest broth, one flask was challenged immediately with 40 mg/L
trimethoprim and the other four at 60, 135, 180 and 240 minutes respectively. A
final flask was unchallenged as a control but its growth was followed by viable
counts. All flasks were inoculated at the same time and incubated shaking at
37°C, the levels of enzyme production and how this relates to viable count are
shown in figure 5.
The results suggest that the bacteria induced dihydrofolate reductase production
if challenged in lag phase. However, once the bacteria were in logarithmic phase
they were able to grow without inducing dihydrofolate reductase production. This
may be explained if bacteria in logarithmic phase are producing something which
antagonises trimethoprim. Even more simply there may have been more cells
present in logarithmic phase so the amount of trimethoprim capable of acting on
any individual cell was less.
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Table 7. The effect of allowing growth before challenge, with Tp (40 mg/L), on
induction of the type IV dihydrofolate reductase.
Time between inoculation and Enzyme specific activity nmol






Table 8. The effect of allowing growth before challenge, with Tp (40 mg/L), on
induction of the type IV dihydrofolate reductase.
Time between inoculation and Enzyme specific activity nmol







Figure 5. Relationship between growth curve, and enzyme induction in E. coli
J62_2 (pUK1123).
Enzyme specific activity (nmol DHF reduced/min/mg protein) when challenged
at various points is also shown.
43 87 40 37 2.6
Time (minutes)
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3.1.4 Effect of Method of Inoculation on Induction
The previous results suggested that bacteria, once growing, produced a factor
which antagonised the action of trimethoprim. It had been observed that in¬
duction was more readily obtained if the challenge flask was inoculated with a
loopful of bacteria directly from an agar plate rather than growing up a loopful
in a nutrient broth starter culture and employing 1 ml of this as an inoculum.
To examine this the two methods of inoculation were compared over a range of
trimethoprim concentrations.
For direct inoculation, a loopful of E. coli J62_2 (pUK1123) was taken from a
DSTA plate and inoculated directly into 250 ml of Isosensitest broth containing
either 0, 20, 40, 80 or 160 mg/L trimethoprim. The cultures were incubated
for 20 hours at 37°C shaking vigorously. Inoculation by nutrient broth starter
culture was performed by growing up a loopful of E. coli J62_2 (pUK1123) in 4.5
ml nutrient broth at 37°C until turbid. One ml of this was used as an inoculum
for a series of 250 ml Isosensitest broth cultures identical to those listed above
and the flasks were incubated as before. After 20 hours, cells were harvested by
centrifugation and disrupted by sonication, the specific activity in the cleared
lysates was determined (table 9).
There was a distinct difference in the level of induction between the two groups.
Higher enzyme levels were obtained with the inoculum from an agar plate and,
furthermore, hyperproduction (specific activity > 20) of dihydrofolate reductase
was achieved at a lower trimethoprim concentration, 20 rather than 40 mg/L. To
verify this result, a further experiment was performed whereby a single colony
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Table 9. The effect of inoculation method on induction of the type IV dihydro-
folate reductase in E. coli J62_2 (pUK1123).
Enzyme specific activity nmol
DHF reduced/min/mg protein
Tp Concentration
mg/L Direct inoculum Starter culture
Table 10. The effect of inoculation method on enzyme specific activity at a Tp



















Tp Concentration Enzyme specific activity nmol








of E. coli J62_2 (pUK1123) was selected and split in two. One half was used
to inoculate 250 ml of Isosensitest broth containing 20 mg/L trimethoprim and
the other half was grown up in 4.5 ml of nutrient broth until turbid and 1 ml of
this used to inoculate an identical flask. Both cultures were incubated shaking
at 37°C for 20 hours, the dihydrofolate reductase specific activity in each culture
was measured. The results (table 10) confirmed that the different inoculation
procedures had a pronounced effect on enzyme induction.
The explanation for a lower level of induction when cells were grown in nutrient
broth may have been the influence of thymidine. The major difference between
nutrient and Isosensitest broth is that the latter lacks thymidine, a compound
known to antagonise trimethoprim (Amyes and Smith, 1974a). The carry over of
thymidine in the nutrient broth may have been affecting induction levels. Addi¬
tionally the results of the experiment, measuring the influence of growth before
challenge, suggested that once in log phase the bacteria were producing a factor
which antagonised trimethoprim, this may have been thymidine. To investigate
this hypothesis, a series of induction experiments were carried out in Isosensitest
broth in the presence of thymidine.
3.1.5 Effect of Thymidine on Type IV Induction
In the first experiment E. coli J62_2 (pUK1123) was challenged with trimetho¬
prim (40 mg/L) in the presence of different thymidine concentrations. Bacteria
were inoculated directly from a DSTA plate into 250 ml of Isosensitest broth
containing trimethoprim (40 mg/L) and thymidine at concentrations of 0, 2, 10,
20 or 50 mg/L. The enzyme specific activities after incubation at 37°C for 20
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hours (table 11) demonstrated that the effect of thymidine was marked. A con¬
centration of 2 mg/L was sufficient to allow the bacteria to grow without inducing
dihydrofolate reductase production. The experiment was repeated at the lower
thymidine concentrations of 2, 0.2 and 0.02 mg/L. The results (table 12) showed
that a tenfold decrease in thymidine concentration from 2 mg/L was sufficient
to force induction to occur, however, it was not clear if the reverse was true,
i.e. at a constant thymidine concentration of 2 mg/L would a tenfold increase
in trimethoprim concentration necessitate enzyme induction. To investigate this
E. coli J62_2 (pUK1123) was challenged as before, however in this case, the
trimethoprim concentration was raised to 40, 160, 240, 400 mg/L respectively
while the thymidine concentration was constant at 2 mg/L. The specific activity
of dihydrofolate reductase (table 13) did not rise as the trimethoprim concen¬
tration was increased indicating that induction had not occurred. Indeed the
specific activity appeared to fall as the trimethoprim concentration increased, at
400 mg/L no enzyme activity was detected although normal growth had occurred.
Because of the importance of thymidine in affecting the induction of the type fV
dihydrofolate reductase it was decided to investigate the effect that thymidine has
on cell elongation and viable count over 24 hours. The experiment was similar
to an earlier experiment in this chapter following the viable count over a 24 hour
period. Three flasks containing 250 ml of fsosensitest broth were prepared; the
first had no additions, the second contained trimethoprim (40 mg/L) and the
third trimethoprim (40 mg/L) plus thymidine (2 mg/L). Each was inoculated
with a loopful of E. coli J62_2 (pUK1123) from a DSTA plate and then incubated
at 37°C and shaken vigorously. Viable counts and Gram-stains were performed
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Table 11. The effect of thymidine on induction of the type IV dihydrofolate
reductase at a Tp concentration of 40 mg/L.
Concentration of thymidine Enzyme specific activity nmol






Table 12. The effect of thymidine on induction of the type IV dihydrofolate
reductase at a Tp concentration of 40 mg/L.
Concentration of thymidine Enzyme specific activity nmol






Table 13. The effect of thymidine 2 mg/L on induction of the type IV dihydro-
folate reductase in the presence of increasing Tp concentrations.
Concentration of Tp Enzyme specific activity nmol





on the three cultures at points throughout the 24 hour period.
The results (figure 6) showed that, as before, unchallenged E. coli J62_2 (pUK1123)
followed a classic growth curve. On the other hand the bacteria challenged with
trimethoprim (40 mg/L) alone showed a drop in viable count to 8 hours but by 24
hours they had recovered. The bacteria challenged with trimethoprim in the pres¬
ence of thymidine (2 mg/L) showed no decrease in viable count and grew as the
unchallenged culture had done. Similarly when the Gram-stains were examined
(figure 7), bacteria challenged with trimethoprim in the presence of thymidine
behaved like unchallenged cells and did not elongate. This experiment demon¬
strated that induction of the type IV enzyme only occurred when the bacteria
were under stress. The presence of a given concentration of trimethoprim is not
enough.
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Figure 6. Viable count of E. coli J62_2 (pUKll23) over 24 hours, challenged with











Figure 7. Gram-stains of E. coli J62_2 (pUK1123) grown over 24 hours with Tp
40 mg/L in the presence and absence of thymidine 2 mg/L.
initial inoculum
control 8 hours Tp 8 hours
Tp and thymidine 8 hours
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81
3.1.6 Effect of 5-Fluoro-2 '-deoxyuridine (FUdR)
Most of the tetrahydrofolic acid formed in E. coli by the action of dihydrofolate
reductase is used for the synthesis of the thymine moiety of thymidylic acid. As
thymidine has such a marked effect on induction, it suggested that the hyper-
production of the type IV dihydrofolate reductase may be triggered by thymine
starvation. To examine this the effect of FUdR on dihydrofolate reductase lev¬
els was examined, FUdR inhibits the enzyme thymidylate synthetase and thus
causes thymine starvation.
E. coli J62_2 (pUK1123) was grown in Isosensitest broth in the presence of a
range of concentrations of FUdR and 2 '-deoxyadenosine (20 mg/L) (to prevent
the breakdown of the FUdR). Bacteria were inoculated directly from a DSTA
plate into 250 ml of Isosensitest broth and grown shaking at 37°C for 20 hours.
The FUdR concentrations used are listed in table 14, after 20 hours incubation
the specific activities in the cleared lysates were determined. Unexpectedly FUdR
did not cause an increase in enzyme production, growth was affected and no pellet
was recoverable from the bacteria incubated in the presence of 10 mg/L FUdR.
The culture containing 1 mg/L FUdR began to grow shortly before the cells
were harvested and in order to check that induction would not have occurred if
left longer the experiment was repeated at this concentration but bacteria were
not harvested until 30 hours. Results (table 15) showed that again no induction
occurred, which suggested that the induction process was triggered by more than
simple thymine starvation.
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Table 14. The effect of FUdR on levels of dihydrofolate reductase in E. coli J62_2
(pUK1123).
FUdR Concentration Enzyme specific activity nmol






10 No pellet recoverable
Table 15. The effect of 1.0 mg/L FUdR on levels of dihydrofolate reductase in
E. coli J62_2 (pUK1123) after 30 hours growth.
FUdR Concentration Enzyme specific activity nmol




3.1.7 Effect of Metabolites
The previous experiment suggested that induction of the type IV enzyme was not
simply a result of thymine starvation and other factors must be involved. Earlier
studies had shown that the MIC of trimethoprim for E. coli J62_2 (pUK1123) was
dependent on the presence of glycine,methionine and adenine in the media (Young
et al., 1986b). These three compounds are closely involved in the thymidine
pathway (Amyes and Smith, 1974c) and it therefore seemed likely that they
would affect induction of the type IV enzyme.
To examine the effect of these three compounds on enzyme production E. coli
J62_2 (pUK1123) was challenged in Davis-Mingioli minimal media containing
the auxotrophic requirements for this strain (proline, histidine, tryptophan and
glucose). In addition different combinations of methionine, adenine and glycine
were added. To compensate for the slower growth rates and the lower bacterial
yield in minimal medium, compared with complex media, one litre cultures were
used, rather than the 250 ml which had been used previously. As larger volumes
were being used a 0.5 ml nutrient broth starter culture was used to initiate growth.
Although starter cultures had been shown to give a lower induction in some of
the previous experiments, that had been in a total volume of 250 ml. It was felt
that the effect of the volume of this starter in one litre would be negligible. The
bacteria were grown for 24 hours in the presence of trimethoprim (40 mg/L) and
the specific activities of the cleared lysates determined.
The results (table 16) indicated that induction only took place if methionine^ade-
nine and glycine were all present. Interestingly, when any of these were absent,
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Table 16. The effect of methionine (met),adenine (ad) and glycine (gly) on the
induction of the type IV dihydrofolate reductase in E. coli J62_2 (pUK1123) when
grown in minimal medium.
Supplements* all at Tp Concentration Enzyme specific Growth
a concentration of mg/L activity nmol DHF
50 mg/L reduced/min/mg protein
0 0 2.5 +++
0 40 5.9 +++
met ad — 0 2.4 +++
met ad — 40 2.2 +++
met — gly 0 2.5 +++
met — gly 40 0.8 +++
— ad gly 0 3.7 +++
— ad gly 40 2.3 +++
met ad gly 0 3.9 +++
met ad gly 40 28.8 +/-
* All media also contained proline,histidine and tryptophan at 50 mg/L and 2.8
mg/ml glucose
normal growth occurred in the presence of trimethoprim. When all three were
present little growth had occurred after 24 hours although the bacteria were pro¬
ducing high levels of dihydrofolate reductase. When these bacteria were examined
under the microscope they were found to be greatly elongated and when reincu-
bated, for a further 12 hours, growth occurred and the bacteria had returned
to their normal size. It appeared, therefore, that what was happening, in the
presence of all three supplements, was similar to the situation in complex media
but over a longer time period.
The effect of thymidine was examined when all three supplements were present
and, as would be expected, it allowed growth over 24 hours in the absence of
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elevated levels of dihydrofolate reductase.
The larger volumes required and lower bacterial yield meant that it was imprac¬
tical to study induction in minimal medium. However the experiment on growth
before challenge had suggested that an inoculum effect may be affecting induc¬
tion levels. It was decided therefore to examine the effect of the inoculum size
in Davis-Mingioli medium plus supplements, as this is a more defined system to
differentiate between the thymidine effect and any inoculum effect. In the follow¬
ing experiments enzyme specific activities were not determined, cell growth and
structure were taken as indications of whether induction had occurred.
A series of E. coli J62_2 (pUK1123) cultures were grown in 250 ml of Davis-
Mingioli medium containing the basic auxotrophic requirements plus methionine^
adenine,glycine and trimethoprim (40 mg/L). A control flask which contained
no trimethoprim was also included. The bacteria for inoculation into the flasks
were grown up in a nutrient broth starter culture until turbid. The inoculum
was varied in each flask as follows: In the first set the starter culture was used
directly as the inoculum with sizes of 0.5 ml, 1.0 ml and 4.5 ml used for the
flasks containing trimethoprim and 0.5 ml for the control. With the second set
the nutrient broth starter culture was spun down and the bacteria washed and
resuspended in Davis-Mingioli minimal medium. This was used as an inoculum
as above. Cultures were incubated shaking at 37°C for 24 hours. To determine if
induction was necessary for growth, cell growth and appearance were monitored.
The results (table 17) obtained from the nutrient broth and Davis-Mingioli in-
ocula were identical indicating that there was a definite inoculum effect. With
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Table 17. The effect of inoculum size on induction of the type IV dihydrofolate
reductase in E. coli J62_2 (pUK1123) when grown in minimal media.
Inoculum size Tp concentration Growth Viable Count Cell
(ml) mg/L bacteria/ml appearance
0.5 (control) 0 +++ 2.7 x 109 normal
Nutrient broth 0.5 40 +/- 1.1 x 107 elongated
inoculum 1.0 40 +/- 2.1 x 106 elongated
4.5 40 +++ 5.6 x 108 normal
0.5 (control) 0 +++ 2.5 x 109 normal
Resuspended 0.5 40 +/- 2.7 x 106 elongated
in DM 1.0 40 +/- 4.8 x 107 elongated
4.5 40 +++ 1.3 x 109* normal
* Inoculated from 0.5 (control) 0 +++ 3.2 x 109 normal
bacteria grown 0.5 40 +/- 8.0 x 105 elongated
in previous 1.0 40 +/- 4.5 x 106 elongated
experiment 4.5 40 +++ 7.0 x 107 normal
inoculum sizes of 0.5 ml and 1.0 ml, the presence of trimethoprim (40 mg/L)
allowed little growth and the cells were elongated, a response associated with
induction. With an inoculum size of 4.5 ml, however, the cells were able to grow
normally similar to the unchallenged control. To establish that no genetic change
had occurred in the cultures started with the large inoculum, the experiment
was repeated with bacteria that had grown from a 4.5 ml starter culture as the
inoculum. The same pattern was obtained as before indicating no mutation had
occurred (table 17).
Clearly metabolites and thymidine are important in expression of the type IV
dihydrofolate reductase but there is also a marked inoculum effect.
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3.1.8 Other Antifolate Agents
Trimethoprim is only one of a series of antifolate agents, and their ability to induce
the type IV dihydrofolate reductase was examined. Induction experiments were
set up with a range of antifolates; tetroxcprim, aminopterin, pyrimethamine,
methotrexate and sulphamethoxazole.
The experiments were carried out exactly as with trimethoprim, E. coli J62_2
(pUK1123) was inoculated directly from a DSTA plate into 250 ml of Isosen-
sitest broth containing different concentrations of the appropriate drug. Cultures
were incubated shaking at 37°C and the specific activity measured in the cleared
lysates.
The results (table 18) show that there was no induction with any of the antifolates
over the range 0 - 160 mg/L, which had produced induction with trimethoprim. It
was possible that a higher concentration of these antifolates was needed to cause
induction. To study this the MIC of these antifolates for E. coli J62_2 (pUK1123)
was tested and compared to the MIC of trimethoprim (table 19). All the antifo¬
lates had higher MICs than trimethoprim suggesting that a higher concentration
would be required to induce enzyme production. Only two of the other antifo¬
lates tested had MICs of less than 1280 mg/L: tetroxoprim and pyrimethamine,
so induction at higher concentrations was confined to these two compounds.
The induction was set up as before and the enzyme levels achieved are shown in
table 20. At these concentrations the antifolates were clearly affecting the growth
of the bacteria and few cells were recovered from concentrations of 1280 mg/L
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Table 18. Induction of the type IV dihydrofolate reductase in E. coli J62_2
(pUK1123) with antifolates other than trimethoprim.
Antifolate Drug Concentration Enzyme specific activity nmol



























Table 19. The minimum inhibitory concentrations of various antifolates for E. coli
J62_2 (pUK1123).
Antifolate drug MIC mg/L

















from both tetroxcprim and pyrimethamine. Interestingly, induction only oc¬
curred with tetroxoprim and not with pyrimethamine.
3.1.9 Induction in Other Strains
Induction had been studied in E. coli J62_2 but it was not known if this effect
was universal as it had not been observed in other strains. Therefore, in order
to establish what factors might influence induction, two further bacterial sys¬
tems were examined. Firstly, as methionine appeared important in determining
whether induction occurred, induction was examined in E. coli J53, a methionine
requiring mutant. Secondly the effect on induction of cloning the type IV gene
into another plasmid was investigated.
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Table 20. Induction of the type IV dihydrofolate reductase in E. coli J62_2
(pUK1123) with high level tetroxoprim and pyrimethamine.
Antifolate drug Concentrations of drug Enzyme specific activity nmol






















Induction in E. coli J53
Plasmid pUK1123 was transferred into E. coli J53 from E. coli J62_2 (pUK1123)
by conjugation. Induction in the transconjugant E. coli J53 (pUK1123) was
studied by a procedure identical to that previously established for E. coli J62_2
(pUK1123). A colony of E. coli J53 (pUK1123), from a DSTA plate, was inoc¬
ulated into a series of flasks, each containing 250 ml of Isosensitest broth and a
different trimethoprim concentration (0 - 160 mg/L). After incubation at 37°C
for 20 hours the specific activities in the cleared lysates were determined.
The results (table 21) were different from those obtained for E. coli J62_2, contain¬
ing the same plasmid. In E. coli J53 production of the type IV enzyme appeared
to be derepressed, high levels of activity occurring in the absence of trimetho¬
prim challenge. At a trimethoprim concentration of 160 mg/L the enzyme specific
activity was not significantly greater than the basal level of production in the ab¬
sence of challenge. Furthermore the bacteria were able to grow normally at this
concentration unlike E. coli J62_2 where viability is reduced at a trimethoprim
concentration of 160 mg/L.
To investigate if this phenomenon was restricted to E. coli J53 or occurred in other
methionine deficient strains, plasmid pUK1123 was transferred into two further
methionine deficient strains: E. coli K12 met- and E. coli C met-. Before in¬
duction studies were performed on these strains the position of the methionine
mutation was established in case this had an effect on induction. The methion¬
ine mutation was mapped by examining if the strains could utilise homocysteine
(figure 8). This revealed that as E. coli J53 and K12 could not utilise homocys-
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Table 21. Induction of the type IV dihydrofolate reductase encoded by plasmid
pUK1123 in E. coli J53.
Tp Concentration Enzyme specific activity nmol













teine, the mutation must be at position A whilst E. coli C, which could grow
on minimal media containing homocysteine, must have a mutation at point B
(figure 8). The MICs of trimethoprim for the three strains were examined on
DSTA plates and on minimal media containing glucose proline and methionine
(table 22). Interestingly, on complex media, E. coli J53 and E. coli K12, which
had the mutation at point A, had the same MIC while E. coli C, which has a
mutation at point B, had a higher MIC. On minimal media all had the same MIC
Induction studies were performed on E. coli C met- and E. coli K12 met- with
trimethoprim over the range 0-160 mg/L. The procedure was identical to that
used before and the specific activities in the cleared lysates are shown in tables
23 and 24. The results clearly demonstrated that induction did not take place
and, like E. coli J53, normal growth occurred at a trimethoprim concentration
of 160 mg/L. It seems clear from these experiments and the earlier studies that
160 mg/L.
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Figure 8. The interconversion of tetrahydrofolate intermediates and their rela¬


























Table 22. MIC's of trimethoprim for E. coli methionine deficient strains.
MIC Tp (mg/L)
Strain
Minimal Media Complex Media
E. coli J53 (pUK1123) 160 20
E. coli K12 met- (pUK1123) 160 20
E. coli C met- (pUK1123) 160 80
E. coli J62_2 (pUK1123)* 160 10
E. coli J62_2 < 5 < 5
* minimal media contained proline, histidine and tryptophan (50 mg/L) and
glucose (2.8 mg/ml).
methionine is an important metabolite affecting the induction of the type IV
enzyme.
Induction in Clones
The effect on induction of cloning the type IV gene into other plasmids was inves¬
tigated. The clones used are described in table 25 and figure 9. Induction studies
were performed as before except that initially only two trimethoprim concentra¬
tions were used: 0 and 40 mg/L. From this study it was apparent that induction
was not likely to occur as the unchallenged bacteria were producing high levels
of dihydrofolate reductase (table 26). Clone 3, which was producing the least
dihydrofolate reductase, was studied further over the full range of trimethoprim
concentrations (0 - 160 mg/L) and again no induction took place (table 27).
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Table 23. Induction of the type IV dihydrofolate reductase encoded by plasmid
pUK1123 in E. coli K12 met-.
Tp Concentration Enzyme specific activity nmol







Table 24. Induction of the type IV dihydrofolate reductase encoded by plasmid
pUK1123 in E. coli C met-.
Tp Concentration Enzyme specific activity nmol








Table 25. Type IV dihydrofolate reductase clones.
Clone
1 E. coli C600 (PUK1148) 1.7 kb C7al
fragment of pUK1123 in pBR322
2 E. coli C600 (pU1140) 4.1 kb EcoRl
fragment of pUK1123 in pBR322
3 E. coli C600 (pUK1152) 4.1 kb EcoKl
fragment of pUK1123 in pACYC184
Table 26. Induction of the type IV dihydrofolate reductase when cloned.
Tp Concentration Enzyme specific activity nmol
mg/L DHF reduced/min/mg protein
Clone 1 0 42.6
40 33.6
Clone 2 0 40.4
40 17.6
Clone 3 0 19.9
40 20.9
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Figure 9. Restriction Map of pUK1123.
EcoRl Hindlll Cla 1
m „ Cla 1 EcoRV Hindlll EcoRV EcoR1
i mpt\.
w ? - \
-— 0.7 kb—~ 1.7 kb ~ 0.8 kb ~ 0.9 kb
Table 27. Induction of the type IV dihydrofolate reductase encoded by plasmid
pUK1152.
Tp Concentration Enzyme specific activity nmol








3.2 N-terminal Sequence and Subunit Struc¬
ture of the Type IV Dihydrofolate Reduc¬
tase
Studies on the induction mechanism of the type IV dihydrofolate reductase had
suggested that the resistance mechanism was more similar to a chromosomal
"swamping" method of resistance, rather than merely the usual bypass mecha¬
nism. This fact coupled with the observation that the type IV enzyme is only
partially resistant to trimethoprim (ID50 0.2 ^M) (Young and Amyes, 1986a)
suggest that the type IV could be an intermediate between the chromosomal and
highly resistant plasmid enzymes. It was, therefore, important to establish how
the type IV enzyme fits into the evolution of plasmid-mediated dihydrofolate
reductases.
Sequence analysis represents the ultimate information currently available for the
distinction and comparison of plasmid-mediated dihydrofolate reductases. There¬
fore it was decided to examine the amino acid sequence of the type IV enzyme.
Two properties of dihydrofolate reductases make them particularly suitable for
sequencing by this method. Firstly, if the enzyme is methotrexate sensitive it
should be relatively easy to purify it sufficiently for sequence analysis. Secondly
the majority of the active site of all dihydrofolate reductases is situated at the
N-terminal end of the protein (Novak et al., 1983; Rouch et al., 1989). Therefore
a single run through an automatic amino acid sequencer should provide enough
information to deduce the evolutionary relationships.
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3.2.1 Purification of the Type IV Dihydrofolate Reduc¬
tase
The overall purification procedure is outlined in figure 10. The enzyme was pu¬
rified from 10 litres of E. coli J62_2 (pUK1123) grown for 20 hours at 37°C in
Isosensitest broth containing trimethoprim (40 mg/L). The activity of the enzyme
preparation was measured at each stage of the purification procedure. Prior to
the gel filtration step 10 ml of the resuspended pellet from ammonium sulphate
precipitation contained 41,059 units of dihydrofolate reductase activity. The re-
suspended pellet was dialysed against buffer A for 4 hours, then concentrated to 2
ml with an Amicon Centriprep 10 Concentrator. The activity in the concentrate
was measured and found to contain 40,790 units. The concentrate was then sep¬
arated on a Sephadex G75 column and 2 ml fractions collected. A clearly defined
peak of enzyme activity was identified (figure 11). Fractions 38 - 57 were pooled
and the activity reassayed, 24,062 units were present.
The pooled fractions were applied to a methotrexate column. No dihydrofolate
reductase activity was detected in the protein which initially passed through the
column indicating that the enzyme had been completely bound to the methotrex¬
ate agarose. The column was washed continuously with buffer A until the ab-
sorbance at 280 nm of the eluate had returned to an OD of less than 0.01, i.e. no
further protein was passing through.
The dihydrofolate reductase activity was eluted by the addition of 2 ml 1M
K2HP04, 2 ml 0.5M K2HP04 containing 4 //moles of dihydrofolate followed by
75 ml of 0.1M K2HP04 containing 1/zM dihydrofolate (Kaufman, 1974). Five
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Figure 10. Purification procedure for the type IV dihydrofolate reductase, the
volumes at each stage are also shown.
Isosensitest broth containing Tp 40mg/L (10L)
Inoculate with E. coli „
J62.2 (pUK1123)
Grown 20 hours at 37°C
Purified to 80% ammonium sulphate saturation (10ml)
Dialyse against buffer A for 4hrs
Concentrate with Centriprep 10 (2ml)
Separate on Sephadex G75 column
Pool peak fractions (40ml)
Run onto methotrexate column and wash
Elute from column
Pool peak fractions (15ml)
Concentrate with Centriprep 10 (1.5ml)
Concentrate with Centricon 10 (60//1)
Analysis
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Figure 11. Elution of DHFR activity of E. coli J62_2 (pUK1123) on Sephadex
G75 gel filtration, the elution points of standard markers are also shown. Enzyme
had been prepared from a large scale (10L) culture.




ml fractions were collected and assayed for enzyme activity. The three fractions
showing peak activity were pooled and contained 14,743 units. This 15 ml sample
was concentrated with Amicon Centriprep 10 and then Centricon 10 Concentra¬
tors to a final volume of 60/d, which retained 8249 units of enzyme activity.
3.2.2 Native PAGE Analysis of the Purified Enzyme
The efficacy of the purification procedure was checked by applying a 2 fi\ aliquot
of the purified protein to an SDS free homogeneous 20% polyacrylamide gel along
with the standard marker proteins. Bovine serum albumin (66,000) ovalbumin
(45,000) and trypsin inhibitor (20,100). The gel was run in a Pharmacia Phast-
system until the bromophenol blue dye front had migrated the length of the gel.
The gel was then stained with coomassie blue and destained as described in the
Materials and Methods (figure 12). This revealed that the enzyme encoded by
plasmid (pUK1123) comigrated with ovalbumin (45,000) and produced a single
protein band. This not only confirmed that the type IV enzyme had been purified
to the native protein but also showed that the protein had a molecular mass of
around 45,000. This is virtually identical to the molecular mass of the type IV
enzyme determined by gel filtration (Young and Amyes, 1986a).
3.2.3 N-terminal Sequence of the Purified Enzyme
As the purification procedure had apparently removed all contaminating proteins,
the native type IV dihydrofolate reductase could be analysed on the automatic
amino acid sequencer. As a final check on purity and to establish how much
enzyme to load, the purified sample was analysed by HPLC. As expected, a
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Figure 12. SDS-free polyacrylamide gel electrophoresis of purified dihydrofolate
reductase from E. coli J62_2 (pUK1123). Standard marker proteins are also
shown.
Track A: Trypsin inhibitor
Track B: Ovalbumin
Track C: Bovine serum albumin
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single protein peak was obtained, this was applied to an Applied Biosystems
477A sequencer. A clear result was obtained for the first 47 amino acids of the
dihydrofolate reductase (figure 13). However a secondary sequence, which was
not a dihydrofolate reductase, could also be determined. This secondary sequence
was weaker than the primary enzyme and only the first 19 amino acids of this
protein could be distinguished. Detailed examination of the GENBANK database
revealed that this secondary protein was NSl, an E. coli DNA binding protein.
The second protein clearly was not a contaminant as a single protein had been
found both on Native PAGE and HPLC. This suggests that the native type IV
dihydrofolate reductase must have been a complex of these two proteins.
If this was the case then the type IV enzyme which gives a single band on native
PAGE should produce subunits of different size when examined under denaturing
conditions.
3.2.4 SDS PAGE of the Purified Enzyme
The purified enzyme from pUK1123 was treated with SDS and then applied to
a 10-15% SDS containing polyacrylamide gel along with Sigma SDS molecular
weight markers (14,000 - 66,000). The gel was run in a Pharmacia Phastsystem
and stained with coomassie blue (figure 14).
Unlike the native gel a number of protein bands were present, one major band
at around 33,000 and a number of smaller bands. This suggests the existence of
subunits of different sizes. The main band is presumed to be the dihydrofolate
reductase as the sequence analysis had shown that it was the major protein in the
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Figure 14. SDS polyacrylamide gel electrophoresis of the purified dihydrofolate
reductase from E. coli J62_2 (pUK1123). Standard marker proteins are also
shown.
Track A: Standard marker proteins (14,000 - 66,000)
Track B: Type IV dihydrofolate reductase
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sample. The bands of lower molecular weight may represent breakdown products
of this and NSl protein which has a monomeric size of 10,000 but can also exist
as a dimer or trimer (Rouviere-Yaniv and Kjeldgaard, 1979). However 33,000 is
a large subunit size for a dihydrofolate reductase and to confirm that the enzyme
was fully denatured, the gel was repeated but the protein sample was boiled in
SDS for up to 30 minutes before being applied to the gel. The result (figure 15)
showed that no further denaturation took place and that the true size of the
dihydrofolate reductase subunit was 33,000 daltons.
3.2.5 N-terminal Amino Acid Sequence of the Type IV
Dihydrofolate Reductase Encoded by pUK1150
The results show that the type IV enzyme was complexed to the NSl binding
protein when encoded by the clinical plasmid pUK1123. However a 2.6 kb Hindlll
fragment from pUK1123 had been cloned into pBR322 to give the hybrid plasmid
pUK1150. E. coli C600 (pUK1150) produced an active dihydrofolate reductase
which was not inducible and had a lower molecular mass than the type IV enzyme
encoded by pUK1123. The molecular mass of the pUK1150-derived enzyme is
33,000 when measured by Sephadex gel filtration (figure 16). Preliminary analysis
might have suggested that the lower molecular mass of this enzyme resulted
from loss of part of the structural gene. However comparison with the results
of pUK1123 suggests that the pUK1150 derived enzyme lacks the NSl binding
protein. In order to investigate this further the pUK1150-derived enzyme was
purified and the sequence determined. The purification procedure was identical
to that for the type IV from pUK1123 and the steps involved and enzyme activity
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Figure 15. SDS polyacrylamide gel electrophoresis of the purified type IV dihy-
drofolate reductase from E. coli J62_2 (pUK1123) after boiling for 10, 20 and 30
minutes. Standard protein markers are also shown.
Track A: Standard marker proteins (14,000 - 66,000)
Track B: Type IV dihydrofolate reductase boiled for 10 minutes
Track C: Type IV dihydrofolate reductase boiled for 20 minutes
Track D: Type IV dihydrofolate reductase boiled for 30 minutes
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Figure 16. Elution of DHFR activity of E. coli C600 (pUK1150) on Sephadex
G75 gel filtration.
The elution points of standard markers are also shown.




Table 28. Purification of the type IV dihydrofolate reductase encoded by plasmid
pUK1150.
Purification stage Enzyme specific activity nmol
DHF reduced/min/mg protein
80% ammonium sulphate precipitate
2 ml concentrate run onto Sephadex
pooled from Sephadex





at each stage are summarised in table 28.
3.2.6 N-terminal Sequence Analysis of the Dihydrofolate
Reductase Encoded by Plasmid pUK1150
The purified enzyme was examined on HPLC and a single peak was obtained,
it was this peak that was analysed on the Applied Biosystems 477A sequencer.
The sequence of the first 49 amino acids was obtained (figure 17) and this was in
agreement with that obtained for the type IV encoded by plasmid pUK1123. No
evidence of any secondary sequence, let alone the NSl binding protein was ob¬
tained, strongly suggesting that the lower molecular mass of the pUK1150 derived
enzyme results from the absence of the NSl DNA binding protein. Comparison
of the N-terminal amino acid sequence of the type IV enzyme with those of the
other plasmid-mediated enzymes and the E. coli chromosomal enzyme, showed
that the type IV was most similar to the chromosomal enzyme (figure 17).
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3.2.7 SDS PAGE of the pUK1150-derived Dihydrofolate
Reductase
The purified enzyme was examined on SDS PAGE and as there was no evidence
of the NSl protein, this enzyme should give a different pattern from the type
IV encoded by pUK1123. The enzyme was treated with SDS and then applied
to a 10 - 15% SDS containing polyacrylamide gel along with Sigma molecular
weight markers (14,000 - 66,000). After electrophoresis the gel was stained with
coomassie blue (figure 18). A single band was observed and this corresponded to
a molecular mass of approximately 30,000.
The result confirms that unlike the pUK1123 derived type IV the smaller pUK1150
derived type IV is monomeric. The most likely explanation for the lower molec¬
ular mass of the pUK1150 derived enzyme is the absence of the NSl protein.
B. Type III Dihydrofolate Reductases
3.3 The Type III Dihydrofolate Reductase in
the United Kingdom
The type III dihydrofolate reductase was first identified in New Zealand in 1979
(Joyner et al., 1984). It was isolated from a single strain of Salmonella ty-
phimurium and the gene encoding the enzyme was located on plasmid pAZl.
The type III enzyme is unusual amongst plasmid-encoded dihydrofolate reduc¬
tases for a number of reasons: it confers only low level resistance on ifchost (MIC
64 mg/L), and is only partially resistant to inhibition by trimethoprim (ID5q
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Figure 18. SDS polyacrylamide gel electrophoresis of the purified type IV dihy-
drofolate reductase from E. coli C600 (pUK1150). Standard marker proteins are
also shown.
Track A: Dihydrofolate reductase encoded by pUK1150
Track B: Standard marker proteins (14,000 - 66,000)
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2/«M). This latter property is offset because the enzyme is extremely efficient at
reducing the substrate as it has a Km for dihydrofolate of 0.4//M. The type III
dihydrofolate reductase has a molecular mass of 16,900 much lower than any of
the dihydrofolate reductases that had been isolated before (Joyner et al., 1984).
Similarly, unlike the dihydrofolate reductases previously identified, the type III
is monomeric.
After the initial isolation of the type III enzyme in 1979, it was never subsequently
detected, although it was not clear if this was because the gene was extremely
rare or simply resulted from inadequacies in the detection technique resulting
from the enzyme's ability to confer only a low level of resistance.
It would seem that the latter is the case as the type III gene has now been detected
in E. coli isolated from the urine of a hospitalised patient in Nottinghamshire.
3.3.1 Isolation and Probing
E. coli TM858 was isolated from the urine of a hospitalised patient in Notting¬
hamshire in 1980. Trimethoprim resistance was not freely transferable and could
only be mobilised to E. coli J53_2 following transposition onto plasmid RP4. The
resulting transconjugant E. coli J53_2 (pUN635 - RP4::3175) was highly resis¬
tant to trimethoprim (MIC > 1000 mg/L). Purified plasmid DNA was therefore
hybridised with those gene probes known to identify high level trimethoprim
resistance genes (i.e. dihydrofolate reductase types I, II and V). However no hy¬
bridisation occurred with any of these probes suggesting the presence of a novel
dihydrofolate reductase gene.
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In collaboration with Dr Kevin Towner in Nottingham a more detailed analysis of
the trimethoprim resistance gene and its products was performed. The trimetho¬
prim resistance gene of E. coli J53_2 (pUN635) was cloned into vector plasmid
pUC18. Plasmid pUN635 was digested with the restriction enzyme PstI and a
0.85 kb fragment encoding trimethoprim resistance was ligated into pUC18. The
resultant recombinant plasmid pUN972 (figure 19) was introduced by transforma¬
tion into E. coli HB101 and selection made for trimethoprim resistant colonies on
DSTA plates containing trimethoprim (50 mg/L). The MIC of trimethoprim for
transformants was found to be 64 mg/L, much lower than the original pUN635
containing bacteria.
Plasmid pUN972 was hybridised with all available plasmid dihydrofolate reduc¬
tase gene probes and positive hybridisation was only obtained with the type III
gene probe. Further evidence suggesting that pUN972 carried a type III gene was
obtained when a 0.7 kb EcoKl-Pstl fragment of pUN972, carrying the trimetho¬
prim resistance gene, was used to probe control plasmids encoding previously
characterised dihydrofolate reductases. Hybridisation was only detected with the
original type III dihydrofolate reductase encoding plasmid pAZl.
In order to confirm that the pUN972-encoded enzyme was a type III detailed
biochemical analysis of the dihydrofolate reductase encoded by pUN972 was per¬
formed.
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3.3.2 Biochemical Properties of the Dihydrofolate Re¬
ductase Encoded by pUN972
Molecular Mass
Dihydrofolate reductase was prepared from E. coli HB101 (pUN972) which had
been grown at 37°C overnight in Isosensitest broth. Enzyme was isolated as
described in the Materials and Methods, and 1 ml of the resuspended 80% am¬
monium sulphate precipitate was applied to a calibrated Sephadex G75 column
equilibrated with buffer A and eluted with the same buffer. Two ml fractions
were collected every 8.3 minutes and assayed for dihydrofolate reductase activity
(figure 20). A single peak of trimethoprim resistant (4//M) dihydrofolate reduc¬
tase activity was obtained and this corresponded to a molecular mass of 17,000
virtually identical to the mass of the type III enzyme (Mr 16,900). The peak
fractions (67 - 72) were pooled for further biochemical analysis.
Inhibition by Trimethoprim
The activity of the partially purified enzyme was assayed in the presence of dif¬
ferent trimethoprim concentrations. The activity of the dihydrofolate reductase
encoded by pUN972 was directly proportional to the logarithm of the trimetho¬
prim concentration (figure 21) and the enzyme was only partially resistant to
trimethoprim with an ID50 of 2pM. This is identical to the type III enzyme.
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Figure 20. Elution of DHFR activity of E. coli HB101 (pUN972) on Sephadex
G75 gel filtration.
The elution points of standard marker proteins are also shown.




Figure 21. Trimethoprim inhibition of partially purified dihydrofolate reductase










Inhibition by Methotrexate and Heat
The heat and methotrexate sensitivities of the type III dihydrofolate reductase
encoded by plasmid pAZl were not known. Therefore, in order to compare the
type III and pUN972 dihydrofolate reductases, it was necessary to determine
these values for the pAZl derived enzyme.
Type III dihydrofolate reductase was prepared from E. coli K12 JM83 contain¬
ing the plasmid pFE1242, a recombinant plasmid consisting of a Taql fragment
containing the type III trimethoprim resistance gene inserted into the AccI site
of pUC9. E. coli JM83 (pFE1242) was grown overnight at 37°C in 2 litres of
Isosensitest broth and the enzyme prepared in the manner described earlier. Af¬
ter separation by Sephadex gel filtration the active fractions were pooled and the
methotrexate and heat sensitivities established and compared with the enzyme
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Figure 22. Methotrexate inhibition of partially purified dihydrofolate reductase
from E. coli HB101 (pUN972) and E. coli JM83 (PFE1242).
• E. coli HB101 (pUN972)











The activities of the dihydrofolate reductases, encoded by pUN972 and pFE1242,
were assayed over a range of methotrexate concentrations (figure 22) both en¬
zymes were sensitive to methotrexate ID50 0.02/iM and 0.03y«M respectively.
Heat Stability
The activities of the two enzymes were compared after incubation in prewarmed
containers at 45°C for various time intervals. Both enzymes were heat stable
maintaining more than 50% of their activity after 12 minutes at 45°C.
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Michaelis Menten Kinetics
One of the distinguishing features of the type III enzyme is that it is extremely
efficient with a Km for dihydrofolate of 0.4/rM. This enables the type III enzyme
to confer a significant degree of resistance despite being only partially resistant to
trimethoprim. The efficiency of the dihydrofolate reductase encoded by pUN972
was investigated by assaying its activity under conditions of partial saturation
with dihydrofolate and the results analysed by the method of Lineweaver and
Burk. The results (figure 23) show that the Km value for dihydrofolate was
0.4^/M, identical to the value previously published for the pAZl encoded enzyme.
When the assays were repeated in the presence of trimethoprim (5^/M), it was
found that the maximum velocity remained the same (figure 23) indicating that
the drug causes competitive inhibition of the enzyme. The inhibitor constant
(Kj) for trimethoprim was 0.04^M, again similar to that reported for the pAZl
encoded type Iff dihydrofolate reductase.
The biochemical properties of the enzyme encoded by pUN972 and pAZl are in¬
distinguishable (table 29). This confirms the probing results which had suggested
that the enzyme was a type III. To confirm that the two enzymes were identi¬
cal and not merely very closely related isoelectric focusing was used. Isoelectric
focusing is extremely useful for detecting differences between proteins as even a
difference in a single amino acid can be identified (Amyes and Tait, 1990).
The pi of the type III dihydrofolate reductase encoded by pAZl was unknown,
therefore, to compare the two enzymes, they were run side-by-side along with
a set of pi markers. Dihydrofolate reductase was prepared from E. coli HB101
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Figure 23. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli HB101 (pUN972).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
I#"1
123
Table 29. Biochemical properties of the type III dihydrofolate reductase and the
enzyme encoded by plasmid pUN972.
Enzyme Tp ID50 Mtx ID50 TD50 DHF Km Tp K,- Size
//M mins //M daltons
Type III 2 0.03* > 12* 0.4 0.019 16900
pUN972 2 0.02 > 12 0.4 0.04 17000
* Established from E. coli pFE1242
(pUN972) and E. coli JM83 (pFE1242) as before; prior to isoelectric focusing the
resuspended 80% ammonium sulphate precipitate was diluted 1 in 5 in buffer A
containing 0.75mM NADPH and dialysed against buffer A (100 volumes) for 4
hours. Ten yX of each sample was then focused and stained as described in the
Materials and Methods. The two enzymes co-migrated (figure 24) confirming that
they were identical. Analysis of the distance moved by the pi markers showed
that each enzyme had a pi of 6.10.
3.4 Low Level Trimethoprim Resistant Dihy¬
drofolate Reductases from Two Outbreaks
of Shigella sonnei
The combination of trimethoprim and sulphamethoxazole (cotrimoxazole) is widely
used in the treatment of Shigellosis (Salter, 1982). Until recently trimethoprim
resistance in Shigella was relatively uncommon (Barada and Guerrant, 1980),
however, increased use of trimethoprim-containing therapy in the treatment of
Shigellosis has resulted in a large increase in trimethoprim resistance (Elwell
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Figure 24. Isoelectric focusing of partially purified dihydrofolate reductase from
E. coli HB101 (pUN972) and E. coli JM83 (pFE1242).
Track A: Dihydrofolate reductase encoded by pUN972





and Fling, 1989). Some studies on trimethoprim resistant Shigella have demon¬
strated the dominance of the type la dihydrofolate reductase when the genes were
probed with dihydrofolate reductase gene probes (Delgado and Otero, 1988). On
the other hand, alternative studies have shown a significant proportion of strains
which do not probe with genes coding for either of the commonly occurring type
I and type II enzymes (Chatkaeomorakot et al., 1987).
Outbreaks of trimethoprim resistant Shigella have been extremely rare in the
United States (Murray, 1986). However two outbreaks of dysentery caused by
trimethoprim resistant Shigella sonnei have been examined. The first outbreak
occurred at a nursing home in East Tennessee in 1985 and involved 60 patients
and several medical personnel. The second outbreak was at the Rainbow Family
gathering in the Smokey Mountains National Park in North Carolina in 1987,
which involved 6000 people (C.D.C., 1987a).
3.4.1 Isolation and Probing of the Trimethoprim Resis¬
tance Genes
Isolation and probing of the trimethoprim resistance genes was carried out by Dr
Neil Barg, Vanderbilt University, Tennessee. E. coli C600 transconjugants were
obtained from the Shigella sonnei responsible for each outbreak. Transconju¬
gants from the nursing home strains contained only a 97.5 kb plasmid (pBH600)
that transferred resistance to chloramphenicol, streptomycin, sulphamethoxazole,
tetracycline and trimethoprim. Transconjugants of the National Park strains
contained a 90 kb plasmid (pBH700) that transferred antibiotic resistance to
ampicillin, streptomycin, sulphamethoxazole and trimethoprim.
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Conjugation experiments between strains containing pBHGOO or pBH700 yielded
transconjugants that contained two plasmids 97.5 kb and 90 kb in size. Since both
R-plasmids could co-exist stably, in the same strain without selective pressure,
the pBHGOO and pBH700 plasmids were of different incompatibility groups. The
two plasmids also gave different restriction patterns after cleavage with EcoRl,
Hindlll or Pstl.
Hybridisation
Southern blots prepared from Pstl digests of pBH600 and pBH700 did not show
hybridisation with probes for types I, II and III dihydrofolate reductases. The
trimethoprim resistance genes were subcloned into plasmid pUC9. Subcloning of
plasmid pBH600 produced the hybrid plasmid pBH6001a, the trimethoprim re¬
sistance gene residing within a 1600bp Pstl fragment. In the case of pBH700, an
1800 bp Pstl fragment of the hybrid plasmid, pBH7001a, contained the trimetho¬
prim resistance gene. Probes prepared from these hybridised to the respective
parent plasmids and not to plasmids pFE872, pUC4-12 and pFE1242, encoding
dihydrofolate reductases types I, II and III respectively. The two probes did not
hybridise to each other, E. coli chromosomal DNA or lambda phage DNA.
The hybridisation data suggested that there may be two distinct plasmid-encoded
trimethoprim resistance genes that were not only different from each other but
also distinct from those previously reported. In order to confirm this, detailed
biochemical characterisation was carried out on the two enzymes.
The enzyme from the nursing home outbreak was examined in the E. coli C600
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(pBH600) transconjugant of the original strain as there was sufficient dihydro-
folate reductase activity in this strain. However in the case of E. coli C600
(pBH700), the transconjugant from the Shigella sonnei responsible for the Na¬
tional Park outbreak there was little detectable dihydrofolate reductase activity.
In this case the dihydrofolate reductase was recovered from the E. coli JM101
strain harbouring plasmid pBH7001a.
3.4.2 Biochemical Properties of the Dihydrofolate Re¬
ductase Encoded by Plasmid pBH600
Molecular Mass
Enzyme was prepared from E. coli C600 (pBH600) as described in the Materials
and Methods and one ml of the resuspended 80% saturation ammonium sulphate
precipitate was separated on a Sephadex G50 column. This had been previously
calibrated with chymotrypsinogen cytochrome C and the chain B of insulin as
molecular mass standard markers. The column was equilibrated with buffer A
and the enzyme was eluted in the same buffer. Two ml fractions were collected
from the column and these were assayed for dihydrofolate reductase activity.
A distinct peak of dihydrofolate reductase activity was obtained at fraction 52
and this corresponds to a molecular mass of 17,000. As this was close to the
molecular mass of the chromosomal enzyme the assays repeated in the presence
of 4^<M trimethoprim and the peak was again found at fraction 52 (figure 25). A
molecular mass of 17000 was low but it was very similar to the size reported for
the type III enzyme which is 16,900 (Joyner et al., 1984). Fractions 50 to 56 were
pooled for further biochemical analysis.
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Figure 25. Elution of the DHFR activity of E. coli C600 (pBH600) on Sephadex
G50 gel filtration.
DHFR activity was assayed in the presence of 4 x 10~6M Tp. The elution points
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Figure 26. Trimethoprim inhibition of partially purified dihydrofolate reductase










The activity of the partially purified enzyme encoded by plasmid pBH600 was
assayed in the presence of different concentrations of trimethoprim (figure 26).
The enzyme was relatively sensitive to trimethoprim and had an ID50 of only
2/fM.
Inhibition by Methotrexate
The enzyme encoded by plasmid pBH600 was sensitive to methotrexate. Assaying
its activity in different methotrexate concentrations showed that only 0.02//M was
required to reduce the enzymes activity by 50% (figure 27).
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Figure 27. Methotrexate inhibition of partially purified dihydrofolate reductase











The enzyme derived from the nursing home strain was heat stable maintaining
more than 50% of its activity after 12 minutes incubation at 45°C.
Michaelis Menten Kinetics
The activity of the enzyme was assayed in limiting concentrations of the sub¬
strate dihydrofolate. The results were analysed by the Lineweaver-Burk plot
(figure 28) and this revealed that the enzyme had a relatively high affinity for
dihydrofolate with a Km of 9.52/<M. When the assays were repeated in the pres¬
ence of inhibitory concentrations of trimethoprim, 2 and 5 the enzyme was
competitively inhibited by this drug with a mean I<8 of 0.40^M.
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Figure 28. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli C600 (pBH600).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
I fM-1
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Table 30. Biochemical properties of the type III plasmid-encoded dihydrofolate
reductases.
Enzyme Tp MIC Tp ID50 Mtx ID50 TD50 DHF Km Tp K, Size pi
Sub-Type mg/L /zM /zM mins /zM /zM daltons
Ilia 64 2.0 0.02 > 12 0.4 0.019 16900 6.10
Illb 128 2.0 0.02 > 12 9.52 0.40 17000 5.34
IIIc 256 3.0 0.007 8 3.12 0.52 22000 5.65
Examination of the properties of the dihydrofolate reductase from pBH600 showed
that it had several properties that were identical to the type III enzyme (table 30)
although the enzyme did differ in its Michaelis Menten Kinetics from the type
III. The results suggested that this may be a closely related enzyme and for this
reason it was named the type Illb and the original type III renamed the type
Ilia.
3.4.3 Biochemical Analysis of the Dihydrofolate Reduc¬
tase Encoded by Plasmid pBHTOOla
Molecular Mass
Dihydrofolate reductase was prepared from E. coli JM101 (pBH7001a) as de¬
scribed in the Materials and Methods and separated on a Sephadex G75 column.
This had been calibrated with ovalbumin, chymotrypsinogen and cytochrome C
as standard molecular mass markers. The enzyme was eluted in buffer A and
2 ml fractions collected, these were assayed for dihydrofolate reductase activity
(figure 29). A clearly defined peak was obtained at fraction 62 and this corre¬
sponded to a molecular mass of 22,000. Repeating the assays in the presence of
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4/xM trimethoprim produced a peak at the same point. Peak fractions (58 - 66)
were pooled for further biochemical analysis.
Inhibition by Trimethoprim
The activity of the enzyme was measured in the presence of different trimetho¬
prim concentrations (figure 30). This showed that the enzyme was sensitive to
trimethoprim with an ID50 of 3.0/iM.
Inhibition by Methotrexate
The dihydrofolate reductase encoded by plasmid pBH7001a was extremely sensi¬
tive to methotrexate. The activity of the enzyme decreased by half in the presence
of 0.007^<M methotrexate (figure 31).
Heat Sensitivity
The enzyme was only relatively heat stable losing 50% of its activity after 8
minutes at 45°C.
Michaelis Menten Kinetics
The activity of the enzyme was assayed in limiting substrate dihydrofolate con¬
centrations with and without trimethoprim (figure 32). This demonstrated that
the enzyme had a relatively high affinity for dihydrofolate (Km 3.12^M) and was
competitively inhibited by trimethoprim (K,- 0.52//M).
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Figure 29. Elution of DHFR activity of E. coli JM101 (pBH7001a) on Sephadex
G75 gel filtration.
Elution points of standard proteins are also shown.
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Figure 30. Trimethoprim inhibition of partially purified dihydrofolate reductase










Figure 31. Methotrexate inhibition of partially purified dihydrofolate reductase











Figure 32. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli JM101 (pBH7001a).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
Tp concentrations: 8-1
• No Tp
O 2 x 10-6M Tp 7"
A8 x 10-6M Tp
I
-0.36 -0.32 -0.28 -0.24 -0.20 -0.16 -0.12 -0.08 -0.04
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Biochemically the enzyme encoded by pBH7001a, derived from the strain re¬
sponsible for the National Park outbreak, was similar to both the Ilia and Illb
enzymes and was, therefore, termed IIIc (table 30). Although all three enzymes
show similar antifolate inhibition profiles, the type IIIc appears to be more heat
sensitive than the other two. The Illb and IIIc have similar Michaelis Menten
Kinetics to one another and they are significantly different from the type Ilia.
On the other hand, the molecular mass of the Illb is indistinguishable from the
Ilia however the IIIc is heavier.
DNA gene probing had suggested that the enzymes from each outbreak were
different from each other and that neither was a type Ilia enzyme. The results of
the biochemical analysis had demonstrated that while this may be the case, the
differences between the enzymes were very small. In order to confirm that these
were three distinct enzymes isoelectric focusing was used.
3.4.4 Isoelectric Focusing of the Type Ilia, Illb and IIIc
Dihydrofolate Reductases
Types Ilia, Illb and IIIc dihydrofolate reductases were prepared from E. coli
JM83 (pFE1242), E. coli C600 (pBH600) and E. coli JM101 (pBH70001a) re¬
spectively. After enzyme extraction in the normal way the resuspended 80%
saturation ammonium sulphate precipitate from each preparation was diluted 1
in 5 in buffer A containing 0.75mM NADPH, and dialysed for four hours against
100 volumes of buffer A. Ten /il of each dialysed sample was subsequently elec-
trophoresed as described in the Materials and Methods. The gel was stained for
dihydrofolate reductase activity also as described in the Materials and Methods.
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The results (figure 33) showed that the three enzymes produced a distinct and
different pattern on an isoelectric focusing gel. Analysis of the distance moved by
the pi markers enabled the pi of each dihydrofolate reductase to be established.
As before the type Ilia focused clearly and had a pi of 6.10, the Illb enzyme also
gave a defined band and this corresponded to a pi value of 5.34. The IIIc enzyme,
however, did not focus as well as the other two enzymes and produced a smeared
band at pi 5.65. This proved to be a characteristic of this enzyme and when the
gel was repeated with a fresh preparation of type IIIc dihydrofolate reductase the
same pattern was obtained.
The results from isoelectric focusing had confirmed that the two enzymes from
the Shigella outbreaks were different from each other and that neither was a type
Ilia enzyme. There were, however, very strong biochemical similarities between
the three, suggesting that they may be closely related in an evolutionary sense.
Although isoelectric focusing had demonstrated that the enzymes were different
from one another it gave no indication of the degree of difference.
The amino acid sequence of the type Ilia enzyme is known (Fling et al., 1988)
therefore if the sequences of the Illb and IIIc dihydrofolate reductases could be
determined this would indicate if these enzymes were closely related. Attempts
were therefore made to purify the Illb and IIIc dihydrofolate reductases in order
to establish their amino acid sequences.
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Figure 33. Isoelectric focusing of partially purified dihydrofolate reductases from
E. coli JM83 (pFE1242), E. coli C600 (pBH600) and E. coli JM101 (pBH7001a).
Track A: Dihydrofolate reductase encoded by pBH600 (type Illb)
Track B: Dihydrofolate reductase encoded by pBH7001a (type IIIc)
Track C: Dihydrofolate reductase encoded by pFE1242 (type Ilia)
ABC
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3.4.5 Purification of the type Illb Dihydrofolate Reduc¬
tase
Purification was performed as for the type IV dihydrofolate reductase (figure 10).
Enzyme was prepared from E. coli C600 (pBH600) incubated shaking at 37°C
for 20 hours in 10 litres of Oxoid Isosensitest broth. Dihydrofolate reductase was
extracted as described in the Materials and Methods and the resuspended 80%
ammonium sulphate precipitate was concentrated to 2 ml with an Amicon Cen-
triprep 10 Concentrator. The activity of the enzyme preparation was measured
throughout the purification procedure and the 2 ml concentrate contained 78,124
units of dihydrofolate reductase activity. The 2 ml concentrate was separated on
a Sephadex G75 column and 2 ml fractions collected. Analysis of these showed
that a clearly defined peak of enzyme activity was obtained, (figure 34) fractions
62 - 72 were pooled and the activity reassayed, revealing a total of 28,874 units
were present. The pooled fractions were run onto a methotrexate agarose column.
No dihydrofolate reductase activity was detected in the protein, which initially
passed through the column, indicating that the enzyme had completely bound to
the methotrexate agarose.
The column was washed continuously with buffer A until the absorbance, at
280nm, of the eluate had returned to an OD of less than 0.01 i.e. no further
protein was passing through. The dihydrofolate reductase activity was eluted by
the addition of 2 ml of 1M K2HPO4, 2 ml 0.5M K2HPO4 containing 4 /xmoles
of dihydrofolate and 75 ml 0.1M K2HPO4 containing 1^/M dihydrofolate. Five
ml fractions were collected and assayed for enzyme activity, the three fractions
showing peak activity were pooled and contained a total of 19,933 units. This
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Figure 34. Elution of DHFR activity of E. coli C600 (pBH600) on Sephadex G75
gel filtration.
Enzyme had been prepared from a large scale (10L) culture.
FRACTION NUMBER
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15 ml sample was concentrated with Amicon Centriprep 10 and Centricon 10
Concentrators to 30//1, which retained 16,499 units. Before sequence analysis this
concentrate was tested for purity by reverse phase HPLC and this revealed the
presence of a single protein peak.
3.4.6 N-terminal Sequence Analysis of the type Illb Di-
hydrofolate Reductase
Fifteen /il of the purified sample was analysed on an Applied Biosystems 477A
automatic sequencer and this gave a clear result for the first 47 amino acids
(figure 35). The molecular mass of the enzyme suggested a protein of 162 amino
acids, thus approximately 30% of the enzyme had been examined. The sequence
obtained starts with a threonyl residue indicating that the initial f-methionyl
must have been removed intracellularly. Comparing the sequence with that of
the other plasmid-encoded dihydrofolate reductases (type I - V and Si) showed
this enzyme was clearly distinct (figure 36). Although biochemically similar to
the type Ilia enzyme, the Illb showed no significantly greater homology with this
enzyme than with many of the other plasmid-mediated dihydrofolate reductases.
3.4.7 Subunit Structure of the type Illb Dihydrofolate
Reductase
The subunit structure of the Illb enzyme was examined by running the purified
enzyme on SDS polyacrylamide gel electrophoresis. The type Illb sample was
run on a 10 - 15% Pharmacia Phastsystem SDS gel according to manufacturer's
instructions. Sigma molecular weight markers (14,000 - 66,000) were run adjacent
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to the sample in order to estimate its molecular mass, and the protein bands were
visualised by staining with coomassie blue. After electrophoresis on the SDS gel
the purified type Illb enzyme produced a single band of protein when stained
(figure 37), this corresponded to a molecular weight of 17,200. As the molecular
mass of the type Illb under conditions, which do not produce denaturation, is
17,000 this result suggests that the type Illb dihydrofolate reductase must be a
monomeric protein.
3.4.8 Purification of the type IIIc Dihydrofolate Reduc¬
tase by Affinity Chromatography
The type IIIc enzyme was purified from E. coli JM101 (pBH7001a) incubated
shaking at 37°C for 20 hours in 10 litres of Oxoid Isosensitest broth and enzyme
was extracted as before. The resuspended ammonium sulphate precipitate was
concentrated to 2 ml with an Amicon Centriprep 10 Concentrator. Separation
by Sephadex gel filtration on a G75 column produced a clearly defined peak of
enzyme activity which corresponded to a molecular mass of 23,000 (figure 38)
fractions 56 to 65 were pooled and this contained a total of 28,874 units.
The pooled fractions were run onto a methotrexate column. In this case consid¬
erable dihydrofolate reductase activity was detected in the protein which initially
passed through the column indicating that the enzyme had not bound. One pos¬
sible reason for this was that the methotrexate column had been used several
times before and it may have been that it was no longer functioning properly.
Therefore a second attempt at purification was carried out with a freshly prepared
methotrexate column.
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Figure 37. SDS polyacrylamide gel electrophoresis of the purified dihydrofolate
reductase from E. coli C600 (pBH600). Standard marker proteins are also shown.
Track A: Type Illb dihydrofolate reductase
Track B: Standard marker proteins (14,000 - 66,000)
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Figure 38. Elution of the DHFR activity of E. coli JM101 (pBH7001a) on
Sephadex G75 gel filtration.
Enzyme had been prepared from a large scale (10L) culture.
FRACTION NUMBER
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An enzyme extract was prepared as before from E. coli JM101 (pBH7001a) and
separated by gel filtration (figure 39). Pooled fractions 55 to 68 were applied onto
the methotrexate column and the dihydrofolate reductase activity in the eluate
which initially passed through was examined. Again considerable dihydrofolate
reductase activity was found indicating that the type IIIc enzyme had again not
bound to the column, as a fresh column had been used this suggested that the lack
of binding must result from a peculiarity of the type IIIc enzyme. The type IIIc
enzyme is as methotrexate-sensitive as the type Illb dihydrofolate reductase (ID50
0.007//M) and it would thus be expected to bind. Dihydrofolate reductase which
had passed through the column was assayed in the presence of methotrexate and
found to be methotrexate sensitive losing 70% of its activity in the presence of
0.02//M methotrexate.
Although dihydrofolate reductase was passing through the affinity column some
may have been binding and this may be sufficient for sequence analysis. A
fresh methotrexate agarose column was prepared and enzyme was extracted from
E. coli JM101 (pBH7001a) as before. The IIIc dihydrofolate reductase was sep¬
arated on a Sephadex G75 column and peak fractions pooled. The pooled frac¬
tions contained 69,781 units and this was run onto the methotrexate column. The
enzyme activity of the protein which had passed through without binding was
assayed and this accounted for 53,025 units. The column was washed with buffer
A until no more protein came off. Elution of any dihydrofolate reductase that
may have bound was attempted by the addition of 2 ml 1M K2HPO4, 2 ml 0.5M
K2HPO4 containing 4 //moles dihydrofolate then 75 ml of 0.1M K2HPO4 contain¬
ing 1//M dihydrofolate. Five ml fractions were collected and these were assayed
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Figure 39. Elution of DHFR activity of E. coli JM101 (pBH7001a) on Sephadex
G75 gel filtration.
Enzyme had been prepared from a large scale (10L) culture.
FRACTION NUMBER
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for dihydrofolate reductase activity, a small amount was found in fractions 2 and
3. These two fractions were pooled and concentrated with Amicon Centriprep
10 and Centricon 10 Concentrators to 55 fil. This was assayed for dihydrofolate
reductase activity and contained 756 units, which meant that 16,000 units had
been lost during the affinity chromotography step. This was probably due to the
effect of the methotrexate on the enzyme as it passed through the column as the
enzyme is very sensitive to this drug.
The concentrated eluate was analysed by HPLC, and four peaks were obtained.
One was significantly larger than the others which were probably breakdown
products of this major protein. The large peak was taken for sequence analysis
but no sequence could be obtained.
The reason why the IIIc dihydrofolate reductase could not be purified by methotrex¬
ate agarose chromotography was not clear although a similar situation has been
found with the methotrexate sensitive plasmid-encoded type Si enzyme from S.
aureus (Hartman et al., 1988).
3.4.9 FPLC Purification of the Type IIIc Dihydrofolate
Reductase
Because of the failure to purify the IIIc enzyme by methotrexate agarose affinity
chromotography another method was tried: separation on an anion exchange
column, as this can be used to purify dihydrofolate reductase (Iwakura et al.,
1983). Enzyme was prepared in the normal way from E. coli JM101 (pBH7001a)
and separated on a Sephadex G75 column (figure 40), fractions 60 to 68 were
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pooled and contained 16,499 units. This was concentrated to 2 ml with an Amicon
Centriprep 10 Concentrator and then separated on a Mono Q anion exchange
column in a Pharmacia FPLC as described in the Materials and Methods.
The collected fractions were assayed for dihydrofolate reductase activity but none
could be detected. The reason for this may be because the IIIc was unstable in
the running buffer used or it may be related to the enzyme's peculiar response
on isoelectric focusing.
The inability to purify the IIIc enzyme meant that its sequence could not be
determined and compared with the Ilia and Illb. If the sequence of this enzyme
is to be established it will need to be achieved from the DNA base sequence of
the type IIIc gene.
C. Type V Dihydrofolate Reductase
The type V plasmid-encoded dihydrofolate reductase was identified during a sur¬
vey of antibiotic resistance in Sri Lanka (Sundstrom et al., 1987). The enzyme
confers high level resistance on the host bacterium (MIC > 1000 mg/L), and the
novel nature of the gene, encoding the type V enzyme, was detected because of
its inability to hybridise with gene probes representing dihydrofolate reductase
type la and II. Partial biochemical characterisation of the enzyme revealed that
it behaved differently on an anion exchange column from both the type la and
II enzymes and it had about a 10-fold lower resistance to trimethoprim than the
type la (Sundstrom et al., 1987; Skold, 1988). The enzyme was subsequently
named the type V (Huovinen, 1987).
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Figure 40. Elution of DHFR activity of E. coli JM101 (pBH7001a) on Sephadex
G75 gel filtration.
Enzyme had been prepared from a large scale (10L) culture.
FRACTION NUMBER
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In the original study, trimethoprim resistant strains had been isolated from all
over Sri Lanka and it appeared that the type V enzyme was ubiquitous. Unusually
the incidence of the type la dihydrofolate reductase was very low (Sundstrom et
al., 1987). Before any firm conclusions regarding the origins of the type V enzyme
could be made further biochemical characterisation was required.
Therefore a complete biochemical profile was performed on the type V dihydrofo¬
late reductase encoded by plasmid pLK09. This recombinant plasmid contained
a 1.25 kb insert which included the trimethoprim resistance gene originally from
plasmid pLM020 which was transferred from an isolate of Enterobacter agglom-
erans (Sundstrom et al., 1987).
3.4.10 Biochemical Analysis of the Dihydrofolate Reduc¬
tase Encoded by Plasmid pLK09
Dihydrofolate reductase was prepared from E. coli HB101 (pLK09) and the crude
extract was treated with streptomycin sulphate followed by ammonium sulphate
as described in the Materials and Methods. One ml of the resuspended pellet
from the 80% ammonium sulphate precipitate was applied to a freshly calibrated
Sephadex G75 column (90 cm x 2 cm2).
Two ml fractions were collected and assayed for dihydrofolate reductase activity
(figure 41). A small peak of dihydrofolate reductase activity was detected at
fraction 60 and a rising level of activity between fractions 72 and 88. The activity
at fraction 60 could be inhibited by the addition of 4//M trimethoprim, this
fraction corresponds to a molecular mass of 21,000 and clearly represents the
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The activity which appeared as a peak at fraction 88 was resistant to trimetho¬
prim at a concentration of 4//M and must result from the plasmid-encoded type
V enzyme. Elution from the column at this point suggests the type V enzyme
is very small and an accurate molecular mass could not be obtained from a G75
column.
To establish a precise mass for this enzyme, it was prepared from E. coli HB101
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(pLK09) as before and 1 ml of the resuspended 80% ammonium sulphate precip¬
itate applied to a calibrated Sephadex G50 column (90 cm x 2 cm2) and 2 ml
fractions collected every 13.5 minutes.
Analysis of the collected fractions for dihydrofolate reductase activity revealed a
small amount of dihydrofolate reductase at fraction 40 (not shown) which was
trimethoprim sensitive and corresponded to the chromosomal enzyme. A major
trimethoprim resistant peak of activity was detected at fraction 74 (figure 42) and
this corresponds to a molecular mass of 2 - 3000 which is unusually low. Peak
fractions were pooled and further biochemical analysis performed.
Inhibition by Trimethoprim
The activity of the type V enzyme was assayed under normal conditions but in the
presence of different concentrations of trimethoprim. The results (figure 43) show
that the activity was directly proportional to the logarithm of the trimethoprim
concentration. The type V enzyme appears moderately resistant with an ID50 of
8//M.
Inhibition by Methotrexate
Similarly the activity of the enzyme was assayed in different methotrexate con¬
centrations. Again enzyme activity was proportional to the logarithm of the
methotrexate concentration (figure 44). A 50% reduction in enzyme activity was
achieved with a methotrexate concentration of 1.5/rM.
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Figure 42. Elution of DHFR activity of E. coli HB101 (pLK09) on Sephadex G50
gel filtration. The elution points of standard marker proteins are also shown.




Figure 43. Trimethoprim inhibition of partially purified dihydrofolate reductase




Figure 44. Methotrexate inhibition of partially purified dihydrofolate reductase

















The partially purified enzyme was incubated in a prewarmed container at 45°C
for various time intervals. The activity of the sample was measured. The type V
enzyme was found to be heat sensitive losing half of its activity after 3 minutes at
45°C. This is in contrast to Sundstrom et al. (1987) who reported the enzyme to
be heat stable maintaining 80% of its activity after 5 mins at 45°C. The difference
may have resulted from the presence of stabilising protein. Therefore the heat
stability of the enzyme was compared when partially purified from a Sephadex
column and as a crude protein extract. The results (figure 45) demonstrated
that the type V enzyme was heat stable only when a significant amount of other
proteins were present.
Michaelis Menten Kinetics
The activity of the type V enzyme was assayed in the presence of decreasing dihy-
drofolate concentrations in the presence of different trimethoprim concentrations.
The results were analysed by the method of Lineweaver and Burk (figure 46). The
Km value for the type V enzyme was 66pM indicating a moderate affinity for the
substrate.
When the enzyme's activity was measured in the presence of 8 and 16 /iM
trimethoprim the response to decreasing substrate was also first order kinetics and
the inverse plot intercepted the ordinate at the same point as the line obtained
in the absence of trimethoprim. This indicates that trimethoprim inhibition of
the enzyme was competitive. The type V had a mean Kt of 2.5/xM.
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Figure 45. Heat sensitivity of the dihydrofolate reductase from E. coli HB101
(pLK09).
O crude enzyme extract
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Figure 46. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli HB101 (pLK09).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
Tp concentrations:
• No Tp
O 8 x 10-6M Tp
A 1.6 x 10-5M Tp
| pM-1
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Table 31. Biochemical properties of the type V dihydrofolate reductase from
E. coli HB101 (pLK09).
Enzyme Tp ID50 Mtx ID50 TD50 DHF Km Tp K8 Size
fiM /uM mins pM //M daltons
la 57 4.4 0.5 5.6 7.4 35000
V 8 1.5 3.0 66 2.5 3000
The results obtained for the type V enzyme were compared with the biochemical
profiles of the other plasmid-mediated dihydrofolate reductases. With the excep¬
tion of the low molecular mass, the type V enzyme appeared most similar to the
type la dihydrofolate reductase (table 31). The type V enzyme had a very similar
K;, was heat sensitive and there was less than a tenfold difference in inhibition
properties between the two.
If the true molecular mass of the enzyme was between 2,000 and 3,000, it was dif¬
ficult to envisage how the enzyme could remain active. A more likely explanation
was that the type V enzyme was, in some way, retarded in its progress through
the column thus giving an artificially low molecular mass. A less likely explana¬
tion could be that, during the cloning procedure, part of the gene had been cut,
resulting in a dihydrofolate reductase of lower molecular mass. However it was
difficult to perceive how such a small protein could be active. Therefore in order
to confirm the molecular mass and properties, biochemical characterisation was
carried out on the dihydrofolate reductase encoded by another type V clone. A
489 bp Hpa 1 fragment encoding trimethoprim resistance inserted into the Sma 1
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site of pUCl8 to give pUK2000 (0. Skold, personal communication).
3.4.11 Biochemical Properties of the Dihydrofolate Re¬
ductase Encoded by Plasmid pUK2000
The type V enzyme was prepared from E. coli HB101 (pUK2000) containing this
recombinant plasmid and 1 ml of the resuspended pellet from the 80% ammo¬
nium sulphate precipitation was separated by Sephadex gel filtration on a G50
column. To obtain an accurate molecular mass it was necessary to have a molec¬
ular weight marker smaller than the type V enzyme. Therefore the column was
calibrated with chymotrypsinogen and cytochrome C as before, but with the B
chain of insulin (Mr=3878) as the low weight marker. A clearly defined peak of
trimethoprim resistant dihydrofolate reductase activity was obtained at fraction
80 (figure 47) and this corresponded to a molecular mass of 5,000. The peak
fractions (74 to 85) were pooled and used for further biochemical analysis.
Inhibition Properties of Trimethoprim and Methotrexate
The activity of the enzyme was measured with different trimethoprim concentra¬
tions and found to be 50% inhibited by a trimethoprim concentration of 20/zM.
For methotrexate the amount required to reduce the activity by half was 2.3^/M
(figure 48).
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Figure 48. Methotrexate and trimethoprim inhibition of partially purified dihy-
drofolate reductase from E. coli HB101 (pUK2000).
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The activity of the type V enzyme was assayed under limiting dihydrofolate
concentrations in the presence and absence of trimethoprim. The reciprocal of
enzyme activity and dihydrofolate concentration were plotted (figure 49). The
Km, for dihydrofolate, of the enzyme was calculated as 15.4//M and the Kt- for
trimethoprim was 3.2//M.
The results obtained from the dihydrofolate reductase encoded by pUK2000 were
in agreement with those from the pLK09 encoded enzyme and were very similar
to the type la enzyme except for the apparent low molecular weight (table 32).
The results confirmed that the type V must be retained in the column. Assuming
the type la and type V are closely related it should be possible to alter the type
la enzyme so that it is retained in the column.
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Figure 49. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli HB101 (pUK2000).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
Table 32. Biochemical properties of the type V dihydrofolate reductase from
E. coli FIB 101 (pUK2000).
Enzyme Tp ID50 Mtx ID50 DHF Km Tp K; Size




57 4.4 5.6 7.4 35000
8 1.5 66 2.5 3000
20 2.3 15.4 3.2 5000
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Figure 50. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli C600 (pFE872).
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the
reciprocal of the dihydrofolate reductase activity (1/V).
i/iM-1
3.4.12 Preparation of the type la Dihydrofolate Reduc¬
tase
A crude type la enzyme extract was prepared from E. coli C600 (pFE872). The
activity of the enzyme was measured in limiting dihydrofolate concentrations
(figure 50) and the Km calculated to be 23/iM. A sample of this crude extract was
dialysed for four hours against lOmM pH 6.0 sodium phosphate buffer containing
lOmM mercaptoethanol in an attempt to disrupt the enzyme, this is a lower pH
and ionic strength than the normal buffer and contains no stabilising EDTA.
After dialysis the enzyme retained 80% of its previous activity and was still
trimethoprim resistant at 4//M. However the Km of the enzyme was 200/iM (fig¬
ure 51) 10 fold higher than before dialysis. Two ml of the dialysed enzyme was
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run on a Sephadex G50 column which had been equilibrated with the same buffer
that had been used for dialysis and 1.8 ml fractions were collected every 10 min¬
utes. Activity was assayed from each of the collected fractions but none could
be detected. This may have been because the enzyme was too unstable in the
absence of EDTA to survive gel filtration. To try and overcome this problem, the
experiment was repeated with 1 mM EDTA in the buffers. The same pattern was
observed; there was a slight reduction in activity after dialysis but no activity
could be detected after 2 ml of the dialysed sample was run through a Sephadex
G50 column.
This suggested that after dialysis the type la enzyme must be very unstable in
low protein concentrations. To examine this the effect of dilution on enzyme
stability was investigated. A crude type la extract was dialysed against lOmM
sodium phosphate pH 6.0 buffer containing lOmM mercaptoethanol and ImM
EDTA for four hours then divided into two aliquots. One of these was diluted 1
in 20 in the same buffer while the other aliquot remained undiluted. The activity
in each sample was measured before and after 8 hours at +4°C. The results
demonstrated that the dialysed enzyme is unstable when diluted losing 50% of
its activity in 8 hours whilst the undiluted sample retained 96% of its activity.
This loss of activity occurred after a 1 in 20 dilution. When an extract is run on
a Sephadex column it is diluted approximately 1 in 100, as the dialysed extract is
evidently unstable when diluted this would explain why no activity was detected
after Sephadex gel filtration.
Although the dialysis was affecting the properties of the type la enzyme, the
dialysed sample was too unstable to run through the Sephadex column. There-
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Figure 51. Lineweaver-Burk plot of the partially purified dihydrofolate reductase
from E. coli C600 (pFE872) after dialysis in lOmM pH 6.0 sodium phosphate
buffer containing lOmM mercaptoethanol.
The reciprocal of the substrate concentration (DHF) (1/S) is plotted against the




fore another approach was tried, an undialysed sample of type la enzyme was
subjected to gentle disruption by freezing and thawing. A 2 ml sample was then
loaded onto a Sephadex G50 column equilibrated with buffer A and 1.8 ml frac¬
tions collected.
The fractions at the end of the run were assayed for dihydrofolate reductase
activity (figure 52). Trimethoprim sensitive chromosomal enzyme was detected
in fractions 44 to 50, however low amounts of trimethoprim resistant dihydrofolate
reductase were found in fractions 72 to 90. This corresponds to a low molecular
mass (less than 5000) and is similar to the type V. The result demonstrated that
the type la and V behaved in a similar fashion and might be closely related.
In addition, it demonstrated that the low molecular mass of the type V from
Sephadex was not its true weight. Attempts were therefore made to measure the
mass of the type V by a further method.
3.4.13 Estimations of Molecular Mass
Firstly in order to establish that the type V did not have a low molecular mass
attempts were made to pass the enzyme through a filter with a molecular weight
cut off of 10,000.
A crude type V extract was prepared from E. coli HB101 (pUK2000), after estab¬
lishing that this preparation was active 5 ml were spun in an Amicon Centriprep
10 Concentrator. This has a molecular weight cut off of 10,000 and only proteins
of lower mass than this can pass through the filter and are collected in the filtrate
collector. After three centrifugations at 4000g the filtrate was assayed for dihy-
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Figure 52. Elution of DHFR activity (after disruption by freeze thawing) of
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drofolate reductase activity and none was found. The retentate was still active
indicating that none of the enzyme had passed through and that the molecular
mass of the type V was greater than 10,000.
Native PAGE
The type la and type V enzymes have similar biochemical properties except for
their molecular mass when they are measured by gel filtration. The previous
experiment had confirmed that the molecular mass of the type V, measured by
gel filtration, was not its true mass. Therefore the molecular mass of the two
enzymes were compared by the alternative method of native PAGE.
The type la and type V enzymes were prepared from E. coli C600 (pFE872) and
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E. coli HB101 (pUK2000) respectively and partially purified with ammonium
sulphate. A sample of each was diluted in bromophenol blue and loaded onto a
20% homogeneous SDS-free polyacrylamide gel. The gel was run in a Pharmacia
Phastsystem until the bromophenol blue dye front had reached the end of the
gel.
As the two enzymes were not purified a specific stain had to be used rather
than coomassie blue. The gel was stained for dihydrofolate reductase activity as
described in the Materials and Methods (figure 53). The two enzymes co-migrated
which indicated that the true mass of the type V enzyme was indeed 35,000 and
underlined the inherent similarities between the two enzymes. A sample of the
type VII dihydrofolate reductase, which also has similar properties to the type la
but a lower molecular mass when measured by gel filtration (Amyes et al., 1989)
was run alongside. However, unlike the type V dihydrofolate reductase the type
VII enzyme genuinely appeared smaller than the type la.
The similarity in biochemical properties between the type la and type V dihy¬
drofolate reductases, including their similar molecular masses, suggested these
enzymes were closely related. Subsequently the gene encoding the type V dihy¬
drofolate reductase has been sequenced, this confirms the similarity of the two
enzymes and the open reading frame predicts an enzyme with subunits of the
same molecular mass as the type la (Sundstrom et al., 1988).
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Figure 53. SDS free polyacrylamide gel electrophoresis of partially purified dihy-
drofolate reductases from E. coli HB101 (pUK2000), E. coli C600 (pFE872) and
E. coli J53_2 (pUN835). C*oa ^ -cknfl.
WXJjaxvCKkA cv*-~c>- O'PJUuoexVj .
Track A: Dihydrofolate reductase encoded by pUN835 (type VII)
Track B: Dihydrofolate reductase encoded by pFE872 (type la)





During the twenty years that trimethoprim has been in clinical use a number of
mechanisms of resistance have been characterised (Huovinen, 1987; Elwell and
Fling, 1989). Of these the most important has been the plasmid-encoded pro¬
duction of an additional trimethoprim-resistant dihydrofolate reductase (Amyes,
1989). The development and spread of this plasmid-mediated resistance has been
studied by biochemical typing of the enzymes responsible, and in recent years,
a number of novel enzymes have been identified (Young and Thomson, 1990).
This probably reflects not only the continuing evolution of plasmid-mediated re¬
sistance, particularly in the Third World, but also reflects more sophisticated
methods for detection and distinguishing between enzymes.
The aims of this thesis have been to examine, in more detail, the biochemical
properties and induction mechanism of the type IV dihydrofolate reductase and
to identify and characterise any novel dihydrofolate reductases which appeared
responsible for plasmid-mediated trimethoprim resistance.
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4.1 Induction of the Type IV Dihydrofolate
Reductase
The type IV enzyme isolated in South India in 1984, is the only plasmid-mediated
dihydrofolate reductase which is inducible. Although hyperproduction of the
Escherichia coli chromosomal dihydrofolate reductase as a resistance mechanism
has been well documented (Baccanari et al., 1975; Sheldon and Brenner, 1976;
Smith and Calvo, 1979), in only one case has this been shown to be inducible
(Tennhammar-Ekman et al., 1986). The type IV dihydrofolate reductase itself
confers only partial resistance on its host. Although the MIC in the host strain
is dependent on the testing media (Young et al., 1986b) the resistance conferred
by the type IV is only moderate even in the optimum medium despite the high
levels of type IV dihydrofolate reductase that can be achieved. Furthermore cell
viability is greatly reduced at trimethoprim concentrations of 160 mg/L when
dihydrofolate reductase production is at its maximum. This is in contrast with the
/?-lactamases, where inducible enzymes confer high levels of resistance (Livermore,
1987). This contrast suggested that the induction mechanism of the type IV
enzyme must be unusual.
Examination of the speed at which Escherichia coli J62_2, containing the type
IV dihydrofolate reductase gene, responded when challenged with trimethoprim,
showed that between 5 and 14 hours was necessary before high levels of dihydro¬
folate reductases were achieved. This contrasts with the induction of the chromo¬
somal enzyme where increased levels of dihydrofolate reductase can be detected
within three minutes of challenge with trimethoprim (Tennhammar-Ekman et al.,
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1986).
It seemed reasonable to presume that the bacteria could not be growing before el¬
evated levels of dihydrofolate reductase were produced, and this was confirmed by
following the viable count of challenged and unchallenged bacteria over a 24 hour
period. It was observed that the viable count of the challenged cells decreased
for 8 hours then increased sharply. This suggested that the induction mecha¬
nism was switched on at around 8 hours and the resulting increased production
of dihydrofolate reductase allowed the bacteria to overcome the inhibitory effects
of the trimethoprim. Gram-staining performed in conjunction with the viable
counts revealed that the drop in viable cells was accompanied by cell elongation.
This was presumably resulting from the metabolic effects of trimethoprim (Pin-
ney and Smith, 1973; Amyes and Smith, 1974c). However, after this point, the
viable count increased and the cells returned to normal.
If Escherichia coli, containing the type IV dihydrofolate reductase gene, are al¬
lowed to grow before being challenged, no induction of the enzyme occurs. This
appeared to be related to the growth in that if bacteria were challenged
in lag phase, high levels of enzyme were produced but this did not occur if the
bacteria were challenged in logarithmic phase.
The fact that the type IV producing Escherichia coli is capable of growing in the
presence of inhibitory levels of trimethoprim, without the necessity of enzyme
induction, does suggest that the induction occurs only when the bacteria are
stressed. It suggests that the resistance mechanism is therefore more akin to
hyperproduction than to a classical bypass system.
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Thymidine is an important antagonist of trimethoprim (Amyes and Smith, 1975)
and its effect on induction is marked. A concentration of 2 mg/L is sufficient to
allow growth of bacteria without induction of dihydrofolate reductase. This cor¬
related with the observation that, in the presence of thymidine, the characteristic
drop in viable count and cell elongation, seen when bacteria are challenged with
trimethoprim, does not occur. This demonstrated that induction was not solely
dependent on the presence of a given trimethoprim concentration. Although
thymidine had a marked effect on induction, suggesting that the trigger for hy-
perproduction may be thymidine starvation, inhibition of the enzyme thymidilate
synthetase with FUdR caused no increase in enzyme production. Clearly other
factors must be involved.
One other area which is certainly important is the presence of metabolites. The
MIC of trimethoprim for Escherichia coli J62_2 (pUK1123) is dependent on the
presence of methionine, adenine and glycine in the media (Young et al., 1986b)
and these are closely involved in folate metabolism (Amyes and Smith, 1974c)
(figure 8). In minimal media, induction of the type IV enzyme is dependent
on the presence of all three of these metabolites. In the absence of any one
of them, bacteria are able to grow without inducing enzyme production. The
importance of these metabolites on induction was further demonstrated by the
fact that when plasmid pUK1123 is transferred to methionine-deficient strains
induction does not occur. The most likely explanation for this is that, in minimal
media containing methionine, glycine and adenine, the presence of trimethoprim
prevents the thymidilate synthetase reaction (Amyes and Smith, 1974c). This,
bearing in mind the effect of thymidine, may be the trigger for enzyme induction.
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If this is the case the reason why FUdR did not cause an increase in dihydrofolate
reductase production was not clear. In minimal media there was also a distinct
inoculum effect.
Trimethoprim is only one of a series of antifolate agents (Sandler and Smith,
1989) and their ability to induce the type IV dihydrofolate reductase was exam¬
ined. Using the same concentrations that had been used for trimethoprim no
induction was obtained. This might be attributable to Escherichia coli J62_2
having higher MICs to these drugs than to trimethoprim. Further studies with
higher concentrations of tetroxoprim and pyrimethamine showed that induction
took place with tetroxcprim. Interestingly, pyrimethamine produced no induc¬
tion even though it inhibited growth at higher concentrations. It is perhaps not
surprising that induction is observed with tetroxcprim as this drug is closely
related to trimethoprim and has the same mechanism of action (Aschhoff and
Vergin, 1979). The reason why pyrimethamine caused no increase in activity
was unclear but is presumably linked to the fact that pyrimethamine is a less
efficient inhibitor of bacterial dihydrofolate reductase (Burchall, 1979).
Induction systems in microbial organisms normally act quickly and, once in expo¬
nential growth, addition of the inducer rapidly elicits maximum production of the
induced enzyme (Wiseman, 1975). It is clear from the results obtained with the
type IV dihydrofolate reductase that this is not a classic induction system. High
levels of enzyme are not apparent until several hours after challenge and induction
does not occur if the bacteria are challenged in logarithmic phase. Furthermore,
inducible enzymes are normally located on the bacterial chromosome, this is true
not only for metabolic systems for example /? galactosidase in Escherichia coli
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(Monod et al., 1962) but also for enzymes conferring resistance to antimicrobial
agents such as the inducible /^-lactamases (Sanders, 1989).
As well as being different because of its plasmid location, the type IV induction
mechanism also differs markedly from the induction of /?-lactamases, where in¬
duction is rapid, peak levels of enzyme occurring in 1 - 2 hours (Sanders, 1989),
and induction leads to high level resistance (Chamberland, 1989).
Hyperproduction of chromosomal dihydrofolate reductase may be relatively well
documented but this is normally the result of stably derepressed mutants, a
situation also seen with /3-lactamases (Chamberland, 1989; Livermore, 1987),
rather than induction. In one case an inducible chromosomal dihydrofolate re¬
ductase has been described and this behaves like most inducible enzymes such
as the /^-lactamases. However the mechanism of induction is not yet understood
(Tennhammar-Ekman et al., 1986).
Investigations of the conditions affecting induction of the type IV dihydrofolate
reductase revealed that induction of this enzyme appears to be a "last ditch"
attempt for the host to survive. Bacteria need to be stressed before induction
occurs; and the presence of a given trimethoprim concentration is not enough, sug¬
gesting that induction is a response to the metabolic effects of the trimethoprim.
Probably the result of stress on the tetrahydrofolate pool although undoubtedly
other factors are involved.
Bearing in mind that the type IV enzyme is only partially resistant to trimetho¬
prim (ID50 0.2/tM) this suggests that the resistance mechanism appears to be
much more similar to a chromosomal swamping type of resistance than a classic
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plasmid-mediated bypass.
How important the type IV enzyme will prove to be clinically is a matter for con¬
jecture. The enzyme has been detected only in South India but did appear to be
common. It is tempting to speculate that such an unusual resistance mechanism
may be the result of conditions prevalent in the Third World. Namely frequent
intermittent low dosing with trimethoprim in combination with frequent infec¬
tions. It is not difficult to imagine how the type IV enzyme could be successful
in these conditions especially if located on the same plasmid as other resistance
genes. It is also possible that there could be carriage of the type IV gene among
the commensal population. Recently bacteria containing transferable low level
resistance to trimethoprim have been isolated from healthy members of the pop¬
ulation in Nigeria (Lamikanra et al., 1989). The survival of the type IV gene in
the West may be hard to visualise but presumably there is the possibility that
if the enzyme became continually derepressed high level resistance may be the
result. However this may produce a significant drain on the energy resources of
the cell.
The similarity of the resistance mechanism with the chromosomal hyperproduc-
tion suggests a close evolutionary relationship and this will be discussed later.
4.2 Biochemical Properties ofDihydrofolate Re¬
ductases
The plasmid determined dihydrofolate reductases conferring resistance to trimetho¬
prim can be considered in two areas. Those that confer a high level of resistance to
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trimethoprim (MIC > 1024 mg/L) and those which confer only a low or moderate
level of resistance (MIC < 256 mg/L).
In 1979 the first plasmid-mediated dihydrofolate reductase which conferred only
a moderate level of resistance to trimethoprim was isolated (Fling et al., 1982).
The enzyme (type III) was encoded on plasmid pAZl, isolated from a strain of
Salmonella typhimurium from New Zealand, and conferred an MIC of 64 mg/L.
Although it subsequently appeared that this enzyme was rare, it was argued
that this was only because strains with a low level of trimethoprim resistance
were assumed to be non-transferable and not studied in detail (Towner and Pinn,
1981). This view seems to have been correct as a number of plasmid dihydrofolate
reductases have now been identified which confer only low level resistance.
The type III dihydrofolate reductase has biochemical characteristics distinctly
different from those of the type I and II enzymes (Table 33). Compared with
these two enzymes, the type III has a lower molecular mass (16,900) and is only
slightly resistant to trimethoprim (ID50 2//M). However despite its susceptibility
to trimethoprim and the fact that the enzyme is only produced in small amounts,
the type III dihydrofolate reductase can confer a significant level of resistance
on its host. It is able to do this because of its high efficiency, having a Km for
dihydrofolate of only 0.4/iM (Joyner et al., 1984). The gene encoding the type III
enzyme has been sequenced and shows the enzyme to be related to Gram-negative
chromosomal enzymes (Fling et al., 1988).
The use of DNA probing has revolutionised the study of plasmid-mediated di¬
hydrofolate reductases (Towner, 1990). The use of such probes has meant that
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Table 33. Biochemical properties of the plasmid dihydrofolate reductases.
Enzyme Tp ID50 Mtx ID50 TD50 DHF Km Tp Ki Size MIC
fiM mins //M pM daltons mg/L
la 57 4.4 0.5 5.6 7.4 35000 > 1000
lb 32 2.8 1.2 11 41 24500 > 1000
Ila 70000 1100 > 12 4.6 6100 35000 > 1000
lib 80000 750 > 12 8.3 150 35000 > 1000
lie 20000 1000 > 12 4.2 400 34000 > 1000
Ilia 2.0 *0.2 * > 12 0.4 0.019 16900 64
Illb 2.0 0.2 > 12 9.5 0.4 17000 128
IIIc 3.0 0.007 8 3.1 0.5 22000 256
IV 0.2 0.02 > 12 37 0.063 46700 10
V 20 2.3 t_ 15.4 3.2 + 5000 > 1000
VI 200 7.25 0.4 31.25 75 10000 > 1000
VII 30 3.0 1.5 20.0 7.0 11500 > 1000
SI 50 0.002 > 12 10.8 11.6 19700 > 1000
* established from E. coli pFE1242
^ apparent molecular weight by Sephadex gel filtration
dependent on protein concentration
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large numbers of trimethoprim resistant strains (including those with only low
level resistance) can be screened rapidly and strains containing any potentially
novel and interesting dihydrofolate reductases can be identified for more detailed
examination (Towner, 1990).
Escherichia coli Tm858, isolated from the urine of a hospitalised patient in Not¬
tinghamshire in 1980, was one such strain. Although this strain and the resultant
transconjugant were highly resistant to trimethoprim (MIC > 1024 mg/L), pu¬
rified plasmid DNA showed no hybridisation with those gene probes known to
identify high level trimethoprim resistance genes, i.e. dihydrofolate reductase
types I, II and V. However when the trimethoprim resistance gene had been
subcloned into pUC18 to give the recombinant plasmid pUN972 and this was in¬
troduced into Escherichia coli HB101, the MIC was only 64 mg/L. Hybridisation
of this plasmid with all available plasmid dihydrofolate reductase probes gave a
positive result only with the original type III dihydrofolate reductase encoding
plasmid, pAZl. Biochemically the dihydrofolate reductase encoded by plasmid
pUN972 was indistinguishable from the pAZl derived enzyme. The molecular
weight and Michaelis Menten kinetics of the enzyme encoded by pUN972 were
similar to those published for the type III. A direct comparison of the inhibition
profiles of the enzymes from plasmids pAZl and pUN972 was necessary as the
methotrexate and heat sensitivities of the type III from pAZl had never been
published before, and this revealed that the two enzymes were similar. The final
evidence that the two enzymes were indistinguishable was obtained from the iso¬
electric focusing, refined in this thesis. The two enzymes could not be separated
by isoelectric focusing.
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It is clear that the enzyme isolated in Nottingham was a type III. One interesting
feature of this work is the apparent reduction in the MIC to trimethoprim of the
strain carrying the cloned type III enzyme compared to the original isolate. One
possible explanation is that a second dihydrofolate reductase gene was present
in the original strain and that this masked the presence of the low level type III
determinant. As no hybridisation was obtained with probes representing dihydro¬
folate reductase types I, II and V any high level resistance gene must presumably
be specifying a novel enzyme.
The fact that a type III enzyme was present in Nottingham in 1980, barely a year
after the initial isolation of this class of enzyme in New Zealand, does suggest
that it is much more widespread than was at first realised. The reasons why it
may have gone unnoticed are not only that strains with low level resistance were
often not studied but, as in this case, the gene may be masked by the presence
of another. The ubiquitous type I dihydrofolate reductase has been found in the
same isolate as a type II enzyme (Fling et al., 1982; Burchall et al., 1982) so there
is no reason why it could not also be present with the type III.
Dihydrofolate reductases conferring low level trimethoprim resistance in two out¬
breaks of Shigella have also been studied. Trimethoprim resistance in Shigella is
now a major problem in many parts of the world, particularly developing coun¬
tries (Murray et al., 1985; Farrar, 1985; Elwell and Fling, 1989; Dupont, 1989).
This is not only because antibiotic usage is higher and less well regulated in
these countries, but also because the conditions enabling the epidemic spread of
Shigella clones are near perfect. Overcrowded housing, inadequate sewage and
water systems and communal cooking facilities all contribute towards the spread
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of infection. Trimethoprim resistance in Shigella is not unique to the Third World
although, in the West, it does tend to be confined to specific subpopulations;
American Indians on reservations, geriatric hospitals and nurseries for example
(Blaser et al., 1983; Tauxe et al., 1986; C.D.C., 1987a, 1987b; Griffin et al., 1989).
The two outbreaks of trimethoprim resistant Shigella sonnei that have been ex¬
amined in this thesis both occurred in the United States. One at a nursing home
involved 60 people the second at the rainbow family gathering in the Smokey
Mountains National Park involved 6000. In the latter case the outbreak was al¬
most certainly the result of the use of communal kitchens, open pit latrines and
untreated drinking water (C.D.C., 1987b). Both strains were only moderately re¬
sistant MIC 128 mg/L and 256 mg/L respectively and again, initial hybridisation
studies demonstrated that the two genes responsible were not of the commonly
occurring types and were different from one another. Biochemical characterisa¬
tions of both enzymes were performed (table 33) and the results suggested that
the two enzymes were indeed different from one another but showed similarities
to the type III. Consequently, the two enzymes were named Illb (nursing home)
and IIIc (Rainbow Family) and the original type III named Ilia.
In general, the importance of transmissible low level resistance to trimethoprim
has not been studied. It is interesting that, like the original type Ilia enzyme,
these low level genes have been found in enteric infections. This could be related
to the fact that lower levels of trimethoprim are found in the gut during treat¬
ment than in the urine. As studies in dogs have shown that after trimethoprim
administration much higher levels occur in the urine than in the gut although
this does even out over several days (Schwartz and Ziegler, 1969). Although the
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type Ilia has been isolated from a urinary tract infection it is important to bear
in mind that another high level resistance gene may also have been present.
The discovery of novel trimethoprim resistance genes was not surprising as other
studies have demonstrated the occurrence of trimethoprim resistance genes in
Shigella which did not hybridise with probes for the commonly occurring enzymes
(Chatkaeomorakot et al., 1987). However, in this case this was not followed up by
detailed biochemical analysis of the enzymes responsible. The ability of antibiotic
resistant clones of Shigella to spread (Frost et al., 1985) presumably means that
a novel resistant enzyme can become widespread in a relatively short space of
time. It is therefore imperative that the situation in Shigella is monitored closely,
not simply for short term treatment strategies, but also to guard against the
development and dissemination of further resistant enzymes.
High level resistance to trimethoprim has been dominated by the spread of the
type la dihydrofolate reductase (Steen and Skold, 1985). Being located on trans-
poson Tn7 (Barth et al., 1976) enabled this gene to spread efficiently. It is now
found integrated in the chromosome as well as on plasmids (Towner et al., 1980;
Amyes et al., 1986b) and has been identified outwith the enterobacteria in Vib¬
rio cholerae (Young and Amyes, 1986b). However recently a number of other
enzymes have been detected which confer high level resistance to trimethoprim.
The first of these, the type V dihydrofolate reductase, was identified during a sur¬
vey of antibiotic resistance in Sri Lanka in 1985 (Sundstrom et al., 1987). Probing
had been used to screen isolates and, unusually, a very low incidence of type la
had been found. Examination of the biochemical properties of the type V enzyme
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produced an unusual result. Although the majority of the properties of the type
V enzyme were like those of the type la (table 33) the enzyme had a very low ap¬
parent molecular weight when measured on Sephadex gel filtration. Examination
of the molecular mass of the type la, under different conditions, suggested that
the low molecular mass was an artefact. Indeed, this was confirmed by native
polyacrylamide gel electrophoresis, which showed that the type V and type la
enzymes were the same size. These results have subsequently been confirmed by
sequence analysis of the type V gene which revealed that it has 75% amino acid
homology with the type la enzyme and the two subunits have the same predicted
molecular mass (Sundstrom et al., 1988).
There may, in fact, be a number of these high level resistant enzymes which are
related to the type la. Young and Amyes (1985) characterised a transposon medi¬
ated enzyme with similar biochemical properties to the type la, interestingly this
also had a lower molecular mass. Whether this was a genuine mass or an arte¬
fact like the type V is not clear. The recently identified type VII enzyme follows
this same pattern (Amyes et al., 1989), although in this case the lower molecular
mass does appear genuine as on native polyacrylamide gel electrophoresis the
type VII appears smaller than the type la. It is also thought that novel type I
like enzymes may be responsible for trimethoprim resistance in Vibrio cholerae
(Ouellette et al., 1988). The reason why some of these enzymes are atypically re¬
tarded by Sephadex gel filtration, and appear smaller than they should, is unclear
but could be related to a greater number of hydrophobic amino acids.
The type V enzyme originally isolated in Sri Lanka has subsequently been de¬
tected in Europe; in Finland (Heikkila et al., 1990) and in the United Kingdom
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(Towner et al., 1990) and it seems likely therefore that this enzyme has been
present for some time. Before recent refinements in probing techniques, it would
undoubtedly have registered as a type la and as probes become more discrimi¬
natory it may transpire that there is a vast range of these type I-like enzymes
conferring high level resistance. This is certainly suggested by a recent study in
Finland which reported 40% of isolates with high level resistance were not due to
dihydrofolate reductase type I, II or V (Heikkila et al., 1990). The finding of the
type VII in an animal isolate also suggests these enzymes are widespread (Amyes
et al., 1989).
The type II dihydrofolate reductases also confer high level resistance but sequence
analysis has revealed these enzymes have a distinctly different origin from the type
la enzyme (Stone and Smith, 1979; Zolg and Hanggi, 1981; Flensburg and Steen,
1986). Recently a novel dihydrofolate reductase, designated type VI, has been
isolated in South Africa. This enzyme is similar in size to a type II subunit and
shows high level resistance to trimethoprim and methotrexate like the type II
(Wylie et al., 1988). It is not as yet clear if the type II and VI are closely related.
A dihydrofolate reductase suspected of being a type II, from probing studies, has
been identified in Vibrio cholerae. However the enzyme only confers a low level
of resistance (MIC 125 mg/L) and biochemical confirmation of this enzyme as a
type II is awaited (Tabtieng et al., 1989).
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4.3 Sequence Analysis of Plasmid Encoded Di-
hydrofolate Reductases
The results of sequence analysis represent the ultimate information in the study
of the evolution of antibiotic resistance genes. As discussed, plasmid-mediated
dihydrofolate reductases have been divided into a number of classes based on their
biochemical profiles. But, in addition, as some of the genes responsible have also
had their DNA nucleotides or the amino acids of the gene product sequenced, the
classification of these enzymes now also takes into account amino acid differences
(Stone and Smith, 1979; Zolg and Hanggi, 1981; Fling and Richards, 1983, Flens-
burg and Steen, 1986; Fling et al., 1988; Sundstrom et al., 1988; Rouch et al.,
1989). The amino acid sequences of the chromosomal dihydrofolate reductases
from several bacterial species have also been established (Gleisner et al., 1974;
Freisham et al., 1978; Smith and Calvo, 1980; Baccanari et al., 1984; Hartman et
al., 1988; Iwakura et al., 1988).
As the number of different enzyme types has increased, sequence analysis has
become even more important as some of these enzymes have very similar bio¬
chemical properties, for example the types la and V. If determination of the
enzymes sequence is to become a crucial feature in the distinction of plasmid-
encoded dihydrofolate reductases, an alternative to DNA nucleotide sequencing
is required since it is too lengthy a process for the routine study of antibiotic re¬
sistance. In this thesis rapid sequence analysis was performed using an automatic
amino acid sequencer. Two properties make dihydrofolate reductases particularly
suitable for this kind of analysis. Firstly most of the active site is situated at the
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N-amino terminal end of the protein and therefore a single sequence analysis pro¬
vides enough information to look at evolutionary relationships (Novak et al., 1983;
Rouch et al., 1989). Secondly in many cases the enzyme is easily purified with
the use of methotrexate agarose and a native protein, sufficient for sequencing,
can be obtained in a few purification steps (Kaufman, 1974).
The known sequences of the plasmid-mediated dihydrofolate reductases are shown
in figure 54 along with the sequences of several bacterial chromosomal dihydro¬
folate reductases. This sequence information can be exploited to evaluate two
features, firstly the evolutionary relationships between proteins and secondly the
structure-function relationships.
If we first consider the evolutionary relationships: it is obvious when looking at
figure 54 that the majority of the enzymes show some degree of homology with
each other. The exceptions are the type II group of enzymes, which are clearly
different and must have originated from a different source. They show little ho¬
mology with any other dihydrofolate reductase and their origin remains a mystery.
It has been speculated that they have evolved from a Gram-negative chromosomal
oxidoreductase (Elwell and Fling, 1989) but this remains unresolved. The recent
identification of the type VI dihydrofolate reductase may shed some light on the
origins of the type II's but, as yet no sequence analysis on this new enzyme has
been performed (Wylie et al., 1988). Likewise the discovery of a type II enzyme
which confers only a low level of resistance may provide some answers as to the
origin of these enzymes (Tabtieng et al., 1989).
There was a great deal of interest in the sequence of the type la dihydrofolate
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reductase encoded by Tn7, as for many years this was the predominate resistance
determinant associated with high level trimethoprim resistance (Steen and Skold,
1985). The type la enzyme shows significant homology with the Escherichia
coli chromosomal enzyme, 29% direct amino acid matching, and the inclusion of
chemically similar residues increases this to 44% (Fling and Richards, 1983). The
recently identified type V enzyme, which is biochemically similar to the type la
is clearly closely related as sequence studies have revealed that the two enzymes
show a greater than 75% amino acid homology (Sundstrom et al., 1988). It seems
likely, therefore, that these two genes have a common ancestry and it would be
interesting to find out if the type lb and VII genes show similar homology.
The type Ilia dihydrofolate reductase sequence suggests that this gene origi¬
nated in Escherichia coli or a closely related Gram-negative organism, as the
amino acid sequence shows 51% identity with the Escherichia coli chromosomal
dihydrofolate reductase and 44% with the Neisseria gonorrhoeae enzyme (Fling
et al., 1988). The type Illb dihydrofolate reductase isolated in Shigella sonnei
shares many properties with the type Ilia enzyme, including the fact that it is
a monomeric protein. Indeed the type Ilia and Illb dihydrofolate reductases are
only distinguishable by isoelectric focusing. This suggested that the enzymes
may be very closely related differing in only one or two amino acids. However,
sequence analysis of the N-terminal end of the Illb has shown that this is not
the case. As expected the type Illb showed no homology with the type II en¬
zymes, but amongst the other plasmid-mediated enzymes the type Illb showed
no greater homology with the type Ilia than any of the other enzymes. Bear¬
ing in mind the similarity in biochemical properties between the types Ilia and
192
Illb dihydrofolate reductases this is very surprising, suggesting that there must
be some evolutionary advantage in the selection of enzymes with this particular
biochemical profile.
Induction studies with the type IV dihydrofolate reductase had suggested that the
resistance mechanism involving this enzyme was more similar to a chromosomal
hyperproduction system than a classic resistant bypass. It was not surprising
therefore that sequence analysis of the first 49 amino acids revealed this enzyme
to be closely related to the Escherichia coli chromosomal dihydrofolate reductase.
Indeed 40% direct amino acid matching was found and homology was increased
to 58% when homologous amino acids were considered. Sequence analysis of
the type IV dihydrofolate reductase also revealed that it was complexed to NSl,
an Escherichia coli DNA binding protein, and that this contributed to the high
molecular mass of this enzyme. The reason why the type IV enzyme is complexed
with a DNA binding protein is not clear but may be related to the induction
mechanism, since proteins which bind to DNA have been implicated in the control
of gene expression (Ptashne, 1986, 1988; Magasanik, 1988).
Interestingly the lower molecular mass cloned type IV enzyme, which is non-
inducible, is not complexed with NSl. The absence of binding protein in the
enzyme from the cloned gene probably results from the lack of NSl gene in the
restriction fragment cloned into pBR322. As this plasmid is a multicopy vector,
the necessity for induction of the type IV to produce trimethoprim resistance has
been removed, and thus the selection pressure for the NSl protein gene was not
present in the cloning process.
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How production of the type IV enzyme is regulated by the DNA binding protein
remains unclear but a number of scenarios are possible including gene activation
by binding at specific sites (Ptashne, 1986, 1988). Another intriguing possibility
may involve the NSl protein interfering with a dihydrofolate reductase DNA
complex. It has been shown that dihydrofolate reductase binds to DNA, and
preferentially binds to the DNA that codes for its own production (Gronenborn
and Davies, 1981). And it has been speculated that this may play a physiological
role in vivo, most likely dihydrofolate reductase reduces the level of expression of
its own gene (Gronenborn and Davies, 1981). It is possible therefore that because
the type IV enzyme is complexed with NSl it cannot bind to DNA and therefore
high expression results (figure 55).
Plasmid-mediated trimethoprim resistance in Staphylococci has only recently be¬
come a problem and at the moment one enzyme, the type Si, predominates (Tait
and Amyes, 1989; Amyes and Tait, 1990). The gene encoding this enzyme has
been sequenced (Rouch et al., 1989). The gene shows a degree of homology
with the plasmid-mediated dihydrofolate reductases from Gram-negatives with
the exception of the type IPs.
The origin of plasmid-mediated antibiotic resistance genes has remained a mys¬
tery. In the case of the plasmid-mediated trimethoprim resistant dihydrofolate
reductases, this may now be partially resolved. The plasmid-encoded type Si
dihydrofolate reductase in Staphylococci shows closest similarity with the chro¬
mosomal dihydrofolate reductase in Staphylococcus aureus (Rouch et al., 1989;
Hartman et al., 1988; Amyes and Tait, 1990). Similarly, the type IV dihydrofolate
reductase shows closest similarity to the Escherichia coli chromosomal enzyme
194
ure 55. Possible control mechanism for the type IV dihydrofolate reductase.
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and, following the Staphylococcal example, appears to be derived directly from
it.
Indeed the sequence analysis and biochemical results suggest that the type IV,
type la, type Ilia, Illb and V may all have originated from the Escherichia coli
chromosome. These enzymes could be classified in the same evolutionary path.
On the other hand, the type II enzymes, and perhaps time will show the type VI,
have followed a completely different evolutionary pathway.
The use of sequence analysis to examine evolutionary relationships among the
plasmid-mediated dihydrofolate reductases has provided some answers but in¬
evitably raised new questions. It may eventually raise questions about how in
fact these enzymes should be classified. Should enzymes with the same biochem¬
ical properties but different sequences be classified in the same subtype or should
sequence analysis be the ultimate determinator. This situation is not unique
to the dihydrofolate reductases but is currently being debated for the classifica¬
tion of the TEM derived /^-lactamases conferring resistance to third generation
cephalasporins (Payne, 1990).
The protein sequences can also be used to examine structure-function relation¬
ships. The biochemical properties of the plasmid-mediated dihydrofolate re¬
ductases are well documented and they vary considerably between the enzyme
types. By comparing the sequences with properties it may be possible to corre¬
late changes in sequence with changes in biochemical properties. The residues
involved in the active site binding of methotrexate trimethoprim and NADPH
have been elucidated (Bolin et al., 1982; Filman et al., 1982; Matthews et al.,
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1985a) and changes at these points would be particularly interesting. Comparing
sequences with biochemical features has enabled the basis of methotrexate sen¬
sitivity to be elucidated. All methotrexate sensitive enzymes have an aspartate
at residue 28 while in methotrexate resistant proteins a homologous glutamate
is present (Fling and Richards, 1983). The type Illb and IV enzymes are both
methotrexate sensitive and each has an aspartate at residue 28.
Alas with trimethoprim binding there seems no such pattern as the residues bind¬
ing trimethoprim seem highly conserved among the plasmid-mediated enzymes,
despite their varying sensitivities to inhibition (figure 54). The only exceptions
are the type II enzymes, which are highly resistant to both methotrexate and
trimethoprim, which have different residues at the crucial positions. The different
sensitivities to trimethoprim in the plasmid-mediated dihydrofolate reductases
(other than the type II) may be derived from conformational changes affecting
the accessibility of trimethoprim into the active site and this may, of course,
involve widely dispersed residues.
However, changes in amino acid sequence leading to resistance have been corre¬
lated forteoeai-jpa^ of chromosomal dihydrofolate reductases. In one case a single
amino acid change from leucine to arginine at position 45 was responsible for a
greater resistance to trimethoprim and lower binding of the inhibitor (Baccanari
et al., 1981). In another strain a change in the trimethoprim binding site at
position 21 from proline to serine lead to increased resistance (Smith and Calvo,
1982). Furthermore use of site directed mutagenesis has revealed the importance
of specific hydrophobic residues on ligand binding and catalysis, including pheny¬
lalanine at position 31 which is highly conserved among the plasmid-mediated
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enzymes (Benkovic et al., 1988).
As mentioned, at present there seems no clear pattern among the plasmid-mediated
dihydrofolate reductases accounting for differences in trimethoprim susceptibility.
As more information is obtained hopefully such a pattern may emerge and may
enable a more rational approach to antifolate drug design. As mentioned in the
introduction trimethoprim like compounds continue to be developed and tested
for antibacterial activity (Roth et al., 1988, 1989; Johnson et al., 1989). Unfortu¬
nately, all studies have, as yet, failed to address themselves as to whether these
new compounds can also inhibit the plasmid-encoded trimethoprim resistant en¬
zymes as well as inhibiting the chromosomal dihydrofolate reductase. Unless they
can, then there is no real advance over trimethoprim.
4.4 Conclusions
Trimethoprim was the first antimicrobial agent that was specifically designed as
a fully synthetic chemotherapeutic agent. It was argued that resistance would
be less of a problem as there would be no naturally occurring enzymes which
could destroy the drug. While it is true that trimethoprim is not subject to
drug inactivation, the bypass mechanism of resistance which evolved is no less
efficient. Furthermore the other resistance mechanisms, though of lesser impor¬
tance, should not be forgotten.
Although resistance to trimethoprim has compromised the use of this drug it is
encouraging that overall resistance is low and with carefully monitoring it should
remain at this level. However the extensive use of trimethoprim in developing
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countries should be watched closely as the high levels and incidences of resistance
in pathogenic species is a worrying trend.
The rapid increase in the number of trimethoprim resistant dihydrofolate reduc¬
tases results from not only the continuing evolution of resistance, but can also
partly be attributed to more discriminatory methods of studying these proteins.
While questions have been answered many more have been generated and there
is still much more to learn.
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C-1M jwo Outbreaks of Dysentery Caused by Antibiotic
Resistant Shigella sonnei (ARS) Elaborating a Type
III Dihydrofolate Reductase (DHFR). N.BARG*, F.HITTS0I1, S.
AMYES, C.THOMSON, M.WHARTON, and W.SCHAFFHER. Vand. Univ.
Hed. School Nash. TN, Univ. of Edinburgh Med. School Edin.
UK., and The Centers for Disease Control, Atlanta, GA.
Bacteria producing a plasmid encoded Type III DHFR en¬
zyme are rare, noted once in a strain of Salmonella typhi-
murium from New Zealand. ARS isolated from nursing home
patients (NH) in 1935 and from campers in a national park
(NP) in 1907 were analyzed by plasmid profiles and biochemi¬
cally. Each one contained the 120 MDa virulence plasmid and
2 (NP) or 3 (NH) small cryptic plasmids. Both strains con¬
tained a transferable plasmid (NH 65'MDa, NP 60 MDa) bearing
different antibiotic resistance determinants, but both plas¬
mids conferred resistance to trimethoprim (Tp) and sulfa¬
methoxazole. Restriction enzyme cleavage of the two R-plas-
mids (different incompatibility groups) produced dissimilar
patterns. Transformants (NH plasmid DNA) contained the 65
MDa plasmid. The MIC of Tp for both Shigella isolates was
64 yg/ml, the same as strains producing DIIFR III. Purified
enzyme from C600 transconjugants of each ARS yielded the
same biochemical profile as the other, and of a type III
DHFR: molecular weighta17 kDa, Tp ID5Qs2pM, Mtx 1^50=•02
yM, DHF Kq=2.8 yiM, Tp Kj-0.15 yH, and TD50=12.5 min. We
think that both of these ARS elaborate a Type III DI'FR and
that its gene, being found on 2 different replicons, may
have originated from a transposable element.
C-111 Etiology of Acute Diarrhea in Ameri^£jnba
Personnel in Cairo. Egypt. R.L. HAB'EW3|fiGSjf.
I.A. MIKHAIL1, J.K. P0DG0RE1, C.R. LISSNER1, —
D. SPEES2, J.C. GLENN1, and J.N. WOODY1.1U.S. Naval Medi¬
cal Research Unit No.3, Cairo, Egypt and 2Health Unit,
American Embassy, Cairo, Egypt.
During a two year period, one-hundred and thirty
eight American Embassy personnel or their dependents were
enrolled in an acute diarrhea study. From the 138 patients
we isolated or identified 33 bacterial pathogens, 6 patho¬
genic parasites including Cryptosporidia and 3 cases where
we detected rotaviral antigen. We looked at Enterotoxi¬
genic E. coli, Enteroinvasive _E. coli and Enteroadherent
E. coli during this investigation in approximately thirty
percent of the specimens examined. We found Enterotoxigenic
E. coli to represent 31% of all pathogens, Shigella sonnei
T9.5%), Campylobacter spp (5%), Rotavirus (2%), Shigella
boydii (1%), SaImonella Group C2 (1%), Shigella dysenteriae
(1%), Aeromonas hydroohila (1%) and Plesiomonas Th~i g e 1 -
loides (1%). Susceptibility to twelve antibiotics including
cinoxacin, norfloxacin, and furazolidone were performed by
the Bauer-Kirby method. All bacterial enteropathogens
were universally susceptible to the quinolones, including
nalidixic acid. All isolates, with the exception of Sal¬
monella Group C2 were susceptible to furazolidone.
(Supported by NMRDC, Bethesda, MD, Work Unit No.
3M161102BS.AK.311).
C-109 Microbial Aetiology of Acute Gastroenteritis among
Children in Kuwait. S.K. SETHI* and F.A. KHUFASH.
Faculty of Medicine, Kuwait University, Kuwait.
Microbial aetiology of infectious gastroenteritis in 621
hospitalized children was studied during a period of 15
months. A specific microbial diagnosis could be made in
79% of the 621 children. In 5-3% of the 152 controls, one
or more enteropathogens could be detected. Rotavirus was
the major aetioloaic agent present in 278 of 621 (44.7%)
patients and 3 • 3 -t- of controls. Sa 1 mone 11a sp. were the
second most important enteropatnogens detected in 126
patients (20.3%) ~ either singly or multiply alo.nawith
other enteropetnogens. Campy 1obacter jejuni and enterotoxi¬
genic Escher j cnia col 1 constituted 7.6 and 7.7% respect¬
ively while Shige11ae and enteropathogenic Eschericnia coli
were present in 3-0 and 3-4% of the patients. Aeromonas
hvdropnila was isolated from stools of 7(1.1%) patients.
Y.enterocol:tica could not be isolated from any of the
stool specimens inspite of using both enrichment and
selective tecnniaues. It is concluded that rotaviruses and
Sa1mone11a so. account for the major proportion of incid¬
ence of gastroenteritis in children in Kuwait. A large
number of children with gastroenteritis were infected with
more than one enteropathogens. Clinical symptoms and
duration of hospital stay of the patients varied according
to the associated enteropathogens.
C-112 r.Asr.roenr.pritis Outbreaks tn Nursing Homes.
F.Y.C. LIN*, C. GROVES, H. WASSERMAN, B.P. LIM,
P.POWERS, E.ISRAEL, K.MIDTHUN, K.Y. GREEN, A.Z. KAPIKIAN,
Maryland Department of Health and Mental Hygiene,
Baltimore, Md, National Institutes of Health, Betnesaa Mc.
From July 1981 to April 1987, a total of 122 outbreaks
of gastroenteritis (GEO) in nursing homer, were reporter to
the Maryland State Health Department. 101 (PH1 GEOs
occurred between Novenoer and March as compared with 21
(17%) between April and October. Salmonella was confirmed
as tne cause in 8(6.6%) outoreaks. Amor.a them 6 were
detected in the warm period (Apr-Oct) while only 2 were
confirmed in the cold months (Nov-Mar) (p<0.01). Non¬
bacterial GEOs in the winter montns were characterized by
self-limited diarrhea/vomiting of 2^-48. nours duration;
mean attack rate of 31% for residents, 20% for employes;
meaic.n duration of outoreak of 7 days. The epidemic curves
suggest person-to-person spread as the mode of tran-
mission. 60 stool specimens and paired sera were
collected from residents durina outoreaks ir. 7 nursing
homes between Dec. 86 and Apr. 87, anc were studied for the
presence of enteric pathogens, rotavirus, Marin Co. Aaent
ana Norwalk virus. All were negative for Salmonella,
Shigella ana Campy!obacter. Onlv ?. out of paired sera
showed seroresponse to Marin Co. Aqent. The rol® of Norwalk
Agents and rotavirus are under current investioation. Our
findir.qs indiciate non-bacteria! GEO is prevalent in winter
months in nursinc home residents. Further studies for
etiological aaents are warrantee.
C-110 Survey of Patients with Bloody Diarrhea on the
Navajo Indian Preservation using Culture Techniques
and DNA Probes for Detecting Bacterial Pathogens.
N. STROCKBINE*1, N. PUHR1, M. VENKATESAN^ N. SHAFFER1,
R. TAUXE1, J. WELLS1, and I. K. WACHSMUTH1. 1 CDC,
Atlanta, Georgia and ^ WRAIR, Washington, D.C.
Shigella species have been presumed to be the major
cause of bloody diarrhea on the Navajo Indian Reservation.
To determine whether other bacterial pathogens are also
important, stool swabs from 45 patients with bloody
diarrhea were collected and studied for the presence of
bacterial pathogens by culture techniques and DNA probes.
Colonies were hybridized with the IpaC probe for
Shigella/enteroinvasive Escherichia coli (ELEC) and with
the SLT-I and SLT-II probes for Shiga-like/Verotoxigenic
£.• coli (SL/VTEC). Shigella species were recovered from 22
specimens and SL/VTEC was recovered from 1 specimen.
Twenty-one of the Shigella isolates were identified by
culture and 21 were identified by the IpaC probe. One
Shigella was detected by culture that was not identiied by
the probe and one was detected by the probe that was
missed by culture. No E1EC were identified; Campylobacter
6pecies were isolated from four specimens. Recognized or
putative bacterial pathogens were recovered from 602
(27/45) of the specimens. These data show that Shigella
and, to a lesser extent, Campylobacter are significant
causes of bloody diarrhea in this population.
C-113 Diarrheal Illness in a Day Care Center Caused by
Enceropathogenic Escherichia coli (EPEC)
Serogroup 0114. C.A. BOPP*, L.K. GILJAHN, V. HUNDLEY,
E.G. SOWERS, T.J. BARRETT, J.G. WELLS, and I.K.
WACHSMUTH, Centers for Disease Control, Atlanta, GA and
Ohio Department of Health, Columbus, OH.
In July 1987, an outbreak of severe, often chronic,
diarrheal illness occurred in a day-care center in
Ohio. Twelve of 24 children from 6 weeks to 10 months
old were ill. Escherichia coli serotype 0114:NM was
isolated from 5 of the 12 ill children. The organism
aahered to HeLa cells, was positive with the EPEC
adherence factor (EAF) probe, and was resistant to
ampicillin, carbenicillin, cephalothin, tetracycline,
sulfisoxazole and trimethoprim-sulfamethoxazole. It was
negative when assayed for heat-labile and heat-stable
enterotoxins, invasiveness, Shiga-like toxins 1 and II,
and diffuse adhesiveness. Only serotype 0114:H2 has
been considered a traditional EPEC within the 0114
serogroup, and it was thought to be EAF-negative, or a
class II EPEC. On the basis of virulence-associated
characteristics, antimicrobial resistance and isolation
from infants with chronic diarrhea, we believe that
0114:NM should be considered a class I EPEC serotype.
BIOCHEMICAL PROPERTIES OF THE TYPE V PLASH!D~ENCODED
TRIMETHOPRIM-RESI STANT DIHYDROFOLATE REDUCTASE
C.J. Thomson, S.G.B. Amyes, Department of Bacteriology,
University of Edinburgh, Teviot Place, Edinburgh EH8 9AG.
Initially, plasmid-encoded trimethoprim-resistance in clinical enterobacteria
resulted from either one of two genes encoding trimethoprim-resi^'tant
dihydrofolate reductases (DHFR), type I and type II. However, recently a number
of new plasmid-encoded DHFRs have been identified (Huovinen, 1987), distinguish¬
able from one another by their biochemical properties (Amyes, 1986). One of
these recently identified enzymes, designated type V, was discovered during a
survey of antibiotic resistance among enterobacteria in Sri Lanka (Sundstrom et
al, 1987). The enzyme was initially identified on the basis that its gene did
not hybridise with a type I or type II DHFR gene probe. However, DNA sequence
analysis of the type V DHFR gene predicts an enzyme similar to the type I
(Skold, 1988). To elucidate where the type V fits into the classification of
the plasmid-encoded DHFRs, its full biochemical profile has been established.
Enzyme preparation was carried out from 2 litre overnight broth cultures as
described by Young & Amyes (1986) and enzyme assays were determined by the
method of Amyes & Smith (1974). The molecular mass (Mr) of the enzyme was
measured by gel filtration on a Sephadex G-50 column (2cm2 x 90cm) employing
chymotrypsinogen, cytochrome c and the B subunit of insulin as standards. Its
heat sensitivity was determined at 45°c in a prewarmed container and, after
the requisite time, the sample was cooled on ice and the enzyme activity
assayed (Young & Amyes, 1986).
A 489 base pair Hpal DNA restriction fragment, containing the whole gene for
the type V DHFR, had been cloned into the vector plasmid pUC18 and the enzyme
was extracted from E. coli containing the resultant hybrid plasmid. The
concentration of trimethoprim required for 50% inhibition of the enzyme was
23uM and of methotrexate was 3.5^. The enzyme had moderate affinity for the
substrate dihydrofolate (Km = 15.5^aM) and it was competitively inhibited by
trimethoprim (Ki = 3.2,pM). In the presence of high protein concentrations, the
type V enzyme was relatively heat stable, maintaining more than 50% of its
activity after 12 minutes at 45°c. When the stablising protein was removed,
the enzyme became more heat labile (TD5Q = 3min). However, the Mr of the type
V DHFR was unusually low at 5000.
Although the type V DHFR gene did not hybridise with the type I gene probe, it
has a nucleotide sequence similar to the type I gene (Skold, 1988). Our results
show that the inhibition properties of the type V would also classify it as a
type I DHFR. However, the most striking feature of the type V was its low Mr,
far lower than the type I or any other plasmid-encoded DHFR. These results
suggest that the type V enzyme may have resulted from a mutation in the type I
DHFR gene, resulting in an enzyme containing little more than the active site.
The sequence of the type V predicts an enzyme of 157 amino acids although the
Mr suggests an enzyme of only 40 amino acids. It may be that a mutation has
inserted a stop codon after 120 base pairs in the open reading frame which
prevents further transcription. The similarity of the biochemical properties,
of the resultant enzyme, to those of the type I DHFR suggests that a large
portion of the protein of the type I enzyme may be unnecessary.
We thank the Wellcome Trust for grant no. 16376/1.5 which supported this work.
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a.72 Tetracycline Resistance (tet) Gene Expression
Increases Aminoglycoside Uptake without Altering Bacterial
Transmembrane Potential. T.L. MERLIN", G.E. DAVIS, and
j K GRIFFITH- Albuquerque VA Med. Ctr. and Univ. of NM
Sch. of Med., Albuquerque, NM.
Extrachromosomal tej genes are common among gram-
negative bacteria. Their expression not only confers
tetracycline resistance but also enhances susceptibility to
commonly-used aminoglycoside antibiotics by increasing
ttieir uptake. The mechanism of this increased uptake of
aminoglycosides is unknown. Aminoglycoside uptake is
usually proportional to the transmembrane potential (Af)
above a definable threshold. We investigated the
relationship between 3H-gentamicin uptake and av in E. coli
?. (hb101) strains expressing jgi at various levels, a1? was
-measured by the distribution of 3H-tetraphenylphosphonium.
|3H-gentamicin uptake increased in proportion to the level ofBjfit expression and was blocked by dinitrophenol, which
j dissipates ail Regardless of the level of tei expression,
Ihowever, Af was identical in all strains. This indicates that
s'lat expression increases aminoglycoside uptake, not by a*
mechanism that affects aw directly, but possibly by one which
reduces the aw threshold.
Transfer of the Conjugative 25.2 Mdal
Tetracycline Resistance Plasmid from
ilsseria gonorrhoeae and Related Species to the Genus
temophilus. M.C. Roberts*. University of Washington,
Iseattle. WA.
gh- level tetracycline resistance in strains of
isseria gonorrhoeae, N. meningitidis, Kingella
denltrificans, and Eikenella corrodens has been
icribed. The resistance in each species is due to the
Requisition of 25.2 Mdal conjugative plasraids that carry
the tetracycline resistance determinant TetM. We have
|[shovn that these plasmids as well as the B-lactamase
fjplasmids can be transferred by conjugation to a variety
gbf il. meningitidis serogroups and commensal Neisseria
ISpecies at detectable conjugation frequencies (> 10"^).
^Because these organisms can be found in the same
^environment as the genus Haemophilus, we determined
jWbether the 25.2 Mdal plasmids could be transferred and
tained in Haemophilus strains. Both the B-lactamase
and 25.2 Mdal plasmids could be transferred into
philus influenzae and H. parainfluenzae. This
;ests that the 25.2 Mdal plasmid could become
blished in clinical isolates of Haemophilus and
■ports the hypothesis that it is very likely that
ileal isolates from other genera will at some time
lire the 25.2 Mdal plasmid.
Identification of a Large R-Plasmid and Cloning of
a Tetracycline Resistance Gene from the Fish
athogen Vibrio salmonicida. H. S0RUM1-3*, M. C.
BERTS2, K. FOSSUM1- and J. H. CROSA3. Norw. Col. Vet. Med1.,
\Norway, Univ. of Washington2, Seattle, WA, and Oregon Health Sciences Univ.3,
*noR.
salmonicida is the causative agent of Hitra disease or cold water
^>sis in farmed Adantic salmon in Norway. From the late seventies
^the disease was first observed, diseased fish have been treated with
cnal drugs, mainly oxytetracyclin In 1985 the first isolates of the
that were resistant to tetracycline and the diagnostically used
i a8e[lt 0/129 were identified. Fifty six percent of 250 strains
fc f h"1 ^seased fish along the whole coast of Norway in 1987,
I uu Un !° ^ resistant. A large, low copy number plasmid, aboutm size, was isolated from resistant isolates. A tetracycline
1* gene from the plasmid was cloned into the vector pACYC177,and subcloned, resulting in a 1.8 kb fragment containing the
L- c °h)ned gene hybridized with the class E tetracycline (tetE)
I ^ cn^!jJescnj>ed from Aeromonas hydrophila and Escherichia coli
i—i,jj n*espon^lng restriction sites have been found. As part of a
§5£e cln*1 h Sene was mutated by introducing a stop linker into
fkifefe ned 8ene was expressed in E. coli, but it has so far not been
|K anouin*nS*&T l^e R-plasmid from V. salmonicida to E. colilicrffL. a^U/n by conjugation. This is the first drug resistance gene
b m the fish pathogen V. salmonicida.
A-75
- „ . , kppri
j <%< / .
Analysis of Che marA region of.ITSsdherichia
coli. S. P. COHEN*, H. HAECHpS:, (and S. B.
LEVY. Tufcs University School of Medicine#Boston, MA.
Chromosomal multiple antibiotic resistant (Mar^ mutants
of Ej. coll require an intact marA region at 34-jal'nj_ah the
chromosome (identified by a Tn5 insertion). This region
has been isolated and subcloned into a low copy plasmid
vector. A fragment of 7.8 kb permits Mar mutants to arise
in cells bearing a chromosomal marA deletion. The plasmid
clone expresses a single RNA transcript of 1.4 kb whose
expression increases at least 50 fold in the resistant
mutant. The same RNA species is expressed by chromosomal
Mar mutants. A region of 2 kb surrounding the Tn.5.
insertion has been sequenced, revealing a single
transcription unit containing three open reading frames.
These- were preceded by a strong promoter and two 11 bp
complimentary sequences which contain internal dyad
symmetry. One is located between the putative -35 and -10
regions and the other just downstream from the putative
transcription start site. These sites may serve as
binding sites for a transcriptional regulator. The
sequence of this promoter region in the opposite
direction contains possible overlapping start signals.
This organization is strikingly similar to that of the
gram negative extrachromosomal tetracycline resistance
determinants. Further sequence analysis should identify
the change from marA"*" to marA.
A-76 Characterization and Significance of 2 Novel
Dihydrofoiate Reductases (DHFR) from Trimethoprim
(Tp) Resistant Shigella sonnei. N. BARG*, F. HUTSON, L.
WHEELER, C. THOMPSON, and S. AYMES. Vanderbilt
University Medical School, Nashville, TN and University of
Edinburgh, Edinburgh, UK.
Two strains of Tp resistant S. sonnei bearing R-plasmids
pBH600 and pBH700 elaborated a DHFR. These enzymes had
been partially characterized and were most like a Type III DHFR
based on TpID50 and molecular radius. By agar dilution, each
enzyme conferred moderate resistance to Tp with MIC's of 128
ug/ml and 512 ug/ml respectively. Further characterization was
provided by DNA hybridization and isoelectric focusing.
Subcloning the Tp resistance gene from the R-plasmids indicated
that the genes resided on an 1800 bp Pstl fragment of pBH600
and a 1600 bp Ps/I fragment of pBH700. Probes generated from
these fragments did not hybridize to each other or to Types I, II,
or III genes on the plasmids pFE872, pUC4-12, and pFE1242.
Types I, II, and III probes did not hybridize to pBH600 or
pBH700. Isoelectric focusing showed distinct pi's for the
enzymes coded for on pBH600 (5.3) and pBH700 (6.5). Neither pi
was the same as the Type III enzyme (6.1). Isolates from 8/13
other outbreaks of Tp resistant S. sonnei hybridized to the
pBH700 derived probe and only 1/13 to the pBH600 derived
probe. 2/13 hybridized to the Type I probe and 2/13 to both the
Type I and pBH700 derived probes. The genes for the enzymes
maintained on pBH600 and pBH700 appear novel. At least the
enzyme elaborated by strains bearing pBH700 appears to be
widespread among Tp resistant S. sonnei isolates in the USA.
A-77 Isolation and Characterization of Dihydrofoiate
Reductase from a High-level Trimethoprim Resistant
Pseudomonas cepacia. J.L. BURNS*, D.M. LIEN, University of
Washington, Seattle.
Antibiotic resistant cepacia is an important pulmon¬
ary pathogen in patients vith cystic fibrosis. We examined
trimethoprim (Tmp) resistance in 124 CF isolates: 80 (65Z)
vere Tmp (MIC>10 ug/ml) vith an MIQjq of 200 ug/ ml, 14
had an MIC>500 ug/ml. We selected one of these high-level
Tmpr strains, PC178, in which to characterize the resis¬
tance mechanism. There vas no evidence of antibiotic inac-
tivation or decreased permeability. Dihydrofoiate reductase
(DHFR), the target for Tmp activity, vas purified from the
Tmpr strain, PC178, and from a Tmp^ strain, PC174, by gel
filtration and ion exchange chromatography. The protein of
interest vas identified on non-denaturing PAGE by DHFR-
specific staining. Electrophoretic mobility vas similar
vith estimated enzyme molecular weights of 24K and 23K for
PC174 and PC178, respectively. The isoelectric point vas
identical for both enzymes (pi 6.8) and the IC (3.1, 4.3
uM) and Vmax (0.60, 0.76 U/min) for dihydrofoiate vere
similar for the Tmps and Tmpr DHFR. Enzyme specific activi¬
ty vas identical in crude (0.02 U/mg protein) and similar
in purified preparations (5.59. vs 10.40 U/rag protein) from
PC174 and PC178. However, inhibition studies found a 2-log
decrease in susceptibility to Tmp in the Tmpr enzyme. We
conclude that high-level resistance in strain PC178 is due
to production of a Tmpr DHFR.




The type VII dihydrofolate reductase: a novel plasmid-encoded
trimethoprim-resistant enzyme from Gram-negative bacteria isolated in
Britain
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"Department of Bacteriology, The Medical School, University of Edinburgh, Teviot
Place, Edinburgh EH89AG; 6Department of Microbiology and PHLS Laboratory,
University Hospital, Nottingham NG7 2UH; 'Department of Biological Sciences,
University of Dundee, Dundee DDI 4HN, UK
Plasmid pUN835 was identified in an Escherichia coli strain isolated from an
outbreak of porcine diarrhoea on a farm near Nottingham, UK. The trimethoprim
resistance gene did not hybridize with any of the gene probes derived from known
plasmid-encoded trimethoprim resistance genes. The trimethoprim resistance gene of
pUN835 was shown to encode the production of a dihydrofolate reductase which
confers high-level resistance on its host. This enzyme was smaller than most plasmid-
encoded dihydrofolate reductases (molecular mass = 11,500) and was labile to heat.
It had relatively low affinity for the substrate dihydrofolate (Km = 20 pM) and it was
resistant to competitive inhibition by trimethoprim (Kj = 7.0 pM). We classify this
novel enzyme as type VII.
Introduction
Three years after the clinical introduction of trimethoprim (2,4-diamino-5-(3,4,5-
trimethoxybenzyl) pyrimidine), bacterial plasmids conferring resistance to this drug
were observed in Gram-negative bacteria isolated in the United Kingdom (Fleming,
Datta & Griineberg, 1972). The resistance mechanism encoded by these plasmids
involves the synthesis of an additional trimethoprim-resistant dihydrofolate reductase
(5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase, EC 1.5.1.3) which enables the inhi¬
bited target of the host bacterium to be by-passed (Amyes & Smith, 1974).
The dihydrofolate reductases encoded by resistance plasmids (R-plasmids) in Gram-
negative bacteria were, prior to 1986, divided into three major classes. Of these, the
type I enzymes are the most common and consist of two sub-types, a and b. They are
heat-labile and have K, values for trimethoprim of about 20 pu (Pattishall et al., 1977;
Amyes & Smith, 1978; Tennhammar-Ekman & Skold, 1979; Young & Amyes, 1985).
The type la dihydrofolate reductase (molecular mass = 35,000) is by far the most
common of all the plasmid-encoded enzymes, and is encoded by the promiscuous
transposon Tn7 (Barth et al., 1976; Fling & Richards, 1983), which has been found in
bacteria isolated from many parts of the world. The type lb enzyme (molecular
mass = 24,500), though clearly related to the type la, has only been found in the
United Kingdom. The type II enzymes consist of four subunits, each with a molecular
mass of about 9000 (Smith et al., 1979; Fling & Elwell, 1980). These enzymes are heat
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stable and have K, values for trimethoprim of about 0.15 mM (Amyes & Smith, 1976;
Tennhammar-Ekman & Skold, 1979). Three different subtypes of these enzymes have
been found. The type Ila sub-type has been found in many parts of the world. The third
type of enzyme is monomeric (molecular mass = 16,900) and is much more sensitive to
trimethoprim (Aj = 19 nM) (Fling, Walton & Elwell, 1982; Joyner et al., 1984). Until
recently, the type III dihydrofolate reductase had only been found in a single
Salmonella typhimurium strain isolated in New Zealand.
Recently, several new trimethoprim-resistant, plasmid-encoded dihydrofolate reduc¬
tases have been identified. The type IV enzyme was identified in Gram-negative bacteria
isolated in South India and differs from the other three types because it is inducible
(Young & Amyes, 1986). It is also larger (molecular mass = 46,700), but has a low
inhibitor constant for trimethoprim (63 mM). Type V dihydrofolate reductase has been
found to be encoded by plasmids isolated in bacteria from Sri Lanka (Sundstrom,
Vinayagamoorthy & Skold, 1987). This enzyme has similar biochemical properties to
the type I dihydrofolate reductases, but there are a number of differences in the amino-
acid sequence. The recently-reported type VI enzyme (Wylie et al., 1988), on the other
hand, is quite different from all those mentioned above. It is small (molecular
mass = 10,000) and is more resistant to trimethoprim than any other dihydrofolate
reductase, except the type II. Finally, a plasmid-encoded dihydrofolate reductase
conferring high-level trimethoprim resistance in a Gram-positive bacterium has been
found in Staphylococcus aureus isolated in Australia. This enzyme, designated type SI,
is unlike those encoded by plasmids in Gram-negative bacteria (Young, Skurray &
Amyes, 1987).
In common with the trimethoprim resistance found in Gram-negative bacteria of
human origin, plasmid-encoded trimethoprim resistance in bacteria isolated from
domesticated farm animals in the United Kingdom has predominantly been mediated
by the type la dihydrofolate reductase (Wise et al., 1985; Carter, Towner & Slack, 1987;
Amyes, 1987). However, an isolate of Escherichia coli implicated in an outbreak of
porcine diarrhoea on a farm near Nottingham, possessed plasmid DNA that did not
hybridize with DNA probes specific for the genes encoding the type I-V dihydrofolate
reductases. This paper describes the characterization of this novel plasmid-encoded
dihydrofolate reductase.
Materials and methods
Bacterial strains, plasmids and DNA probes
E.coli P20/10/82 (Tpr) was isolated from an outbreak of porcine diarrhoea in 1982.
Plasmid pUN835 was transferred to E.coli K12 strain J53-2 in bacterial conjugation
experiments as previously described (Wise et al., 1985). Control plasmids encoding
previously characterized dihydrofolate reductases were as follows:— R483 (type la);
pUK163 (type lb); R67 (type Ila); R388 (type lib); R751 (type lie); pAZl (type III);
pUKl 123 (type IV); and pLK09 (type V). All the plasmids were carried by E. coli K12
derivatives. Plasmid DNA was isolated as described previously (Carter et al., 1987).
DNA probes specific for known dihydrofolate reductases comprised the following:—
499 bp Hpal fragment of pFE872 (type I) (Fling & Richards, 1983); 275 bp Sau3A-
EcoRl fragment of pWZ820 (type II) (Zolg, Hanggi & Zachau, 1978); 822 bp £coRI-
Hindlll fragment of pFE1242 (type III) (M. Fling, personal communication); 1.7 kb
Clal fragment of pUK1148 (type IV); 500 bp Hindi fragment of pFK09 (typeV)
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(Towner, Young & Amyes, 1988). Probes were isolated and labelled with biotin-11-
dUTP as described by Towner et al. (1988).
Hybridization conditions
Plasmid DNA was isolated on agarose gels and transferred to nitrocellulose filters using
a Semidry Electroblotter (Sartorius Ltd.) as described previously (Towner et al., 1988).
Routine hybridization conditions were those of Carter et al. (1987), with detection of a
positive hybridization result by means of a BlueGENE kit (Bethesda Research Labora¬
tories Ltd). The conditions and protocols used were as recommended by the manufac¬
turer. Low stringency hybridization experiments were performed in the same manner,
except that only two post-hybridization washes were performed, each in 0.03 M sodium
citrate buffer pH 7.0, containing 0.3 M sodium chloride at room temperature for
15 min.
Enzyme preparation and assay
Lor the determinations of specific activity, dihydrofolate reductase was prepared from
1 1 overnight cultures of bacteria grown in Isosensitest Broth (Oxoid Ltd.) with
vigorous agitation at 37°C, as detailed by Young & Amyes (1986). The cells were
harvested by centrifugation (6000 g, 10 min, 4°C) and resuspended in buffer A (50 mM
sodium phosphate pH 7.4 containing 10 mM 2-mercaptoethanol and 1 mM EDTA). The
bacteria were disrupted by sonication and the cell debris removed by centrifugation
(40,000 g, 1 h, 4°C). Dihydrofolate reductase activity was assayed at 37°C in 40 mM
sodium phosphate buffer pH 6.0, as described previously (Amyes & Smith, 1974). One
unit of dihydrofolate reductase activity was defined as the amount of enzyme required
to reduce 1 nmol of dihydrofolate per minute. Protein concentrations were estimated by
the method of Waddell (1956). Lor enzyme purification, extracts from 3-1 cultures were
prepared as above. Ammonium sulphate was added to 50% saturation. After centrifu¬
gation (14,000 g, 30 min, 4°C), further ammonium sulphate was added to the superna¬
tant to give 80% saturation. After further centrifugation, the pellet was resuspended
and dialysed against buffer A. The dialysed sample was applied to a Sephadex G-50
column (2 cm2 x 100 cm) that had previously been equilibrated with buffer A and eluted
with the same buffer. Molecular mass was determined by Sephadex exclusion
chromatography as described previously (Amyes & Smith, 1974). Heat sensitivity,
enzyme kinetics and inhibitor studies were investigated as previously described (Amyes
& Smith, 1976).
Isoelectric focusing of dihydrofolate reductases
Isoelectric focusing was performed by a modification of the method of Broad & Smith
(1982). Aliquots (10 pi) of the dissolved and dialysed pellet obtained from precipitation
with 80% saturated ammonium sulphate were applied to the surface of standard
polyacrylamide plates containing ampholines capable of producing a gradient from
pH 3.5-9.5 (LKB Products No. 1804-101). Standard pi markers were also applied to
each gel. The samples were focussed for six hours on a cooled (9°C) Ultrophor
electrophoresis system (LKB No. 2217) at 500 V and 20 mA, limited by constant power
set at 1 W. The gels were stained for dihydrofolate reductase activity by the method of
Broad & Smith (1982).
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Results
Isolation and characterization of the trimethoprim resistance plasmid pUN835
E. coli P20/10/82 was isolated from the faeces of a pig in Nottinghamshire in 1982. The
strain was highly resistant to trimethoprim (MIC > 1024 mg/1) and the trimethoprim
resistance gene freely transfered at a frequency of 5 x 10"5 to the recipient E. coli K12
strain J53-2 by conjugation (Wise et al., 1985). Isolation of the plasmid DNA showed
that the trimethoprim resistance determinant was carried on a single plasmid (pUN835)
of approximately 100 kb. Plasmid pUN835 was shown also to carry resistance genes to
kanamycin, ampicillin, streptomycin, sulphonamides, tetracycline and chloramphe¬
nicol.
Hybridization ofpUN835 with specific gene probes
A previous study (Carter et al., 1987) demonstrated that 82% of trimethoprim
resistance plasmids from the Nottingham area carried the gene for dihydrofolate
reductase type la. Plasmid pUN835 was one of 15 plasmids in the study which failed to
hybridize with the type la probe. In this present study we confirmed this lack of
hybridization, even under low stringency conditions. Plasmid pUN835 was tested
therefore, in further hybridization experiments with the available DNA probes for
other, previously characterized dihydrofolate reductase types. No hybridization was
detected with the probes specific for types II, IV or V enzymes. Hybridization was
detected with the type III probe; however, the type III gene has, until recently, been
found only in a single Salm. typhimurium isolate from New Zealand, and it is known
that the type III probe contains a large sequence of DNA external to the dihydrofolate
reductase structural gene (Fling et al., 1988). It was decided therefore, to carry out a
detailed biochemical analysis of the dihydrofolate reductase encoded by pUN835.
Specific activity of dihydrofolate reductase encoded by pUN835
Cell-free extracts were obtained from E. coli (pUN835) cultures grown in the presence
and absence of trimethoprim (10 mg/1). When the strain was grown in the absence of
the drug, the specific activity of dihydrofolate reductase was 11.5 enzyme units/mg
protein and when the strain was grown in the presence of trimethoprim the enzyme
preparation had a specific activity of 10.5 enzyme units/mg protein, indicating that the
enzyme was not inducible in the presence of the inhibitor. In both cases, the level of
enzyme was approximately 10-fold greater than that found in trimethoprim sensitive
E. coli strains.
Purification of the dihydrofolate reductase encoded by pUN835
Dihydrofolate reductase activity was purified from three litres of culture. After removal
of nucleic acids with streptomycin sulphate, the protein was selectively precipitated
with ammonium sulphate between 50-80% saturation. The precipitated protein was
dialyzed against buffer A and applied to a Sephadex G-50 column. A major dihydrofo¬
late reductase peak was detected (Figure 1). To distinguish the plasmid enzyme from
the E. coli host dihydrofolate reductase, the fraction assays were repeated in the
presence of 4 p.M trimethoprim, a concentration shown previously to be sufficient to
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Figure 1. Elution profile of pUN835-encoded enzyme during Sephadex G-50 gel filtration. The dihydrofo¬
late reductase activity obtained after Sephadex exclusion chromatography of a 50-80% ammonium sulphate
precipitate from E. coli K12 strain J53-2 (pUN835) (#). Elution of standard marker proteins: chymotrypsi-
nogen, molecular mass = 25,000; cytochrome c, molecular mass = 12,384; aprotinin, molecular mass =
6500 (O).
eliminate chromosomal dihydrofolate reductase activity (Amyes & Smith, 1974). The
peak value was reduced slightly but the maximum enzyme activity was still found at the
same position. When the gel filtration was repeated in the presence of standard
proteins, the peak of activity for the plasmid dihydrofolate reductase corresponded to a
relative molecular mass of 11,500 (Figure 1).
The peak fraction of the plasmid enzyme (58) had a specific activity of 815.0 enzyme
units/mg protein which represented a greater than 50-fold purification of the crude
extract. This fraction was used in the further characterization of the enzyme. The
plasmid enzyme was heat labile, losing 50% of its activity after 90 sec at 45°C (Table I).
Properties of the dihydrofolate reductase encoded by pUN835
The activity of the pUN835-encoded enzyme was assayed in the presence of increasing
concentrations of trimethoprim and methotrexate in order to determine the concentra¬
tion of each antifolate required to give 50% inhibition (ID50). The ID50 of trimethoprim
for the plasmid enzyme was 30 pu and of methotrexate was 3 pM. In both cases, the
enzyme activity was inversely proportional to the logarithm of the inhibitor concentra¬
tion (Table I).
The activity of the peak fractions was investigated under conditions of partial
saturation with dihydrofolate (DHF) and full saturation with NADPH (50pM). In
control studies, we found that concentrations of NADPH above 10 pu do not limit the
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Figure 2. Lineweaver-Burk plot of the partially purified dihydrofolate reductase coded by plasmid pUN835
in the presence (A) and absence (#) of 10/rM trimethoprim.
activity of this enzyme. The results, analysed by the method of Lineweaver and Burk,
showed that the Km value for dihydrofolate of the plasmid enzyme (Figure 2) was
20 [xm. This is similar to the values for most of the other types of dihydrofolate
reductases coded by plasmids that occur in Gram-negative bacteria but is about 25-fold
greater than the value obtained with the type III enzyme (Amyes, 1986).
When the assays were repeated in the presence of trimethoprim it was found that the
Vmax of the plasmid dihydrofolate reductase remained (Figure 2) identical to that for the
uninhibited enzyme indicating that the drug caused competitive inhibition. The inhibi¬
tor constant (A!,) for trimethoprim was 7.0 /xm, similar to that reported for the type la
enzyme (Pattishall et al., 1977).
Examination of the enzyme by isoelectric focusing revealed that the dihydrofolate
reductase encoded by plasmid pUN835 had an isoelectric point (pi) of 7.1. This is very
Table I. Comparison of dihydrofolate reductases encoded by pUN835 with the
type I and V enzymes
Relative
Enzyme molecular Tp°ID50 Mtx IDS0 td50 DHF Km Tp K,
mass (flM) (JJM) (min) (/TM) (HM)
Type VII 11500 30.0 3.0 1.5 20.0 7.0
Type la 35000 57.0 5.6 0.5 5.6 7.4
Type lb 24500 32.0 2.8 1.2 11.0 41.0
Type V 18000" 23.0 3.5 3.0 15.5 3.2
"Mtx, methotrexate; Tp, trimethoprim; DHF, dihydrofolate; TD50, time taken for the
enzyme to lose half its activity at 45°C;
"Subunit size.
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similar to the pi that we find for the type la enzyme (7.1), which has similar
biochemical properties but a quite different molecular mass. The pUN835 dihydrofo¬
late reductase is distinct from all other plasmid-encoded enzymes on isoelectric
focusing.
Discussion
Plasmid pUN835 encodes the production of a dihydrofolate reductase that is relatively
insensitive to inhibition by trimethoprim and confers a high level of resistance to the
drug. Failure of pUN835 DNA to show significant hybridization with any of the
available gene probes specific for previously characterized dihydrofolate reductase
genes identified the enzyme as worthy of detailed biochemical analysis. The properties
of this enzyme are distinct from those of the type II, III, IV and VI plasmid-encoded
dihydrofolate reductases of Gram-negative bacteria (Amyes, 1986; Young & Amyes,
1986; Wylie et al., 1988) and from those of the type SI plasmid-encoded dihydrofolate
reductase found in staphylococci (Young et al., 1987). However, the pUN835-encoded
enzyme does show some similarity to the type la, lb and V dihydrofolate reductases
(Amyes, 1986; Thomson & Amyes, 1988). It has similar inhibition profiles with respect
to trimethoprim and methotrexate and shares the heat lability of these enzymes.
Additionally, the type VII enzyme has a very similar pi to the type la enzyme produced
by plasmid pFE872, a composite plasmid comprising the type la dihydrofolate reduc¬
tase gene cloned into the vector plasmid pBR322. The pi value of 7.1 is slightly higher
than that previously reported for the type la enzyme encoded by plasmid R483 (Broad
& Smith, 1982). On the other hand, the molecular size of this enzyme is quite different
from either the type I or the type V dihydrofolate reductases. In addition, genetic
probes made from the type I and type V genes did not hybridize with plasmid pUN835,
even under low stringency conditions, thereby demonstrating the lack of DNA homo¬
logy between the genes coding for these enzymes.
Although pUN835 was isolated from an E. coli strain of animal origin, a previous
study of the ecology of trimethoprim R-plasmids in the Nottingham area has provided
evidence that, although there may only be limited overlap of the bacterial strains from
humans and animals, there is a common pool and, therefore, exchange of certain types
of R-plasmids carried by these strains (Towner, Wise & Lewis, 1986). It seems almost
certain, therefore, that the new type VII dihydrofolate reductase will in the future also
be detected in bacteria isolated from the human community.
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PURIFICATION AND RAPID AUTOMATIC AMINO ACID SEQUENCING OF THE
TYPE IV DIHYDROFOLATE REDUCTASE \A J*)
C.J. Thomson, S.G.B. Amyes, Department of Bacteriology, Medical School,
University of Edinburgh, Edinburgh EH8 9AG.
Resistance to trimethoprim is usually mediated by the plasmid-encoded
production of an additional trimethoprim-resistant dihydrofolate reductase
(Amyes & Smith, 1974). Thirteen different trimethoprim-resistant dihydrofolate
reductases have been identified and distinguished biochemically (Amyes, 1989).
Some of the genes responsible for these enzymes have had their DNA nucleotides
sequenced. The results of this type of gene sequencing represent the ultimate
information in the study of the evolution of genes conferring resistance to
antimicrobial agents. However DNA sequencing is a lengthy process for the study
of the epidemiology of antibiotic resistance. We report the use of automatic
amino acid sequencing to give a rapid partial sequence sufficient to determine
evolutionary relationships among trimethoprim resistance genes.
Amongst the plasmid mediated dihydrofolate reductases the type IV is unique as
the enzyme is only partially resistant to trimethoprim. In addition, it is the
only inducible plasmid-encoded dihydrofolate reductase. In order to see how the
type IV enzyme fitted into the evolution of plasmid-mediated dihydrofolate
reductases it was essential to determine its amino acid sequence. Two
properties make dihydrofolate reductases suitable for rapid amino acid
sequencing; firstly the active site is situated at the N-amino terminal of the
protein and secondly purification to the native protein is relatively easy with
the use of methotrexate agarose affinity chromatography.
Dihydrofolate reductase was prepared from 10L overnight culture of Escherichia
coli J62-2(pUK1123) in Isosensitest broth, and the bacteria were harvested by
centrifugation and disrupted by sonication. The enzyme was precipitated with
ammonium sulphate (50-80% saturation) and separated on Sephadex G-75 gel
filtration column (2cm^ x 90cm). The fractions showing peak activity were
pooled and then applied to a column containing methotrexate agarose (0.375cm2
x 20cm). This column was washed until the absorbance at 280nm was less than
0.01 OD units and all the unbound protein had been removed. The dihydrofolate
reductase was then eluted with 2mL of 0.5M K2HPO4 containing 4^imoles
dihydrofolate and 5mL fractions were collected. The three eluted fractions
containing peak activity were pooled and concentrated with Amicon centriprep
and centricon concentrators to 60 jiL. Reverse phase HPLC analysis showed this
preparation to be pure and it was then analysed on an Applied Biosystems 477A
protein sequencer.
Sequence analysis gave a clear result for the first fifty amino acids.
Comparison of the sequence to that of the other plasmid-mediated dihydrofolate
reductases shows the type IV to be clearly distinct. It shows most homology to
the E. coli resistant chromosomal enzyme with 20 out of the first 50 amino
acids showing direct matches. In particular the type IV sequence has a
phenylalanine at residue 31, which is the only substitution that the E. coli
resistant enzyme has compared with the normal sensitive enzyme. The similarity
of the type IV dihydrofolate reductase to the E. coli resistant enzyme suggests
that the induced mechanism of the type IV dihydrofolate reductase is more
similar to the hyper-production mechanism of trimethoprim resistance, mediated
by the bacterial chromosome, rather than a classic plasmid-mediated resistant
by-pass. In this mechanism, sufficient moderately-resistant dihydrofolate
reductase is produced which binds all the available trimethoprim and still
allows the reduction of dihydrofolate to tetrahydrofolate.
We thank the Wellcome Trust for their support of this work.
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EMERGENCE OF TEICOPLANIN-RESISTANT COAGULASE-NEGAT I V,E
STAPHYLOCOCCUS.
C. Branger*, C. Rigal, B. Bruneau, Ph. Goullet.




Although Staphylococcus haemolyticus and S ._ e p i d e r m i d i s ha y e,
been shown to be less sensitive to teicoplanin than S. aureus,
few observations with resistant clinical strains have been
published. We have recently isolated two strains of coagulase-
negative StaphyIococcus resistant to teicoplanin, from blood
cultures of compromised patients receiving teicoplanin.
The first patient, a 62 year-old woman with lymphoid leukemia
received teicoplanin for the cure of a Streptococcus sanguis I I
bacteriemia. After 3 days of treatment, fever persisted and
blood cultures yielded S. haemo1yticus. The second patient, a 64
year-old man with diabetes, developed a central catheter-
associated S. aureus bacteriemia. While on teicoplanin therapy,
he developed fever and S. epidermidis was isolated from blood
cultures. Treatment with IV vancomycin resulted in cure of the
infection for both patients. Mies of teicoplanin, by broth
dilution, was 32 pg/ml for S. haemoIyticus and 16 pg/ml for
?_• epidermidis. Both strains were fully sensitive to vancomycin
(Mies = ljjg/ml). Presence of a teicoplanin inactivating enzyme
could not be demonstrated by microbiologic techniques. A
decrease of binding affinity of teicoplanin to the cell wall
could be shown for S_. haemo 1 y t i cus strain which did not resist
to bacteriolysis by lyzozyme after pretreatment by teicoplanin.
Teicop 1 anin-resistant strains of coagu1ase-negative Staphy-
1ococcus seem to have an increasing clinical importance.
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INDUCTION MECHANISM OF THE TYPE IV DIHYDROFOLATE REDUCTASE
C.J. Thomson* and S.G.B. Amyes, Bacteriology Department, Medical School,
University of Edinburgh, Edinburgh, UK.
A number of plasmid-encoded dihydrofolate reductases (DHFR) have been
reported which confer resistance to trimethoprim (Tp). Induction systems
are uncommon in Gram-negative plasmid-encoded resistance genes and only one
of the trimethoprim resistance genes is inducible. Little is known about
this induction mechanism other than increasing the Tp challenge causes a
600-fold increase in the production of DHFR and that this increase does not
result from a genetic change. Further experiments have now been carried out
to determine the induction mechanism. DHFR production was not switched on
immediately the cells were challenged with Tp. There was a considerable
drop in viable count and change in cell morphology before the resistance
mechanism was switched on. When E. coli J62-2 (pUK1123) was challenged with
Tp induction occurred while the bacteria were in lag phase but not in
logarithmic phase. The induction of the type IV DHFR was also very
sensitive to the presence of thymidine and this could not be overcome by
increasing the Tp concentration. When plasmid pUK1123 was transferred into
E. coli J53 and challenged with Tp, no induction occurred and this could be
related to the different auxotrophic requirements of this strain. It is
known that the type IV DHFR is only moderately resistant to Tp when compared
to other plasmid mediated DHFRs. These experiments show that the type IV
DHFR is only induced when the organism is under considerable stress. This
resistance mechanism is novel for a plasmid mediated enzyme in that it
overcomes the inhibition of Tp by producing large quantities of a partially
resistant DHFR. It is more similar to the mechanism reported for some
strains which have become resistant by over-production of the chromosomal
DHFR.
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Identification and cloning of the Type Ilia plasmid-
encoded dihydrofolate reductase gene from
trimethoprim-resistant gram-negative bacteria isolated
in Britain
C.J.THOMSON, K.J.TOWNER*, H.-K. YOUNG+ and S. G. B. AMYESt
Department of Bacteriology, The Medical School, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG;
*Department of Microbiology and PHLS Laboratory, University Hospital, Nottingham NG7 2UH; and
tDepartment ofBiological Sciences, University of Dundee, Dundee DDI 4HN
Summary. A clinical strain of Escherichia coli isolated in Nottinghamshire in 1980
was shown to harbour the type Ilia trimethoprim-resistant dihydrofolate reductase
gene, previously identified on only one occasion, in New Zealand in 1979. The gene
was identified by hybridisation with an 855-bp type III gene probe and its classification
as a type Ilia dihydrofolate reductase was confirmed by detailed biochemical analysis
of the enzyme product. The dihydrofolate reductase was identical in size and iso¬
electric point with the original type Ilia enzyme and shared similar inhibitory and
kinetic profiles. The trimethoprim resistance gene was subsequently cloned and the
type Ilia dihydrofolate reductase gene was localised to a 700-bp EcoKVPstl fragment.
This smaller fragment may prove to be a more specific DNA probe for the future
identification of type Ilia dihydrofolate reductase genes.
Introduction
The synthetic antimicrobial agent trimethoprim
(Tp) selectively inhibits the bacterial enzyme
dihydrofolate reductase (DHFR) (5,6,7,8-tetra-
hydrofolate: NADP+ oxidoreductase, EC1.5.1.3)
which catalyses the reduction of dihydrofolate to
tetrahydrofolate, an essential cofactor involved in
the biosynthesis of purines, pyrimidines and amino
acids. Resistance to trimethoprim mediated by
resistance plasmids (R-plasmids), was first reported
by Fleming et al.' The mechanism of resistance
involves the plasmid-encoded synthesis of an
additional trimethoprim-resistant dihydrofolate re¬
ductase which enables the inhibited host enzyme to
be by-passed.2
Seven major types of plasmid DHFRs present in
gram-negative bacteria have been characterised on
the basis of their biochemical properties (see
review).3 They vary in molecular size, heat lability,
antifolate sensitivities and Michaelis Menten ki¬
netics. Specific gene probes have now been devel¬
oped which can identify several of the genes
Received 3 July 1989; accepted 2 Oct. 1989.
f Correspondence should be sent to Dr S. G. B. Amyes,
Department of Bacteriology, The Medical School, University of
Edinburgh, Teviot Place, Edinburgh EH8 9AG.
encoding the various enzyme types (see Materials
and methods).
Strains producing each of the enzyme types I, II,
V, VI and VII exhibit a characteristically high level
of resistance to trimethoprim—minimum inhibi¬
tory concentration (MIC) > 1000 mg/L. In contrast,
strains producing the types III and IV plasmid
DHFRs are only moderately resistant to trimetho¬
prim (MIC ^64 mg/L). Unlike other plasmid
DHFRs, the type III and IV enzymes are only
slightly more resistant than the Escherichia coli
chromosomal DHFR to the inhibitory action of
trimethoprim (Ki = 19nM and 63 nM respec¬
tively).4' 5
The gene encoding the prototype type III enzyme
(now designated type Ilia) was found on a single
plasmid (pAZl) originating in a clinical isolate of
Salmonella typhimurium in New Zealand in 1979.6
Two other biochemically similar plasmid-encoded
enzymes (types Mb and IIIc) have recently been
reported in Shigella strains isolated in the USA.7
The other moderately resistant DHFR gene, type
IV, has been identified on several different plas¬
mids, all of which originated in clinical isolates of
bacteria in Southern India.8
In this paper we describe the identification of the
type Ilia plasmid-encoded DHFR in bacteria
isolated in Great Britain. This is the first report of
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the type Ilia trimethoprim resistant DHFR since
its original discovery in New Zealand in 1979.
Materials and methods
Bacterial strains andplasmids
E. coli TM858 (Tpr) was isolated in 1980 from a urine
specimen from a hospitalised patient in Nottingham.
Trimethoprim resistance was mobilised, in bacterial
conjugation experiments, to E. coli K12 strain J 53-2,
following transposition on to the incP group plasmid RP4
as previously described.9 Control plasmids encoding
previously characterised DHFRs were as follows: R483
(type la); pUK163 (type lb); R67 (type Ha); R388 (type
lib); R751 (type lie); pFE1242 (type Ilia); pUK1123
(type IV); and pLK09 (type V) (see review).10 All the
plasmids were carried by E. coliK12 derivatives. Plasmid
DNA was isolated as described previously." DNA
probes specific for known DHFR genes comprised the
following: 499-bp 11pal fragment of pFE872 (type I);12
275-bp Sa«3A-£coRI fragment of pWZ820 (type II);13
855-bp £coRI-//mdIII fragment of pFE1242 (type III)
(M. E. Fling, personal communication); 1-7-kb Clal
fragment of pUK1148 (type IV);14 500-bp Hincll
fragment of pLK09 (type V).14 Probes were isolated and
labelled with biotin-11-dUTP as described by Towner et
aid* Cloning procedures were as described by Maniatis
etald5
MIC determination
The MIC of trimethoprim for E. coli strains was
determined on Diagnostic Sensitivity Test Agar (DSTA;
Oxoid) as described previously.8
Hybridisation
Plasmid DNA was isolated on agarose gels and
transferred to nitrocellulose filters with a Semidry
Electroblotter (Sartorius Ltd) as described previously.14
Hybridisation conditions were those of Carter et a/.,11
with detection of a positive hybridisation result by means
of a BlueGENE kit (Bethesda Research Laboratories
Ltd); the conditions and protocols used were those
recommended by the manufacturer.
Enzymepreparation and assay
DHFR was prepared from 2-L overnight cultures of
bacteria grown in IsoSensitest Broth (Oxoid) with
vigorous agitation at 37°C, as described by Young and
Amyes.5 The cells were harvested by centrifugation
(6000 <7, lOmin, 15°C) and re-suspended in buffer A
(50 mM sodium phosphate, pH 7-4, containing 10 mM /}-
mercaptoethanol and 1 mM EDTA). The bacteria were
disrupted by sonication and the cell debris was removed
by centrifugation (40 000 g, 1 h, 4°C). DHFR activity
was assayed at 37°C in 40 mM sodium phosphate buffer,
pH 6 0, as described previously.2 One unit of DHFR
activity was defined as the amount of enzyme required to
reduce 1 nmol of dihydrofolate/min. Ammonium sul¬
phate was added to 50% saturation. After centrifugation
(14 000 g, 30 min, 4°C), further ammonium sulphate was
added to the supernate to give 80% saturation and,
following further centrifugation, the pellet was dialysed
against buffer A. It was applied to a Sephadex G-75
column (2 cm2 x 90 cm) previously equilibrated with
buffer A and eluted with the same buffer. Molecular mass
was determined by Sephadex exclusion chromatography
as described previously.2 Heat sensitivity, enzyme kinet¬
ics and inhibitor studies were performed as previously
described.16
Iso-electric focusing ofDHFRs
Iso-electric focusing was performed by a modification
of the method of Broad and Smith;17 10-/d volumes of
the re-suspended and dialysed 80% saturation ammonium
sulphate pellet were applied to the surface of standard
LKB polyacrylamide plates containing ampholines ca¬
pable of producing a gradient from pH 3-5 to 9-5 (no.
1804-101). Standard pi markers were also applied to
each gel. Samples were focused for 6 h on a cooled (9°C)
LKB Ultrophor electrophoresis system (no. 2217) at
500 V and 20 mA, limited by constant power at 1 W. The
gels were stained for DHFR activity by the method of
Broad and Smith.17
Results
Identification and cloning of the type Ilia DHFR
gene
E. coli TM858 was isolated from the urine of a
hospitalised patient in Nottinghamshire in 1980.
This strain was highly resistant to trimethoprim
(MIC> 1024 mg/L). Trimethoprim resistance was
not freely transferable and could be mobilised to E.
coli K12 strain J53-2 only following transposition
on to plasmid RP4. The resulting transconjugant,
E. coli J53-2 (pUN635 = RP4 : : Tni/75), was also
highly resistant to trimethoprim (MIC> 1024 mg/
L). Therefore, purified plasmid DNA was hybrid¬
ised with those gene probes known to identify high
level trimethoprim resistance genes (i.e., DHFR
types I, II and V gene probes). However no
hybridisation occurred with any of these probes,
which indicated the presence of a novel DHFR
gene.
To expedite a more detailed analysis of the
trimethoprim resistance gene and its product, the
trimethoprim resistance gene of strain J53-2
(pUN635) was cloned into the vector plasmid




Fig. 1. Restriction map of recombinant plasmid pUN972
carrying the type Ilia DHFR.
pUC18. Plasmid pUN635 was digested with the
restriction enzymes Pstl and the resulting fragments
were ligated into pUC18. The recombinant plas-
mids were then introduced by transformation into
E. coli HB101 and selection was made for trimeth-
oprim-resistant colonies on DSTA containing tri¬
methoprim 50 mg/L. A single trimethoprim-
resistant clone was obtained which was found to
contain an 0-85-kb Pstl fragment ligated to pUCl 8.
This recombinant plasmid was designated pUN972
(fig. 1). The MIC of trimethoprim for HB101
(pUN972) was found to be 64 mg/L, much lower
than the original pUN635-containing bacteria.
Plasmid pUN972 was hybridised with all avail¬
able plasmid DHFR gene probes. A positive
hybridisation result was obtained only with the
type Ilia DHFR gene probe. Further evidence
suggesting that pUN972 carried a type Ilia DHFR
gene was obtained when a 0-7-kb EcoRl-Pstl
fragment of pUN972 (hg. 1), carrying the trimeth¬
oprim resistance gene, was used to probe control
plasmids encoding previously characterised
DHFRs. Hybridisation was detected only with the
original type Ilia DHFR-encoding plasmid, pAZ 1.
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Fig. 2. Sephadex G-75 gel filtration of the type Ilia DHFR. x x, DHFR activity obtained after sephadex exclusion
chromatography of a 50-80% saturation ammonium sulphate precipitate from E. coli HBlOl (pUN972). • •, Elution of standard
marker proteins (OD!80),
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Purification of the DHFR encoded by pUN972
DHFR activity was purified from 2 L of culture.
After removal of nucleic acids with streptomycin
sulphate, the protein was selectively precipitated
with ammonium sulphate between 50 and 80%
saturation. The precipitated protein was dialysed
against buffer A and applied to a pre-calibrated
Sephadex G-75 column. A major DHFR peak was
eluted during gel filtration corresponding to a
molecular weight of 17 000 daltons (fig. 2). This is
indistinguishable from the 16 900 daltons reported
for the original type Ilia enzyme encoded by
plasmid pAZl.
Characterisation of the pUN972 andpAZl encoded
DHFRs
Inhibitor profiles. To compare the pUN972-
encoded enzyme with the original type Ilia enzyme,
the DHFR encoded by pAZl was also purified and
separated by gel filtration of Sephadex G-75.
Fractions containing peak DHFR activity were
pooled for each enzyme preparation and used for
comparative characterisation.
Both enzymes were found to be heat stable, they
retained more than 50% activity after being held at
45°C for 12 min. Partially purified DHFR activity
was assayed in the presence of increasing concen¬
trations of trimethoprim and methotrexate. Both
enzymes were approximately 10 times more resist¬
ant to inhibition by trimethoprim than the E. coli
chromosomal DHFR, losing 50% of their activity
in the presence of 4-5 pM trimethoprim. This is also
similar to the value previously reported by Joyner
et alf for the pAZl-encoded enzyme. Similarly,
both enzymes were inhibited by 50% in the presence
of 10 times greater concentrations of methotrexate
(0 02 pu) than that required to inhibit the E. coli
chromosomal enzyme.
Michaelis Menten kinetics. The activity of the
pUN972 encoded enzyme was investigated in
conditions of partial saturation with dihydrofolate
and the results were analysed by the method of
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Fig. 3. Lineweaver-Burk plots of the partially purified type Ilia DHFR. The reciprocal of the dihydrofolate concentration (1 /[DHF])
is plotted against the reciprocal of the rate of DHFR activity (1/V) in the presence and absence of trimethoprim. •, No
trimethoprim; o, 5 [M trimethoprim.
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show that the Km value for dihydrofolate was
0-41 /rM, a value similar to that previously published
for the pAZl encoded enzyme. When the assays
were repeated in the presence of trimethoprim it
was found that the maximum velocity remained the
same (fig. 3), indicating that the drug causes
competitive inhibition of the enzyme. The inhibitor
constant (Ki) for trimethoprim was 0 04 /im, again
similar to that reported for the pAZl-encoded, type
IIIaDHFR.
Iso-electric focusing. Final evidence indicating
that the pUN972-encoded dihydrofolate reductase
was identical to the type Ilia enzyme encoded by
pAZl was obtained by determination of the iso¬
electric point of the two enzymes. When run
concurrently, both enzymes were found to co-focus
with a pi of 6-1, thus confirming the classification
of the pUN972-encoded enzyme as a type Ilia
DHFR (fig. 4).
Discussion
The original strain of E. coli studied in this paper
exhibited high level resistance to trimethoprim,
characteristic of plasmid DHFR types I, II, V, VI
and VII. However, hybridisation studies employing
the available DNA probes specific for these DHFR
gene types failed to identify a previously character¬
ised DHFR gene. Further genetic analysis, involv¬
ing cloning of the trimethoprim resistance gene
into the vector plasmid pUC18, revealed a DHFR
gene conferring only a moderate level of trimetho¬
prim resistance in the recombinant strain. Detailed
biochemical analysis of the enzyme product of this
gene showed it to be identical with the type Ilia
enzyme, encoded by pAZl, described by Fling et
al.6 This is the first report of the type Ilia DHFR
gene since its original detection in a clinical isolate
in New Zealand.
One interesting feature of this work is the
apparent reduction in MIC of trimethoprim for the
strain carrying the cloned type Ilia DHFR com¬
pared to the original isolate. One possible explana¬
tion is that a second DHFR gene, conferring a high
level of resistance, was present on the original
transposon and that this "masked" the presence of
the low level type Ilia determinant; however, other
more complicated scenarios involving gene copy
numbers or gene regulation are perhaps more
feasible. For example, the MIC could vary depend¬
ing on the orientation of the insert and whether the
gene was utilising its own promotors or those of
pUC18.
An important consequence of this study has been
6 1
Fig. 4. Iso-electric focusing pattern of the type Ilia DHFRs.
Track A, type Ilia enzyme originally obtained from plasmid
pAZl (New Zealand); track B, type Ilia enzyme obtained from
plasmid pUN972 (Nottingham).
the production of a new type Ilia DHFR gene
probe. The previously available 855-bp DNA probe
for the type Ilia gene contains approximately
350 bp extraneous to the structural gene;18 conse¬
quently it has been shown to produce occasional
"false positive" hybridisation reactions (K. J.
Towner, unpublished results). The gene probe
constructed in this study is smaller (700 bp) and
may prove, therefore, to be more specific. The
elaborate techniques involved in the detection and
confirmation of the type Ilia DHFR gene suggest
that the apparent low incidence of the type Ilia
enzyme may result from a lack of detection rather
than a scarcity of the gene. Therefore, the new gene
probe constructed in this study may be very useful
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in clarifying the epidemiology of what has previ¬
ously been considered to be an extremely unusual
resistance gene.
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N-terminal amino acid sequence of the noyel type Illb trimethoprim-
resistant plasmid-encoded dihydrofolate reductase from Shigella sonnei
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The type Illb dihydrofolate reductase, a novel plasmid-encoded enzyme recently identified in Shigella sonnei, has
been shown to have some similar biochemical properties to the type Ilia dihydrofolate reductase which was first
identified in New Zealand in 1979. However, the type Illb enzyme has a K{ for trimethoprim of 0-4 pM, and a pi of
5-35 (as compared to 19 nM and 61 for the type Ilia); both these results suggest that it is a different enzyme from
the prototype type Ilia. The type Illb dihydrofolate reductase was purified by methotrexate agarose affinity
chromatography, yielding a pure protein as determined by HPLC. Automatic amino acid analysis of the purified
enzyme showed it to be distinct from all other known plasmid-encoded dihydrofolate reductases and quite different
from the type Ilia enzyme. The purified enzyme was examined by SDS-PAGE, which revealed that the type Illb
dihydrofolate reductase was a monomeric protein of Mr 17200.
Introduction
Trimethoprim [2,4-diamino-5-(3,4,5-trimethoxybenzyl)
pyrimidine] prevents the bacterial NADPH-dependent
reduction of dihydrofolate to tetrahydrofolate by compe¬
titively inhibiting the enzyme dihydrofolate reductase
(5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC
1.5.1.3) (Burchall & Hitchings, 1965). A number of
mechanisms of resistance to trimethoprim have been
reported, the most important of these being the plasmid-
encoded production of an additional trimethoprim-
resistant dihydrofolate reductase enabling the trimetho¬
prim blockade of the chromosomal enzyme to be
bypassed (Amyes & Smith, 1974). The trimethoprim-
resistant dihydrofolate reductases found in Gram-
negative bacteria have been divided into a number of
classes based principally on their biochemical profiles
(for reviews see Amyes, 1989; Huovinen, 1987). In
addition, as some of the genes responsible have also had
their DNA nucleotides sequenced, the classification of
these enzymes now also takes into account amino acid
differences (Stone & Smith, 1979; Zolg & Hanggi, 1981;
Fling & Richards, 1983; Flensburg & Steen, 1986; Fling
et al., 1988; Sundstrom et al., 1988). Initially resistance
The amino acid sequence reported in this paper has been registered
in the protein database of the National Biomedical Research
Foundation (NBRF), Washington, DC, USA, and has been assigned
the accession number A33005.
was dominated by the spread of two genes encoding
dihydrofolate reductases types I and II. The type I was
particularly common, probably because the gene respon¬
sible was located on a transposon, Tn7 (Barth et al.,
1976). However, more recently a number of new enzymes
have been identified and now seven main groups have
been distinguished in Gram-negative bacteria on the
basis of their biochemical properties, DNA/DNA
hybridization and amino acid sequences (for a review see
Amyes, 1989).
Trimethoprim-sulphamethoxazole is widely used in
the treatment of shigellosis (Salter, 1982). Until recently
trimethoprim resistance in Shigella was relatively un¬
common. However, increased use of trimethoprim in the
treatment of shigellosis has resulted in a large increase in
trimethoprim resistance. This now represents a major
concern in many parts of the world. In Bangladesh the
level of trimethoprim resistance rose from 5% in 1979 to
83% in 1983 (Zaman et al., 1983; Shahid et al., 1985)
whilst in England and Wales the level of resistance rose
from 1-3% to 17% in the same period (Gross etai, 1984).
Some studies on trimethoprim-resistant shigella have
demonstrated the dominance of the type I dihydrofolate
reductase whilst others have shown a significant propor¬
tion of strains which do not react with probes for genes
encoding for either of the commonly occurring type I and
type II enzymes (Chatkaeomorakot et al., 1987). Re¬
cently, two novel plasmid-encoded dihydrofolate reduc-
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tases have been identified from epidemic strains of
trimethoprim-resistant Shigella sonnei isolated in the
USA (Bargef al., 1989). These novel dihydrofolate reduc¬
tases were identified both by their inability to hybridize
with gene probes for dihydrofolate reductases I, II and III
and by their biochemical properties. However, in many
respects, they appeared biochemically most similar to the
type III dihydrofolate reductase. One in particular was
very similar; it conferred only a moderate level of
trimethoprim-resistance (MIC 128 mg 1_I) and its ID50
of trimethoprim was 2 pM, which is identical to the value
for the type III dihydrofolate reductase (Joyner et al.,
1984). The original type III enzyme has been shown to be
a monomeric protein of Mx 16900 and the novel enzyme
was similarly small. On this basis this enzyme was named
the Illb and the original type III dihydrofolate reductase
the type Ilia (Barg et al., 1989). However, the Illb
enzyme did differ in some biochemical properties, most
notably in its isoelectric point, from the type Ilia.
To investigate the relationship between these enzymes
it was essential to examine the amino acid sequence of
this new dihydrofolate reductase. Here we report the use
of methotrexate agarose as an affinity column matrix to
purify the Illb dihydrofolate reductase, enabling its N-
amino terminal amino acid sequence and subunit
structure to be determined.
Methods
Bacterial strains and plasmids. The type Illb dihydrofolate reductase
was prepared for sequence and subunit analysis from Escherichia coli
C600(pBH600) (Barg et at., 1989).
Enzyme preparation for sequence analysis. Dihydrofolate reductase
was prepared from 10 litre overnight cultures of E. coli in Oxoid
Isosensitest Broth, grown at 37 °C and shaken vigorously (Young &
Amyes, 1986). Bacteria were harvested by centrifugation at 6000 £ for
15 min and resuspended in buffer A (50 mM-sodium phosphate buffer
pH 7-4, containing 10 mM-2-mercaptoethanol and 1 mM-EDTA). The
bacteria were disrupted by sonication (2 x 30s, 8 pM, MSE Soniprep)
and the lysate cleared by centrifugation at 40000 £ for 1 h at 4°C.
Dihydrofolate reductase activity was assayed at 37 °C in 40 mM-sodium
phosphate buffer pH 6 (Amyes & Smith, 1974); the units of activity
were nmol dihydrofolate reduced min"1.
Enzyme preparation for biochemical analysis. Enzyme preparation,
biochemical analysis and iso-electric focusing were done as described
by Amyes et al. (1989).
Enzyme purification and sequence analysis. Dihydrofolate reductase
activity was precipitated from the crude preparation by the addition of
ammonium sulphate from 50 to 80% saturation. The enzyme was
resuspended in buffer and separated on a Sephadex G75 gel filtration
column (2 cm: x 90 cm). Fractions showing peak enzyme activity
were pooled and applied to a methotrexate-agarose column
(0-375 cm: x 20 cm) made up according to the manufacturer's instruc¬
tions (Sigma). This column was washed with buffer A until the P280
was less than 0-01 and all the unbound protein had been removed. The
dihydrofolate reductase was then eluted with 2 ml 0-5 m-K2HP04
containing 4 pmol dihydrofolate and washed with 75 ml 0-1 m-K2HP04
containing 1 pm-dihydrofolate (Kaufman, 1974). Fractions of 5 ml
were collected. The three eluted fractions showing peak activity were
pooled and concentrated with Amicon Centriprep and Centricon
concentrators to 30 pi. Prior to sequence analysis the preparation was
checked for purity by reverse-phase HPLC analysis. The only protein
peak was selected from the reverse-phase HPLC and analysed on an
Applied Biosystems 477A protein sequencer (Hayes et al., 1989).
Gel electrophoresis. SDS-PAGE was done on a Pharmacia Phast
system according to the manufacturer's instructions. A Sigma
molecular weight kit (14000-70000) was used to calibrate the gel.
Results
Biochemical properties of the type Illb dihydrofolate
reductase
The plasmid-bome dihydrofolate reductase gene from
the Shigella sonnei strain responsible for an outbreak of
dysentery at a nursing home in East Tennessee in 1985
was transferred to E. coli C600(pBH600). The dihydro¬
folate reductase from this transconjugant was then
examined in detail.
The Mr of the dihydrofolate reductase produced by the
transconjugant was 17000 when measured by Sephadex
gel filtration. When the measurement was repeated in
the presence of 4 pM-trimethoprim to remove any
chromosomal dihydrofolate reductase the position of the
peak was unchanged. The enzyme was sensitive to the
presence of trimethoprim, requiring 2 pM of the drug to
give 50% reduction in activity. It was also sensitive to
methotrexate, with 0-02 pM-methotrexate reducing the
enzyme's activity by half. The enzyme was, however,
heat stable, maintaining more than 50% of its activity
after 12 min at 45 °C.
The activity of the enzyme was measured at limiting
substrate concentrations in the presence and absence of
trimethoprim. Analysis by the method of Lineweaver
and Burk showed that the type Illb dihydrofolate
reductase had a Km for dihydrofolate of 9-5 pM and that it
was competitively inhibited by trimethoprim with a Kx of
0-4 pM.
Biochemically the enzyme had several properties
which were very similar to the type Ilia dihydrofolate
reductase isolated in New Zealand in 1979. However,
iso-electric focusing of the type Illb enzyme showed that
it focused clearly with a pi of 5-34 which was distinct
from that of the New Zealand type Ilia dihydrofolate
reductase (Table 1).
Enzyme purification
The activity of the enzyme preparation was measured
throughout the purification procedure. Prior to gel
filtration the resuspended pellet from ammonium sul-
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Fig. 1. Elution profile of pBH600-encoded enzyme during Sephadex
G-75 gel filtration. •, Dihydrofolate reductase (DHFR) activity
obtained after Sephadex exclusion chromatography of a 50-80%
ammonium sulphate precipitate from E. coli C600(pBH600). The
positions of the elution peaks of the standard marker proteins are
indicated by arrows.
phate precipitation contained 78124 units of dihydro¬
folate reductase activity. Separation on Sephadex gel
filtration gave a clearly defined peak of enzyme activity
(Fig. 1). Fractions 62-72 were pooled; they contained a
total of 28874 units. The pooled fractions were run onto
the methotrexate column. No dihydrofolate reductase
activity was detected in the protein which initially
passed through the column, indicating that the enzyme
had been completely bound to the methotrexate agarose.
The column was washed continuously until the Az80 of
the eluate had returned to a value of less than 0-01, i.e. no
further protein was passing through. The dihydrofolate
reductase activity was eluted by the addition of 2 ml
0-5 m-K2HPOa containing 4 pmol dihydrofolate. Frac¬
tions of 5 ml were collected and assayed for enzyme
activity. The three fractions showing peak activity were
pooled and contained a total of 19933 units. This 15 ml
sample was concentrated with Amicon Centriprep and
Centricon concentrators to 30 pi, which retained 16499
units. Before sequence analysis this sample was tested for
purity by reverse-phase F1PLC and this revealed the
presence of a single protein peak.


































Type Ilia M L 1 S L I A A L A H N N L 1 G K D N L I P w - H L P A D L R H F K A V T L G k P V V M G R R T
E. coli K.12 M I S I I A A L A V 0 R V I G M E N A M P w - N L P A D L A W F K R N T L N k P V J_ M G R H T
Type la M K L S L M V A 1 S K N G V I G N G P 0 I P u - S A K G E q L L F K A J_ T Y N q W L L V G R k T
Type V M K V s M A A K A K N G V 1 G C G P H I P M - S A K G E q L L F k A I r Y N 0 W L I V G R k T
Type SI M T L s I 1 V A M D K Q R V 1 G Y Q N q L P W - H L P N D L K H I k q L T T G N T I V M A R k T
Type I la M E R s S N E V S N P V A G N F V F P s N A T F G M G 0 R I 8 K K S G A A w q g q 1 V G W Y C T
Type lib M G Q s S 0 E A N A P V A G Q F A L P I S A T F G l g 0 R 1 R K K S G A A mm V V g w Y C T
Type lie M 0 Q H N N G V S T L V A G q F A L P s h A t F G I G D R V R K k S G A A w q g Q v V G w Y k T
10 20 30 40
Fig. 2. Determined N-terminal amino acid sequence (47 amino acids) of the type Illb plasmid-encoded dihydrofolate reductase.
Identical amino acids are shown by shading. Homologous amino acids, (D E) (R K H) (Q N) (FYW)(IVL M), are underlined. The
amino acids involved in the active site are shown by the symbols at the top of the diagram: binding positions of trimethoprim; A.
additional binding positions of methotrexate; ■, binding positions of NADPH. Positions are taken from Rouch et at. (1989) and
numbering is based on the type Illb sequence.
Table 1. Comparison of the biochemical properties of the type Ilia and Illb dihydrofolate reductases
Tp ids0 Mtx ids0 td50 dhf Km Tp K, Tp MIC
Enzyme (pM) (pM) (min) (pM) (pM) M, pi (pg ml-1)
Ilia 20 0-02 >12 0-4 0019 16900 6-10 64
Illb 2-0 0-02 >12 9-5 0-4 17000 5-34 128
Abbreviations'. Tp, trimethoprim; Mtx, methotrexate; DHF, dihydrofolate.




F.g. 3. PAGE of purified dihy,lrofolate reductase encoded by plasmid
pBH600. The bands were visualized by staining with Coomassie blue.
A, dihydrofolate reductase from E. coli C600(pBH600); B, Sigma
standard marker proteins (M, 14000-70000)
Sequence analysis of the type [jjfo dihydrofolate reductase
Fifteen microlitres of the purified sample was analysed
on an Applied Biosysterns 477A automatic sequencer.
This gave a clear sequence for the first 47 amino acids
(Fig. 2). The Mt of the enzyme suggests a protein of 162
amino acids, thus approximately 30% of the protein has
been examined. The sequence obtained starts with a
threonyl residue, indicating that the f-methionyl residue
had been removed intracellularly. Comparing the se¬
quence with that of the other known plasmid-encoded
dihydrofolate reductases (types I-V and SI) showed this
enzyme to be clearly distinct. Although the type 1Kb
enzyme is biochemically similar to the type Ilia enzyme
isolated in New Zealand in 1979, its homology with this
enzyme is not significantly greater than that with any of
the other plasmid-encoded dihydrofolate reductases.
Submit structure of the type Illb dihydrofolate reductase
The subunit structure of the type Illb dihydrofolate
reductase was examined by running the purified enzyme
on a Pharmacia Phast system SDS gel. The sample was
run on a 10-15% Pharmacia Phast gradient gel accord¬
ing to the manufacturer's instructions. After running on
the SDS gel the type Illb enzyme produced a single band
of protein when stained (Fig. 3); this corresponded to an
Mr of 17200. As the Mr of the native type Illb enzyme
determined by Sephadex gel filtration is 17000, the
enzyme is presumably a monomeric protein.
Discussion
The major groups of plasmid-encoded dihydrofolate
reductases have, in the past, been distinguished from one
another primarily by their biochemical profiles (Amyes,
1986). Recently, however, the number of different
enzyme types has increased (for a review see Amyes,
1989). In some cases the different dihydrofolate reduc¬
tases have quite similar biochemical properties (e.g. the
types I and V) and so it has become necessary to look at
the structure of these enzymes in more detail. This has
been achieved by the examination of either the DNA
nucleotide or amino acid sequences of the enzymes.
If determination of the enzyme's amino acid sequence
is to become a crucial feature in the distinction of
plasmid-encoded dihydrofolate reductases, an alterna¬
tive to DNA nucleotide sequencing is required since it is
too lengthy a process for the routine study of antibiotic
resistance. Therefore a more rapid method is needed and
we thus report the use of such an alternative, namely
rapid automatic amino acid sequencing to give a partial
sequence sufficient to determine evolutionary relation¬
ships amongst trimethoprim resistance genes. Two
properties make dihydrofolate reductases suitable for
rapid automatic amino acid sequencing. Firstly, most of
the active site is situated at the N-terminal end of the
protein so that a single run through a sequencer provides
enough information to evaluate the relationships (Rouch
etal., 1989; Novak et al., 1983). Secondly, in many cases
the enzyme is easily purified with the use ofmethotrexate
agarose, and a native protein, sufficient for sequencing,
can be obtained in a few steps.
Biochemically, the type Illb dihydrofolate reductase is
more similar to the type Ilia enzyme isolated in New
Zealand in 1979 than to any other plasmid-encoded
dihydrofolate reductase. However, it does differ from the
type Ilia enzyme in pi value and in Michaelis-Menten
kinetics.
Comparison of the amino acid sequence for the first 47
amino acids with the sequence of the type Ilia plasmid-
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encoded dihydrofolate reductase shows the type Illb
enzyme to be clearly distinct (Fig. 2). Only fifteen direct
matches are found between the two enzymes; two further
amino acids in the type 1Kb enzyme were homologous to
the amino acids at the same position in the type Ilia. The
type Illb enzyme showed slightly less direct matching
with the E. coli chromosomal dihydrofolate reductase,
with only 13 direct matches and three further homolo¬
gous amino acids. This in contrast to the Ilia enzyme,
which shows a high degree of homology with the E. coli
K12 chromosomal dihydrofolate reductase. The type
1Kb sequence was also compared with the sequences of
the other plasmid-encoded dihydrofolate reductases
types I, II, V and SI (Fig. 2). The type Illb enzyme was
distinct from these, showing 10 direct matches with the
type la and five, six and six direct matches with the types
Ha, lib and lie respectively. The type Illb showed 12
direct matches with the type V and 13 with the type S1. It
showed 13 direct matches with the type IV enzyme
(unpublished results). The sequence data show that
although the Ilia and 1Kb dihydrofolate reductases are
biochemically similar these enzymes are not closely
related in an evolutionary sense.
Like the type Ilia enzyme, the type 1Kb dihydrofolate
reductase is monomeric. It also has a similar Mr.
Therefore, there does appear to be some evolutionary
advantage in the selection of enzymes with this bio¬
chemical profile.
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Introduction. Trimethoprim resistance was first recognised in gram-negative bacteria
20 years ago. Workers in several research centres have studied the epidemiology and
molecular aspects of trimethoprim resistance over the intervening years, initially in
gram-negative bacteria and more recently in gram-positive bacteria. The introduction
of this completely novel synthetic antimicrobial provided a unique opportunity to
study the full evolution of bacterial resistance to an antimicrobial drug, without the
pre-existing influence of resistance genes selected by other related compounds.
Consequently, the model provided by trimethoprim resistance has considerable
relevance to our understanding of the evolution ofbacterial resistance to antimicrobial
agents in general. Recent years have seen exciting and major advances in the use of
modern DNA technology to study the epidemiology of trimethoprim resistance.
Considerable progress has been made in evaluating the importance of the different
resistance mechanisms, especially those carried by resistance plasmids. Nevertheless,
in most countries resistance to trimethoprim has only recently reached clinically
significant proportions and it remains a widely used and valuable component of the
antimicrobial armamentarium. The papers presented in this review are based on a
Symposium held at the 4th European Congress of Clinical Microbiology in April
1989. The Symposium provided a forum for the various aspects of trimethoprim
resistance to be brought together and resulted in the collation of research material
which forms this review.
Evolution and spread of trimetho¬
prim resistance in gram-negative
bacteria
F.W.GOLDSTEIN and J. F. ACAR
Laboratoire de Microbiologie Medicate, Hopital Saint-
Joseph, Paris, France
Trimethoprim, in association with sulphon-
amides, has been used for 20 years in human and
veterinary medicine and is still one of the most
widely used antibiotics in the world. The reasons
for its success are: a broad spectrum of activity, a
marked synergic effect on both sulphonamide-
Received 17 July 1989; accepted 28 July 1989.
susceptible and -resistant strains, excellent clinical
results and, particularly important, a very low price.
This success has nevertheless one drawback,
namely the emergence of bacterial resistance.
Epidemiology of trimethoprim resistance
Comparisons of the incidence of bacterial resist¬
ance are difficult because many factors such as
methodology, selection and choice of specimens
and strains, type of patients and local epidemics
greatly influence the percentage of resistant strains.
For these reasons, assessment of changes in tri¬
methoprim resistance are really only significant if
they come from long-term follow-up studies within
a single laboratory.
Resistance to trimethoprim has been carefully
monitored for a long period in Finland, the United
1
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Kingdom and France. In Finland, from 1978 to
1984 resistance to trimethoprim in Escherichia coli
isolates from outpatients increased slowly (e.g.,
5-4% to 9-2% in Turku).1 A sharper increase has
been observed in the last 3 years and is best
illustrated by data from the town of Rovanienui,
where resistance to trimethoprim was stable at
about 5% between 1980 and 1986, but rose
dramatically to 14-7% in 1987 and has remained at
that level since (P. Huovinen, personal communi¬
cation). In Paris, resistance to trimethoprim in E.
coli increased slowly from 1972 to 1979 and then
very sharply to 1982 (fig. 1). From 1983 to 1988,
resistance to trimethoprim decreased in all groups
of isolates. On the other hand, in Nottingham, in a
study involving nearly 74 000 bacterial isolates
from 1978 to 1988, trimethoprim resistance in¬
creased progressively throughout the study period2
(K. J. Towner, personal communication). In E. coli,
resistance rose from 2-0% to 15-5% and in Proteus
spp. from 7-2% to 24-9%. A marked increase in
resistance was found between 1979 and 1980 and
between 1983 and 1984. Between 1983 and 1984
this sharp increase was found in both hospital
strains (E. coli from 9-3% to 16-2%, Proteus spp.
from 11 -0% to 22-0%) and community isolates (E.
coli from 8-5% to 13-7%, Proteus spp. from 7-3% to
17-5%).2 More recently, between 1987 and 1988,
another profound increase has been observed in
community isolates of Klebsiella/Enterobacter spp.
(15-2% to 24%) and Proteus spp. (18-2% to 25-2%)
(K. J. Towner, personal communication). In com¬
plete contrast, in the USA, the incidence of
resistance to trimethoprim has remained very low
both in the community as well as in nosocomial
strains. The highest incidence amongst hospitalised
patients has been 13%.3
In developing countries, the incidence of trimeth¬
oprim resistance is very disquieting. In Thailand,
trimethoprim-resistant bacteria represented 40% of
urinary isolates.4 Similarly, Young et al.5 found
that 64% of urinary isolates in India in 1984 were
resistant to trimethoprim. In Johannesburg Hospi¬
tals (South Africa), 50% of enterobacterial species
isolated in 1986-1987 were resistant to trimetho¬
prim.6 The same problems exist in South America
where, in 1987, 25-41% of strains isolated from the
community in Santiago de Chile were resistant to
trimethoprim.
The importance of antibacterial drug resistance
in general, and trimethoprim resistance in particu¬
lar, becomes acute when considering specific
pathogens such as Shigella spp., which are respons¬
ible for a high rate of morbidity and mortality.
Data from several countries indicating an increase
in the percentage of trimethoprim-resistant strains
among isolates of shigellae are summarised in table
I. What are the reasons for this situation?
Year
Fig. 1. Proportion of trimethoprim resistance in E. coli in the St Joseph Hospital in Paris and its relation to the usage of trimethoprim.
• • Percentage of E. coli resistant to trimethoprim, o O Consumption of trimethoprim.
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Bangladesh 1980 0 1018
1984 55 890
Mexico 1980 0 55
1984 6 23
Thailand 1979-1984 35 1033
1986-1988 611 211
Chile 1983 25 85
1987 37 100
Brazil 1983 23 57
Resistance to trimethoprim, or to any other
antibiotic, will spread if three favourable conditions
are met: (1) the emergence of stable resistance
genes; (2) the presence of resistance vectors such as
epidemic strains, plasmids or transposons; (3)
continuous or periodic selection pressure.
Emergence ofstable trimethoprim resistance genes
Low level resistance to trimethoprim usually
results from mutational events such as decreased
permeability and quantitative or qualitative modi¬
fications of the bacterial target of trimethoprim,
dihydrofolate reductase (DHFR).8 Plasmid-me-
diated low level resistance has been described, but
only on a few occasions (see section by Young and
Thomson in this review). Impermeability mutants
are particularly interesting because of the cross-
resistance to trimethoprim and other antibiotics,
especially quinolones, which can act as selectors.
This type of mutation has been seen in Klebsiella,
Enterobacter and Serratia and is much more
prevalent than it is often assumed to be.9
High level resistance to trimethoprim is usually
specified by plasmids which encode an additional
trimethoprim-resistant DHFR (reviewed by
Amyes10). Trimethoprim resistance plasmids were
first isolated in London in 197111 and have quickly
spread to all enterobacterial species, Vibrio cholerae
and even Acinetobacter and Pseudomonas, although
these latter species are intrinsically resistant to
trimethoprim. Trimethoprim resistance plasmids
have been found in various enterobacteria. This is
especially true of Salmonella spp., some of which
have been implicated in human infections (for
review, see Goldstein et al.12).
The main characteristics of a successful resist¬
ance plasmid are to be transferable from one
bacterium to another and to encode resistance to
several unrelated antibiotics. Sequential studies
from different centres have shown fluctuating levels
of transferable resistance to trimethoprim among
high level resistant strains. For example, in Edin¬
burgh in 1982-83, a sharp decrease (50-7% to 37-2%)
in the transferability of high-level trimethoprim
resistance genes (normally associated with plasmid-
mediated resistance) was observed, even though
the incidence of high level resistance had remained
constant.13,14 Similarly at the St Joseph Hospital
in Paris, transferable trimethoprim resistance
reached a peak during 1980-81 (62-6% of highly
resistant strains) then decreased to 45-50% by 1988.
These fluctuations in the transferability of high-
level resistance can be explained, at least in part,
by the presence of transposable elements encoding
resistance to trimethoprim which can jump from
one plasmid to another plasmid or on to the
bacterial chromosome.15 Transposon Tn7, which
encodes resistance to streptomycin, spectinomycin
and trimethoprim (DHFR la), was the first and the
most common of the trimethoprim transposons
described.16 Its presence has been more or less
demonstrated or presumed in many bacterial
species by hybridisation studies with a probe
encoding the DHFR la gene.12 Other transposons,
very similar and probably identical to Tn7, have
been isolated from enterobacteria and Vibrio chol¬
erae.17 A second group of transposons, clearly
different from Tn7, is represented by 7n4132\ these
encode resistance to trimethoprim alone.18 Finally,
a third group of transposons, represented by Tn402,
encode a type II DHFR.19
Extensive studies of the occurrence of Tn7 in
enterobacteria have been performed in Finland in
1980-81 and in 1983.20 A general increase in the
percentage of enterobacteria harbouring Tn7 was
observed between the two study periods (47-3% in
1980-81 and 56-1% in 1983); however, the percent¬
age of Klebsiella strains harbouring Tn7 was
significantly lower than in other enterobacteria
during the study periods (12-9% in 1980-81 and
23-5% in 1983). All these fluctuations in the
transferability rates can be explained by the
movement of Tn7 into the bacterial chromosome.
In a study from Glasgow the percentage of
chromosomal Tn7 rose from 38% to 70% in hospital
isolates during two study periods, 1979—80 and
1982.21 The percentage of chromosomal Tn7 was
also very high in community isolates from Glasgow.
Therefore, a general phenomenon can be proposed:
after the initial "infection" of a bacterial cell by a
plasmid carrying Tn7, the transposon will jump
and remain on the chromosome even when the
initial plasmid is cured spontaneously.
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Several other trimethoprim-resistance transpo-
sons have been found on transferable plasmids; an
epidemic with DHFR type II has been described
in Boston.22 In Paris, we found that 36% of
unrelated plasmids isolated during 1981-84 were
able to hybridise with a DHFR II specific gene
probe. However, there is no evidence yet to suggest
that a transposon carrying the type II DHFR gene
has migrated into the bacterial chromosome.
Selection pressures
The last factor responsible for the increase in
trimethoprim resistance is selection pressure. As
seen from fig. 1, the percentage of trimethoprim-
resistant E. coli did not always follow the consump¬
tion of sulphonamide-trimethoprim. After 1982,
with the increased use of new cephalosporins and
fluoroquinolones, the consumption of sulphonam¬
ide-trimethoprim clearly decreased and so did the
percentage of trimethoprim-resistant strains. A
very interesting study concerning the effects of
selection pressure has been done in Nottingham.2
With the increased use of trimethoprim alone, the
percentage of trimethoprim-resistant strains which
are susceptible to sulphonamides increased dramat¬
ically, especially in Proteus spp., such that by 1988,
67% of the Proteus strains isolated in the community
were susceptible to sulphonamides (K. J. Towner,
personal communication).
In several studies, Amyes and other authors
demonstrated that ampicillin, which is widely used
in many clinical settings, may select bacteria
harbouring plasmids encoding joint resistance to
ampicillin and trimethoprim.23'24 Indeed, in our
own hospital, between 53 and 87% of the plasmids
encode joint resistance to both trimethoprim and
ampicillin.
Conclusions
As inferred from epidemiological and genetic
studies, resistance to trimethoprim is borne by
many different replicons and can be mediated by
epidemic strains, plasmids or transposons. These
factors, combined with a widespread use in man
and animals of trimethoprim, related substances
and even unrelated antibiotics, may explain the
emergence and spread of trimethoprim resistance
in different species and provides a unique epide¬
miological model of the interaction between genetic
elements, antibiotic policy and the resulting emerg¬
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Plasmid-mediated trimethoprim resistance in
gram-negative bacteria emerged within 3 years of
the clinical introduction of the drug.11 The plasmid
carriage of trimethoprim resistance undoubtedly
contributed to the spread of resistance and the high
proportion of resistant gram-negative isolates in
certain areas of the world.5
Emergence of trimethoprim resistance in
staphylococci
In gram-positive bacteria, the story is quite
different. Amongst staphylococci, the incidence of
trimethoprim resistance is very low, despite the
continuous challenge with the drug for 20 years.
Indeed, until the advent of methicillin-resistant
Staphylococcus aureus (MRSA), trimethoprim re¬
sistance was virtually unheard of. In MRSA, the
first trimethoprim-resistant strains were character¬
ised by a low minimum inhibitory concentration
(MIC) ranging from 10 to 250 mg/L.25-29 This
resistance was presumed to be encoded by genes
located on the bacterial chromosome as no transfer
of the resistance determinants could be achieved.
The mechanism of this moderate level of resistance
is still unknown, although it has been suggested
that it results from an over-production of the
bacterial DHFR.30 This type of chromosomal
resistance has been found in both eastern and
western Australia, the USA and Europe.25-29 It is
likely that this chromosomal resistance represents
an initial stage in the development of high-level
resistance to trimethoprim in MRSA.
Plasmid-mediated trimethoprim resistance in
staphylococci did not emerge until 1983, when it
was found in Australian MRSA isolates.28'31 They
were characterised by their high MIC of trimetho¬
prim (>512 mg/L). At that time, 10% of S. aureus
strains in the USA were found to be trimethoprim
resistant, but this resistance had not then been
shown to be plasmid-mediated.29 Archer et al.29
demonstrated that strains from Virginia and from
Pennsylvania were able to transfer their trimetho¬
prim resistance genes and strains from both areas
carried trimethoprim resistance plasmids (pGOl
and pG05). Although the plasmids from the two
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areas were different, they did show common
restriction sites which indicated their relatedness
to one another.29
The trimethoprim resistance plasmids isolated
from staphylococci from different parts ofAustralia
were compared and were also shown to have similar
restriction patterns to one another, suggesting that
they too came from a common source. However,
these restriction patterns were, by and large,
different from those found in the plasmids obtained
in the USA.30 The one exception was the restriction
pattern around the trimethoprim resistance gene,
which was common to plasmids from both conti¬
nents.30 Thus, although the trimethoprim resist¬
ance gene appeared ubiquitous, the plasmids on
which it was carried were quite different. In
Australian MRSA, 50% of the high-level trimetho¬
prim resistance was mediated by the 28-4-kb
plasmid, pSKl. The trimethoprim resistance gene
could be located to a 2-75-kb region of plasmid
pSKl by comparing it to spontaneous deletion
mutants which had become trimethoprim-sensi-
tive.32 A 5-1-kb £coRI fragment of pSKl was
cloned into plasmid pACYC 184, to form the hybrid
plasmid pSK407. This hybrid plasmid was shown
to express high-level trimethoprim resistance in
Escherichia coli. Transposon mutagenesis, with Tn5,
of the trimethoprim resistance gene showed that it
comprised between 0-55 and 0-75 kb, suggesting it
could code for a protein of up to 20 Kda.33
The type SI DHFR
The pSKl-containing clinical strain encoded a
high level ofDHFR (Specific Activity = 129-6 nmol
dihydrofolate reduced/min/mg of protein). How¬
ever, staphylococci generally encode much higher
levels of chromosomal DHFR than their gram-
negative counterparts. The high background en¬
zyme activity made the initial identification of a
plasmid-encodedDHFRmuchmore difficult. How¬
ever, the 5-1-kb £coRI fragment of pSKl, which
encoded the trimethoprim resistance gene, had
been cloned by Lyon et al.33 into the multi-copy
plasmid pACYC 184 in E. coli. The specific activity
of the chromosomal DHFR in this strain was much
lower than in staphylococci. Indeed, the DHFR
activity encoded by the recombinant plasmid in E.
coli was more than 20 times higher than that of the
same host containing the same plasmid lacking the
insert. The plasmid DHFR, which had originally
been encoded by pSKl, was partially purified by
ammonium sulphate precipitation and gel filtration.
The molecular size of the enzyme, when estimated
by Sephadex G-75 gel filtration, was 19-7 Kda,34
which was very close to the 20 Kda predicted by
Lyon et al33 from transposon mutagenesis of the
gene. From these results, the enzyme appears to be
monomeric.
The pSK 1-encoded enzyme is far less susceptible
to inhibition by trimethoprim, as 50 pu of the drug
is required to inhibit the enzyme by 50% compared
with 40 nM for the 5. aureus chromosomal enzyme.
This 1000-fold difference in inhibitory capability is
matched by the difference in the MIC of trimetho¬
prim for S. aureus strains containing a trimethoprim
resistance plasmid and a fully sensitive plasmid-
free S. aureus strain. Surprisingly, the plasmid-
encoded DHFR confers no resistance to the
dihydrofolate analogue, methotrexate. All the
gram-negative plasmid-encoded DHFRs which
confer high-level trimethoprim resistance (MIC>
1000 mg/L) are also resistant to the inhibitory
action of methotrexate. Considering the close
structural similarity of methotrexate and dihydro¬
folate, the gram-negative enzymes are remarkable
in their ability to distinguish these two compounds
by resisting methotrexate, but retaining a high
affinity for the substrate dihydrofolate. This makes
it virtually impossible to devise a new drug that
more closely mimics dihydrofolate than methotrex¬
ate but is also selective. However, as the gram-
positive enzyme is methotrexate sensitive, the
possibility exists to design a new DHFR inhibitor
with the inhibitory properties of methotrexate, but
the selectivity of trimethoprim, and still be able to
overcome the plasmid-encoded enzyme.
The DHFR encoded by pSKl retained a high
affinity for the substrate dihydrofolate, showing a
higher binding capability (Km = 10 pu) than the S.
aureus chromosomal enzyme (Km = 80 pu). Fur¬
thermore, although the plasmid enzyme is compet¬
itively inhibited by trimethoprim, it has a much
higher Ki (11-6/tm) than that of the S. aureus
chromosomal enzyme (Ki = 6-5 nM). All the prop¬
erties show that the plasmid-encoded enzyme from
Australia was different from the S. aureus chromo¬
somal enzyme and from the 12 plasmid-encoded
DHFRs found in gram-negative bacteria. We have
thus designated this enzyme the type SI.34
In the USA, plasmid pGOl was also subsequently
shown to encode a DHFR which, by examination
of protein production with [35S] methionine in
minicells, was estimated to be 18-5 Kda.35 In this
study, the enzyme was less susceptible to inhibition
by trimethoprim than the chromosomal DHFR
with an ID50 of 7-3 pu. This was around 2000-fold
less susceptible than the staphylococcal chromo¬
somal enzyme. These results strongly suggested a
6 S. G. B. AMYES AND K. J. TOWNER
link between the trimethoprim-resistant DHFR
encoded by the Australian and the American
plasmids. In our hands, the American DHFR had
a Mr of 21 000 and very similar kinetic and
inhibition properties to the type SI from Australia.
The dfrA gene, encoding the type SI DHFR, has
also been found in coagulase-negative staphylococci
isolated in Australia. In particular, when the 0-9-
kb ZscoRI-iscoRV restriction fragment of plasmid
pSK407 (which consists almost entirely of the
trimethoprim resistance gene) was used as a probe,
the DNA of fourmulti-resistant coagulase-negative
bacteria hybridised.32 In three strains (two 5".
epidermidis and one S. hominis I), the gene was
located on a plasmid. In each case the plasmids
were different from each other and from either
pSKl or pGOl, the prototype trimethoprim resist¬
ance plasmids in S. aureus. In the final strain, S.
epidermidis SK683, no plasmid location for the dfrA
gene could be found and it was presumed to be
located on the bacterial chromosome. The biochem¬
ical properties of the DHFRs were all very similar
to the type SI with the exception of the specific
activity. In the case of the three plasmid-containing
strains, the activity ranged between 27 and
101 nmol dihydrofolate reduced/min/mgofprotein,
which is high and consistent with the view that the
genes are located on small, multi-copy plasmids.
On the other hand, the specific activity in S.
epidermidis SK683 was 7-7 nmol dihydrofolate
reduced/min/mg of protein, which is compatible
with the location of the gene on the limited copy-
number chromosome.
The similarity of the biochemical properties
suggest that all the DHFRs are closely-related.
However, DHFRs with less than 70% DNA
homology have been shown to display identical
properties.10 Conventional DNA-DNA hybridisa¬
tion studies, performed under stringent conditions,
will reveal DNA homologies of greater than 75-
85%. Without sequencing the gene, it is impossible
to state that two genes or gene products are
identical. However, isoelectric focusing is ex¬
tremely sensitive in its ability to reveal differences
of just one amino acid in proteins consisting of 200
residues or more. However, the magnitude of the
differences in pi gives no indication of the actual
difference between the proteins, merely a demon¬
stration that they are not the same. Conversely, it
is rare for two enzymes with different amino acid
sequences to have exactly the same isoelectric
focusing pattern. The DHFRs encoded by not only
the Australian and American S. aureus plasmids,
but also the Australian and American coagulase-
negative staphylococcal plasmids, were examined
by isoelectric focusing, employing a modification
of the method of Broad and Smith.36 In every case,
the plasmid-encoded DHFR band co-focused at pi
6-54, suggesting that the dfrA gene is ubiquitous in
staphylococcal strains on both continents (S. Tait
et al., unpublished results).
Sequence of the dfrA gene and the type SI DHFR
The dfrA gene in plasmid pSK 1 has been ascribed
to a 0-75-kb region of the plasmid.32 This region is
flanked by three directly repeated copies of an
insertion sequence, IS2J7.37 Their presence sug¬
gests that the dfrA gene and the flanking insertion
sequences form a composite transposon, Tn4003?°
The ubiquitous nature of the type SI DHFR and
the location of the dfrA gene in many different
replicons, strongly supports a transposon location
of the gene. Furthermore, there is a close similarity
of the restriction endonuclease map ofTn4003 from
the Australian plasmid pSKl with that of the
trimethoprim resistance region on the American
plasmid pGOl, even though the rest of the plasmid
is quite different from the American plasmids.38
This suggests that the American plasmid also has
the flanking IS257 insertion sequence as well as the
trimethoprim resistance gene.
DNA sequence analysis has confirmed that the
trimethoprim resistance gene is located on a unique
composite class I transposon, which is flanked by
three rather than the normal two insertion se¬
quences, namely IS257.39 The direct orientation of
the three insertion sequences has been shown to
confer instability to the carriage of the transposon,
by promoting spontaneous deletions of Tn4003.
Plasmids with these specific deletions have been
found both spontaneously within the laboratory
and within clinical isolates.
The open reading frame for the dfrA gene has
been found, by sequence analysis, to be 486 bp,
corresponding to a protein of 162 amino acids. The
active site of the DHFRs is at the N-terminal, the
first 50 amino acids of which are shown in fig. 2.
There are some similarities between this sequence
and the type la plasmid-encoded enzyme in gram-
negative bacteria. A closer similarity was noted
between the sequence of the gram-positive chro¬
mosomal DHFRs from Lactobacillus casei, Strepto¬
coccus faecium and Bacillus subtilis.39-42 However,
a recent automated amino acid sequence of the N-
terminal of the S. aureus trimethoprim-sensitive
chromosomal DHFR suggests that the origin of the
plasmid-encoded enzyme may lie in the same
species in which it was first discovered.43
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Type la Met Lys Leu Ser Leu Met Val Ala He Ser Lys Asn Gly |Val lie Gly Asn Gly Pro Asp He Pro Trp Ser A1 a
Type SI Met Thr Leu Ser He lie Val Ala His Asp Lys Gin Arg Val lie Gly Tyr Gin Asn Gin Leu Pro Trp His Leu
S. aureus |thr Leu Ser He Leu Val A1 a His Asp Leu Gin Arq Val lie Gly Phe Glu Asn Gin Leu Pro Trp His Leu
5 10 15 20 25
Type la Lys Gly Glu Gin Leu Leu Phe Lys A1 a lie j Th r Tyr Asn Gin Trp Leu Leu Val Gly Arg Lys Thr Phe Glu Ser
Type SI Pro Asn Asp Leu Lys His He Lys Gin Leu Thr Thr Gly Asn Thr Leu Val Met A1 a Arg Lys Thr Phe Asn Ser
S. aureus Pro Asn Asp Leu Lys His Val Lys Lys Leu Ser
30 35 40 45 50
Fig. 2. Comparison of the N-terminal amino acid sequence of the type SI plasmid-encoded dihydrofolate reductase with the
sequence of the S. aureus chromosomal enzyme.
Conclusions
Plasmid-encoded trimethoprim resistance in
staphylococci appears to be mediated by one gene,
dfrA, which encodes the type SI DHFR. The
location of this gene on a transposon (Tn4003) has
ensured that it has spread widely, not only geograph¬
ically but also within the species of the genus
Staphylococcus. The spread of the gene encoding
the type SI DHFR by Tn4003 appears to be very
reminiscent of the spread of the type la DHFR
gene by transposon Tn7 amongst the plasmids and
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Plasmid-encoded trimethoprim resistance in
gram-negative bacteria was first reported in 197211
and was originally associated with extremely high
minimum inhibitory concentrations (MICs) of
trimethoprim (>1000mg/L). The mechanism of
resistance was later shown to result from the
plasmid-mediated production of an additional,
trimethoprim-resistant DHFR.44,45 So far a total
of 12 different plasmid-encoded DHFRs belonging
to seven major groups (types I—VII) have been
identified in gram-negative bacteria (table II).
DHFR types I and II, encoded by plasmids R483
and R388 respectively, were the original plasmid
DHFRs described and have now been reclassified
as DHFR types la and lib.10 Both these enzymes
are much larger than the chromosomal enzyme
with a molecular size of 35 Kda, but differ from
each other in their subunit composition—the type
la enzyme being composed of two identical, inactive
sub-units of 18 Kda, whereas the type lib enzyme
is made up of four identical, inactive sub-units of
8-5 Kda.46 The type II enzymes are also much more
heat stable and are, at least, one thousand times
more resistant to the inhibitory action of trimetho¬
prim than the type I enzymes.47,48
In 1986, a second sub-class of type I DHFR was
identified, the type lb, coded by plasmid pUK163.
This enzyme has very similar biochemical proper¬
ties to the type la enzyme encoded by R483,
differing only in its molecular size (24-5 Kda). The
sub-unit composition of this enzyme has not yet
been determined, but it has been postulated that
the type lb DHFR may comprise two partial type
la sub-units.18 Both the type la and lb DHFR
genes are carried on resistance transposons, Tn7
and Tn4132 respectively.
The amino acid sequence of the type la DHFR
has been determined and compared with the E. coli
chromosomal DHFR sequence.49 The two enzymes
show 29% identity, increased to 44% when chemi¬
cally similar residues are included, with the greatest
regions of homology being in the amino terminal
region which comprises most of the active site of
the enzyme.
A number of sub-groups have also been distin¬
guished among the type II DHFRs: the type Ha
enzyme, encoded by plasmid R67;48 the original
R388 encoded type lib enzyme;46 and the type lie
enzyme coded by plasmid R751,50 All three DHFR
type II enzymes are very similar in their biochemical
properties and share extensive (>78%) amino acid
sequence homology.51"53 However, sequence com¬
parisons with other DHFRs reveal them to be quite
unlike other plasmid or bacterial DHFRs. Indeed
it has been postulated that the type II DHFRs may
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Table II. Properties of the plasmid-encoded dihydrofolate reductases
Plasmid DHFR MIC for Tp Ki for Tp Mr Countries where
type sub-type (mg/L) (MM) (Kda) reported
I a >1000 7-4 35-0 All continents
b >1000 41 24-4 UK
II a >1000 6100 35-0 Europe, America, Asia
b >1000 150 35-0 Europe, America, Asia
c >1000 400 34-0 UK
III a 64 0019 16-9 New Zealand, UK
b 128 015 17-0 USA
c 512 0-64 22-0 USA
IV 10 0-063 46-7 India
V >1000 3-2 36-0 Sri Lanka, UK
VI > 1000 162 90 South Africa
VII > 1000 7-0 11-5 UK
SI >1000 11-6 19-7 Australia, USA, UK
have been derived from an oxidoreductase which
originally acted on some other substrate.46,51
The type III DHFR, which has now been re¬
classified as the type Ilia, was first described by
Fling et al.SA and is characterised by its low
molecular size (16-9 Kda) and unusually low resist¬
ance to trimethoprim inhibition.55 As a result,
organisms producing this enzyme exhibit only a
moderate level of resistance to trimethoprim (MIC
64 mg/L). Until recently, this enzyme had only
been reported on one occasion in a clinical strain of
Salmonella typhimurium isolated in New Zealand.
However, in 1988, C. J. Thomson and colleagues
(unpublished observation) identified the type Ilia
enzyme in a clinical strain in Nottingham. Recently
developed techniques for isoelectric point determi¬
nation of DHFRs36 have lead to the identification
of two further sub-groups of type III enzymes, types
Illb and IIIc, encoded by plasmids from Shigella
strains isolated in the USA (N. Barg et al.,
unpublished observation). These enzymes also
confer only a moderate level of trimethoprim
resistance on their host, are very similar biochemi¬
cally to the type Ilia enzyme, but differ markedly
in their isoelectric points.
Sequence analysis of the type Ilia enzyme has
shown it to share 51% homology with the E. coli
chromosomal DHFR, suggesting that the type Ilia
gene may have originated in either E. coli or in a
closely related gram-negative organism.56 Prelimi¬
nary sequence data on the type Illb DHFR,
however, indicates it to be quite distinct from both
the sensitive E. coli DHFR and the type Ilia
plasmid enzyme (C. J. Thomson and S. G. B.
Amyes, unpublished results). Thus, despite the
similarities in biochemical properties between the
two plasmid enzymes, their origin and evolution
appear to have occurred independently of each
other.
The type IV plasmid DHFR, identified in a
number of different clinical isolates in South India,
is larger than other plasmid DHFRs (46-7 Kda), is
only 10 timesmore resistant to the inhibitory action
of trimethoprim than the E. coli chromosomal
DHFR, but is unique in its ability to be induced in
the presence of increasing concentrations of tri¬
methoprim.57 Bacteria producing the type IV
DHFR appear almost sensitive to trimethoprim
when tested on conventional sensitivity test agar,
although in complex broth containing trimethoprim
these organisms show a significant level of resist¬
ance to the drug, similar to that exhibited by strains
producing type III DHFR.58 The mechanism of
resistance conferred by the type IV DHFR differs
from other plasmid DHFRs and is believed to
occur by a "swamping" mechanism which involves
fhe removal of trimethoprim through binding of
the drug to the large number of type IV enzyme
molecules induced in its presence. Amino acid
sequence data has been obtained for the first 50
residues of the amino terminal region of the type
IV DHFR. Comparison with the amino terminal
regions of other DHFRs shows that the type IV
enzyme shares 40% and 34% homology with the E.
coli chromosomal enzyme and the type la plasmid
enzyme respectively (C. J. Thomson and S. G. B.
Amyes, unpublished results). This may indicate a
common ancestry for the genes encoding these
enzymes.
The type V plasmid DHFR was originally
identified in clinical isolates from Sri Lanka.59 This
enzyme shows many biochemical similarities to the
type la plasmid DHFR, although it differs signifi¬
cantly in molecular size, being only 17-5 Kda—a
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similar molecular size to the type la subunit. The
type V DHFR has now been identified in clinical
bacteria in Nottingham (K. J. Towner et al.,
unpublished results). The complete amino acid
sequences of the types la and V DHFRs have been
compared.60 The two enzymes share 75% homology
over their entire amino acid sequence and differ in
only six amino acids within the first 50 residues
forming the active sites of the enzymes. It seems
likely, therefore, that these two enzymes share a
common ancestral gene which, in each case, has
followed a slightly different evolutionary path.
Finally, two further plasmid-encoded enzymes
have recently been identified. The type VI plasmid
DHFR has been found in only one clinical strain of
Proteus mirabilis isolated in South Africa. This
enzyme has a low molecular size (10 Kda) and, like
the type II enzymes, requires very high concentra¬
tions of trimethoprim to inhibit its activity by 50%.
These characteristics might indicate a possible
relationship with an active type II DHFR subunit.
Hybridisation studies, however, appear to indicate
that extensive sequence homology does not exist
between these two genes.6 A type VII DHFR has
recently been identified in an E. coli isolate of
animal origin in Nottingham.61 This enzyme, like
the type VI enzyme, is also small and heat labile.
However, it has similar inhibitory profiles to the
types la and V enzymes.
It is evident from the numerous recent reports of
new plasmid-encoded trimethoprim-resistant
DHFRs that these enzymes are continuing to
emerge and evolve in a manner comparable to the
/^-lactamase enzymes. With advances in molecular
and biochemical technologies it is to be expected
that novel plasmid-encoded DHFRs will continue
to be identified and, hopefully, relationships be¬
tween, and the origins of, those already distin¬
guished will become clearer.
DNA probes for trimethoprim-
resistant dihydrofolate reductases
K.J.TOWNER
Department of Microbiology and PHLS Laboratory, Univer¬
sity Hospital, Nottingham NG7 2UH
As described earlier in this review, seven major
types of trimethoprim-resistant DHFRs encoded
by plasmids have now been characterised in gram-
negative bacteria, with several of these major
groups being further divided into related sub¬
types.10 Trimethoprim resistance in gram-positive
bacteria has been slower to evolve, but at least one
distinct trimethoprim-resistant DHFR has been
identified in multi-resistant Staphylococcus au¬
reus.34 These enzymes can be distinguished from
each other, and from the host chromosomal DHFR,
on the basis of several biochemical and biophysical
criteria,18l 36'48'55 but such identification is imprac¬
ticable to perform for large scale epidemiological
studies, primarily because of the time required to
extract and purify each individual enzyme.
An alternativemethod ofcharacterisation, which
is simple to perform and can potentially be carried
out on a large scale in routine microbiology
laboratories, involves the use of non-radioactively-
labelled DNA probes specific for particular DHFR
genes. Carter et al.62 demonstrated that a biotin-
labelled DNA probe could be used to rapidly screen
a large number of trimethoprim R plasmids for the
presence of the DHFR type I gene. This method
can be adapted for usewith any antibiotic resistance
gene for which a suitable DNA probe is available
and, consequently, efforts have been made to
develop specific DNA probes for each of the known
DHFR types. The DNA probes which are currently
available for these genes are listed in table III.
Information on their specificity is reviewed and
updated in the following sections.
DHFR I
The type I DHFR probe consists of a 499-bp
Hpal fragment of pFE872, derived originally from
R483.49 This DNA fragment is comprised almost
Table III. DNA probes for specific dihydrofolate reduc¬
tase genes
DHFR type Probe
I 499 bp Hpal fragment of pFE87249
II 850 bp EcoRl fragment of pFE364 (or pFF.700)22
280 bp Sau3A/EcoRl fragment of pWZ82063
III 855 bp £coRI///;'ndIII fragment of pFE1242 (M.
E. Fling, personal communication)
700 bp Pstl/EcoRl fragment of pUN972 (K. J.
Towner, unpublished results)
IV 1700 bp C/al fragment of pUKl 14864
V 500 bp Hincll fragment of pLK0964
VI no probe currently available
VII 300 bp£coRV fragment of pUN1042 (K. J.
Towner and G. I. Carter, unpublished results)
SI 500 bp £coRI///mdIII fragment of pG01835
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entirely of the structural gene and forms an
extremely useful probe for screening purposes.
When biotinylated and used in conjunction with
the high stringency wash conditions described by
Carter et al.,62 hybridisation is detected only with
DHFR enzymes belonging to subtypes la and lb.
If low stringency wash conditions are used (two
post-hybridisation washes only, each for 15 min in
2 x SSC/0-1% SDS), hybridisation can additionally
be detected with the type V DHFR gene (K. J.
Towner and G. I. Carter, unpublished results). This
is not surprising since DNA sequence analysis has
shown that there is 68% similarity at the nucleotide
level between the type la and type V enzymes.60
DHFR II
There are at least three subtypes within the
DHFR II group, all of which seem to be closely
related at the hybridisation level. Fling and col¬
leagues produced a series of probes derived from
R67 (subtype Ila), culminating in the use of a 850-
bp EcoR\ fragment from pFE364 or pFE700.20
This probe (and its relatives) will readily eliminate
any resistance genes which do not belong to any of
the DHFR II subtypes (i.e., there are no "false-
negatives")- Unfortunately, it also includes several
hundred bases upstream of the type II structural
gene, including a region of homology contained
within the widely distributed transposon Tn2/.60- 65
This probe consequently generates fairly frequent
"false-positives" when used to screen trimethoprim
R plasmids for the presence of the type II gene.
Putative positive hybridisation results should there¬
fore be confirmed either biochemically or by use of
alternative probes.
One possible alternative probe for the type II
DHFR group is the 280-bp Sau3A/EcoRl fragment
of pWZ820, derived originally from R388 (subtype
lib). Sequencing data shows that the DHFR lib
structural gene is only 234 bp long,66 of which
153 bp of the 3'-terminal end are included in the
probe. When biotinylated and used under high
stringency conditions62 we have observed hybridi¬
sation of this probe only with plasmids which have
also been subsequently shown by conventional
biochemical criteria to belong to one of the DHFR
group II subtypes.
DHFR III
The type III structural gene is contained within
a 808-bp Taq\ partial DNA fragment derived from
the prototype III DHFR R plasmid pAZl.56 This
fragment has been inserted into pUC9 to form the
recombinant plasmid pFE1242. When used in
conjunction with high stringency wash conditions,
the 855-bp EcoRl/Hindlll fragment of pFE1242
forms a reliable probe for eliminating resistance
genes which do not belong to the type III group
(i.e., there are no "false-negatives"). The probe
does, however, contain approximately 350 bp ex¬
ternal to the structural gene and therefore generates
occasional "false-positive" hybridisation results.
The recent recognition of the type III resistance
gene in E. coli responsible for urinary infection in
the UK has enabled an alternative probe to be
identified following cloning of the resistance gene
into the recombinant plasmid pUN972 (K. J.
Towner, unpublished results). A 700-bp Pstl/EcoRl
fragment of pUN972 readily detects genes belong¬
ing to the type III group and contains less DNA
extraneous to the structural gene than the probe
derived from pFE1242. Further evaluation is in
progress.
DHFR IV
The gene responsible for the type IV DHFR has
been cloned into pBR322 to form the recombinant
plasmid pUK1148.64 The 1-7-kb C/«I fragment of
pUK1148 forms a useful probe for the type IV
gene. This probe also contains DNA sequences
external to the type IV structural gene and,
therefore, although it was very specific when tested
against "control" DHFR plasmids, it can be
anticipated that occasional "false-positives" may
be generated when it is used to screen trimethoprim
R plasmids on an epidemiological scale. To date,
however, such "false-positives" have not been
observed and the type IV gene has been detected
only in bacterial isolates from Southern India.10
DHFR V
The type V DHFR gene was cloned into pBR322
by Sundstrom et al.59 to form the recombinant
plasmid pLK09. It was subsequently demonstrated
by Towner et aI.M that a 500-bp Hincll fragment
of pLK09 could be used successfully as a probe for
genes belonging to the type V group. This probe
consists almost entirely of the structural gene, but
because of the 68% similarity at the nucleotide level
between the type la and type V enzymes60 it is
important that it is used in conjunction with high
stringency wash conditions. When biotinylated and
used as a probe under the conditions described by
Carter et al.62 we have detected no cross-hybridi¬




A probe is not yet available for this DHFR gene,
which has to date only been detected on R plasmids
isolated in South Africa.10 However, no hybridisa¬
tion has been observed between the plasmid
carrying the prototype DHFR VI gene (pUK672)
and the probes available for the other DHFR
groups (K.J. Towner, unpublished results).
DHFR VII
This new enzyme group has recently been
characterised in a trimethoprim-resistant strain of
E. coli isolated in the UK. It was originally
recognised on the basis of the failure of the
trimethoprim R plasmid contained within the strain
to hybridise with the probes for any of the other
known DHFR types.61 The type VII gene has now
been cloned into pUC18, forming the recombinant
plasmid pUN1042, and a 300-bp JfcoRV fragment
used as a preliminary probe (K. J. Towner and G.
I. Carter, unpublished results). Unfortunately this
probe contains only part of the structural gene. The
type VII enzyme has very similar biochemical
properties to the type I and type V groups,61 and
some cross-hybridisation was indeed detected be¬
tween the type VII probe and the type V gene (but
none of the other groups). Enzymes belonging to
the type VII group can, however, be clearly
distinguished as neither the type I nor the type V
probes show any hybridisation with the type VII
gene. Development of a more specific type VII
probe is currently in progress.
DHFR SI
The type SI DHFR is the only trimethoprim-
resistant DHFR reported to date from gram-
positive bacteria.10 The gene has been cloned into
pBR322 by Coughter et a/.,35 who also reported the
use of a 500-bp EcoRl/HindlU fragment of the
recombinant plasmid pGOl 8 as a probe. This probe
should be an intragenic fragment of the structural
gene and was shown to fail to hybridise, even under
low stringency conditions, with the type I, II or III
genes.35 It has now also been shown that there is a
lack of hybridisation between the type SI gene and
the probes capable of recognising the other known
DHFR types (K. J. Towner and G. I. Carter,
unpublished results).
Conclusions
New groups of trimethoprim-resistant DHFRs
are now being reported on a regular basis and it
seems that DNA hybridisation procedures offer the
best approach for monitoring the evolution and
distribution of these important resistance genes on
an epidemiological scale. The use of cloning
procedures enables DNA probes to be constructed
for a particular need. Although requiring a certain
amount of specialist expertise, these procedures are
relatively inexpensive to carry out. When combined
with the development of non-radioactive detection
systems for use in hybridisation experiments, it is
now certainly feasible for studies on the epidemiol¬
ogy of trimethoprim-resistant DHFR genes to be
carried out in most routine microbiology laborato¬
ries.
Clinical importance of trimethoprim
resistance in staphylococci isolated
in Europe
A. BURDESKA and R. L. THEN
Pharmaceutical Research, F. Hoffmann-La Roche & Co. Ltd,
CH-4002 Basel, Switzerland
Among the gram-positive bacteria, staphylococci
are the most important pathogens in both commu¬
nity- and hospital-acquired infections.67- 68 The two
most important species are Staphylococcus aureus
and S. epidermidis and this communication focuses
on these two species only. S. aureus is more virulent
than 5. epidermidis and may cause a number of
serious infections including wound infections,
abscesses, urinary tract infections, endo¬
carditis, pneumonias and bacteraemias with a high
mortality.69-70
S. epidermidis was, in the past, often regarded as
a culture contaminant, but it is now well established
that it is a pathogen. Most S. epidermidis infections
are hospital-acquired and related to the ability of
this organism to colonise skin and indwelling
foreign devices.71 The most serious consequences
are bacteraemias and, in the USA, coagulase-
negative staphylococci are currently the leading
cause of nosocomial bacteraemias, with S. epider¬
midis accounting for 60-80% of cases.72
Antibiotic therapy
The frequency and severity of staphylococcal
infections demands suitable antibiotic therapy. For
non-/Mactamase producing staphylococci, penicil-
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lin G or V are the drugs of choice. Since nearly all
staphylococci nowadays produce /(-lactamase, a
penicillinase-resistant penicillin such as methicillin
or cloxacillin is required, or alternatively, a cephalo¬
sporin, imipenem or clavulanate potentiated amox¬
ycillin can be used. These agents, however, are
rendered useless once methicillin-resistant staphy¬
lococci (MRS) prevail. Since MRS are almost
uniquely multi-resistant, i.e., also resistant to
gentamicin, erythromycin, tetracycline, and many
other antibiotics, few alternatives are left.68-72,73
Vancomycin is the drug ofchoice in these instances.
Co-trimoxazole and, recently, the fluoro¬
quinolones have proved to be valuable drugs against
MRS.74'75 Resistance to the fluoroquinolones,
however, is being acquired at a surprisingly fast
rate, especially by MRS.
Resistance to trimethoprim
Trimethoprim resistance in staphylococci has
been reported since the early 1980s.26,32 Trimeth¬
oprim resistance genes reside on large plasmids or
in the chromosome and code for a novel, trimetho-
prim-insensitive DHFR.32,34 In view of the impor¬
tance of trimethoprim-sulphonamide combinations
such as co-trimoxazole in the treatment of infections
by MRS, we undertook a study to evaluate the
relationship between resistance to trimethoprim,
methicillin and sulphonamide, the level of trimeth¬
oprim resistance, its mobility and its mechanism.
In this study a total of 269 strains was investi¬
gated—196 strains of S. aureus and 73 strains of S.
epidermidis. Only strains exhibiting resistance to
one or more of the following antimicrobials were
included: trimethoprim (Tp), methicillin (Mt), co-
trimoxazole (TpSu) or gentamicin (Gm). All strains
came from University Hospitals in Hungary (54 5.
aureus, 21 S. epidermidis), Germany (30 S. aureus),
Switzerland (43 S. aureus, 19 S. epidermidis), the
UK (30 S. aureus) and Spain (39 S. aureus, 33 S.
epidermidis). All strains were identified by growth
onmannitol-salt agar, their DNAase and coagulase
reaction, the API-Staph system (API SYSTEM
S.A., Montalieu Vercieu, France) and the Staph-
rapid test (Roche). The susceptibility to eight
antimicrobials—Tp, sulphamethoxazole (Su), Mt,
penicillin (Pc), chloramphenicol (Cm), Gm, eryth¬
romycin (Em) and tetracycline (Tc)—was deter¬
mined on Mueller Hinton Agar (Difco) at 30°C.
The breakpoints for resistance were chosen accord¬
ing to the NCCLS recommendations76 and were-
^16mg/L for Tp, Mt and Gm, and 5s512mg/L
for Su.
Among the S. aureus strains, 117 (60%) were
resistant to Mt, 51 (26%) to Tp, 68 (35%) to Su, 85
(43%) to Gm, 186 (95%) to Pc, 54 (28%) to Cm, 118
(60%) to Em and 134 (68%) to Tc; 36 strains (18%)
were resistant to MtTp, 48 (24%) to TpSu and 35
(18%) to MtTpSu. Coupled resistance to Mt plus
Gm was more frequent; it was present in 66 strains
(34%).
Large differences were observed if the results
with strains from different sources were analysed
separately. Of the 54 S. aureus strains from
Hungary, 49 were resistant to Mt, 5 to Tp, 15 to Su,
16 to Gm, 4 to MtTp, 5 to TpSu and 4 to MtTpSu.
Of the 39 isolates from Spain, 14 were resistant to
Mt, 3 to Tp and only 1 to Su. None of these
exhibited simultaneous resistance to MtTp or triple
resistance to MtTpSu, whereas 14 were resistant to
Mt plus Gm. Coupled resistance to MtTp was also
rare in the isolates from Switzerland (1 strain), and
none was resistant to MtTpSu. The isolates from
Germany were generally the most resistant. Of 30
S. aureus strains studied, 22 were resistant to Mt,
25 to Tp, 28 to Su, 24 to Gm, 21 to MtTp, 25 to
TpSu and 21 to MtTpSu. A rather high proportion
of strains resistant to MtTp, TpSu and MtTpSu
was also present in the 5. aureus isolates from the
UK (10, 11 and 10 strains, respectively, out of 30).
In contrast to S. aureus, the majority of S.
epidermidis strains were resistant to Tp (56 out of
73, 77%); 27 (37%) were resistant to Mt, 45 (62%)
to Su, 48 (66%) to Gm, 73 (100%) to Pc, 25 (34%) to
Cm, 44 (60%) to Em and 55 (75%) to Tc. As in S.
aureus, double resistance to MtTp occurred in 18
strains (25%), to TpSu in 43 (59%) and triple
resistance to MtTpSu in 13 (18%). Analysis of the
strains of different origin again showed large
variation. Of the 21 S. epidermidis from Hungary, 6
were resistant to Mt, 17 to Tp, 10 to Su, 4 to MtTp,
10 to TpSu and 4 to MtTpSu, 6 to MtGm. Fifteen
of the 19 Swiss isolates were resistant to Tp, 2 to
Mt, 11 to Su, 5 to Gm, 2 to MtTp, 11 to TpSu, 1 to
MtTpSu and none to MtGm. Twelve of the 33
isolates from Spain were resistant to MtTp, 22 to
TpSu and 8 to MtTpSu.
From these data it seems that resistance to
trimethoprim occurs more frequently in S. epider¬
midis than in 5. aureus, and is also more frequently
connected tomethicillin resistance in 5. epidermidis.
The occurrence of strains resistant to MtTp or
MtTpSu varies widely from country to country but
is generally low. This underscores the role of co-
trimoxazole as a valuable alternative in the treat¬
ment ofmulti-resistant staphylococcal infections.74
As regards the mechanism of trimethoprim
resistance, the level of resistance was of interest.
As shown in fig. 3, the majority of S. aureus strains
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Fig. 3. Distribution of MICs of trimethoprim in S\ aureus (196 strains; ■) and S. epidermidis (73 strains; ®).
resistant to trimethoprim have MIC values of 64
and 128 mg/L. Only 7 ofl 96 strains tested exhibited
high level resistance with MICs >512 mg/L. In
contrast, there is a clear tendency in 5. epidermidis
towards high level trimethoprim resistance, with
30 strains exhibiting MICs of >512 mg/L. These
differences in the level of trimethoprim resistance
may reflect differences in the mechanism of resist¬
ance and in the genetic localisation of the respons¬
ible trimethoprim resistance gene.38
Transfer of Tp-resistance
Plasmid DNA was isolated from 46 trimetho-
prim-resistant strains as described by Bennett7 7
with slight modifications. Agarose gel electro¬
phoresis showed plasmids in all strains and gener¬
ally two or more plasmids were present. Protoplast
transformation was then carried out with S. aureus
113 (NCTC 8325 r") following the procedure from
Goetz and coworkers78 with some modifications.
No transformants could be obtained after selection
on trimethoprim 8 mg/L from the 21 S. aureus
strains exhibiting MICs for trimethoprim between
32 and 256 mg/L. In the four strains with MICs of
512-1024 mg/L, trimethoprim resistance was trans¬
ferable. With S. epidermidis only two strains with
MICs for trimethoprim of 32 and 256 mg/L were
tested and trimethoprim resistance was not trans¬
ferable. In contrast, in 8 of the 19 strains with MICs
of 512-1024 mg/L, trimethoprim resistance could
be transferred. Details of those strains which
showed transferable trimethoprim resistance are
shown in table IV. Generally, only one plasmid was
transferred to the host, ranging in size from 8-5 to
45 kb. In addition to trimethoprim, resistance to
penicillin, cadmium nitrate (Cd), HgCL (Hg),
sulphonamides or ethidium bromide (EtBr) was
often cotransferred. In no case, however, was
resistance to gentamicin transferred, in contrast to
findings with Australian isolates.79 Occasionally
a small plasmid carrying chloramphenicol (Cm)
resistance was simultaneously co-transferred. Over¬
night growth at 44° in Mueller Hinton broth cured
the majority of strains with transferable trimetho¬
prim resistance and loss of trimethoprim resistance
always coincided with loss of the large plasmid,
whereas the small plasmids (< 5 kb) conferring
chloramphenicol resistance could not be cured.
Trimethoprim-resistant DHFR
The trimethoprim-resistant clinical isolates ex¬
hibited DHFR activities in the crude extract which
ranged from 38 to 226 mU/mg of protein, in most
cases above 100 mU/mg of protein. This is higher
than the basal chromosomal enzyme level, i.e., in
5". aureus ATCC 25923 34 mU/mg of protein or S.
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Table IV. Resistance profiles in staphylococci with transferable Tp resistance
Resistance patterns
MIC for Tp
Strain Origin 0tg/L) original isolate transformant
S. aureus 157/4696 CH >1024 Tp Su Pc Cm Tc Cd Tp Pc Cd
S. aureus 853 D 512 Tp Su Mt Pc Em Tc Cd Hg Tp Pc Cd Hg
S. aureus V21571 D 1024 Tp Su Mt Gm Pc Cm Em Tc Cd Tp Pc Cd
S. aureus 1075 CH >1024 Tp Su Pc Cm Tc Cd Tp Pc Cd
S. epidermidis 955 CH > 1024 Tp Su Gm Pc Em Tc EtBr Tp EtBr
S. epidermidis 961 CH >1024 Tp Su Gm Pc Em EtBr Tp EtBr
S. epidermidis Hub CH > 1024 Tp Su Pc Cm Tp Pc Cm
S. epidermidis H8915 H > 1024 Tp Gm Pc Cm Em Tc EtBr Tp EtBr
S. epidermidis H15043 H >1024 Tp Su Gm Pc Em EtBr Tp Su EtBr
S. epidermidis SP26 SP 1024 Tp Su Pc Tp
S. epidermidis SP33 SP 1024 Tp Su Mt Gm Pc Em Tc Tp Pc
S. epidermidis Mur78 SP >1024 Tp Su Gm Pc Em Tp Su
CH = Switzerland; D = Germany; H = Hungary; SP = Spain.
aureus 113 (NCTC 8325r~) 50 mU/mg of protein.
As far as investigated, two enzymes with DHFR
activity were found in these strains.34'43 DHFR
activity in the transformants was 1-5-2-fold higher
than in the original isolate (with only two excep¬
tions), probably due to the presence of only one
plasmid resulting in a higher copy number. The
trimethoprim resistance gene from S. aureus strain
157/4696 has, meanwhile, been cloned into the
pUC18 vector and its nucleotide sequence is
presently being determined.
Conclusions
A considerable number of MRS were found also
to be resistant to "trimethoprim. S. epidermidis
strains were more generally resistant than S. aureus,
as observed elsewhere.38'7 2 However, the frequency
of strains with resistance to both methicillin and
trimethoprim varies widely among strains of differ¬
ent origin, but is generally low. Thus, trimethoprim-
sulphonamide combinations may often constitute a
valuable alternative treatment of infections due to
MRS. As observed by others,32 trimethoprim
resistance could be transferred only from strains
with a high MIC for trimethoprim. The clear
tendency towards high level trimethoprim resist¬
ance in S. epidermidis, in contrast to S. aureus, is in
line with previous observations and supports the
idea that S. epidermidis constitutes a reservoir of
resistance genes and that the trimethoprim resist¬
ance gene may have evolved in S. epidermidis.38,12
The dissemination of trimethoprim
resistance plasmids in a large iso¬
lated community
B.J. MEE
Department of Microbiology, Queen Elizabeth II Medical
Centre, The University of Western Australia, Nedlands 6009,
Perth, Australia
Perth, the capital of Western Australia, is a large
modern city with a population in excess of one
million people. It is, however, nearly 3000 km from
the nearest city of similar size and thus is ideal for
a study of the appearance and spread of R plasmids
in a large isolated community. Trimethoprim, in
the form of co-trimoxazole was first introduced into
Australia for general clinical use in February 1973.
Six years later, records at our hospital showed that
there was a low incidence of trimethoprim-resistant
enterobacteria. However, 1 year later, in 1980, a
marked increase in the number of such isolates was
noted.
This paper describes the results of surveys for
trimethoprim resistance in human clinical isolates
of enterobacteria carried out in 1980-81 and in
1985. In both surveys, isolates were examined for
resistance pattern and transferability, together with
the size and incompatibility group ofany R plasmid
conferring trimethoprim resistance. In the first
survey, trimethoprim-resistant isolates from pigs
were also included although trimethoprim had
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Table V. Clinical isolates with trimethoprim resistance
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Number of isolates
Year Source E.coli K.pn. K.ox. Ent. Citro. Proteus Total
1981 man 33 11 5 3 1 0 53
pigs 59 59
1984 man 19 24 2 9 1 4 59
K. pn. = Klebsiella pneumoniae, K. ox. = Klebsiella oxytoca; Ent. = Enterobacter spp.;
i Citro. = Citrobacter sp.
never been used for growth promotion or therapeu-
f tic purposes in the pig farm. These isolates were
part of the normal faecal flora of healthy weaned
piglets and were obtained at very low frequencies.
Trimethoprim-resistant human clinical and porcine
isolates are listed in table V. More than 75% of the
human clinical isolates came from urine specimens
and Escherichia coli and Klebsiella spp. accounted
for the majority.
A high proportion (86%) of the porcine isolates
were capable of transferring trimethoprim resist¬
ance, whereas in the human clinical isolates, a
lower proportion of transferable resistance was
detected (table VI). The incompatibility groups for
the transferable trimethoprim plasmids indicate
that IncFFW and ZncN R plasmids were initially
important in the appearance of trimethoprim
resistance in both the human and porcine isolates.
Four years later, however, IncC R plasmids had
virtually replaced IncFlV plasmids in the human
isolates.
from various genera among the human clinical
isolates. Representatives of each category had
characteristic restriction endonuclease digest pat¬
terns and plasmids conferring SmSpSuTp resist¬
ance hybridised to the type I DHFR probe used
(pFE506) whereas plasmids conferring SuTpHg
resistance hybridised to the type II DHFR
(pFE420). Both types of IncN plasmids were also
detected in isolates from the pigs.
By 1985 the IncN plasmids had changed. They
were larger in size (65-77 kb) and hybridised to the
type I DHFR probe. Two thirds conferred resist¬
ance to ApTcSmSuTp and were detected in a K.
pneumoniae strain causing nosocomial infections in
the hospital. The remaining six plasmids in this
survey came from a variety of hosts including E.
coli, Enterobacter spp. and a Citrobacter sp. They
were also larger and had some additional resistance
determinants. The ZncN R plasmids had success¬
fullymaintained themselves in our community over
that period.
IncN trimethoprim R plasmids
In the first survey of trimethoprim resistance, the
ZncN R plasmids ranged in size from 51 to 57 kb.
They comprised two categories (SuTpHg resistance
and SmSpSuTp resistance) and were transferred




Number of isolates in Inc
group
Tra+ (%) FIV N C Uc*
1981 59 pig 51 (86) 30 3 t 1
53 man 19(36) 11 8 0 0
1985 59 man 35 (59) 1 21 10 3
*Uc = unclassified, i.e., compatible with all plasmids tested,
t — = undetected among the number studied.
Tra + = transfer positive.
IncFIV trimethoprim R plasmids
The 7«cFIV R plamids are of great interest. They
had rarely been reported in other parts of the world
prior to their isolation by Mee and Nikoletti.80
They ranged in size from 125 kb to 175 kb (table
VII). The plasmids from human isolates exhibited
a variety of resistance patterns, only some of which
included resistance to Hg, whereas all the plasmids
from porcine isolates conferred resistance to Hg.
The plasmid collection was divided into six sets,
labelled A-F, based mainly on their patterns of
resistance.81 Digestion of the porcine and human
IncFFW plasmids, using the restriction enzyme
EcoRI, showed that plasmids in sets A, B and C
shared 13 restriction fragments > 1 kb in size
amongst all representatives, while three other
restriction fragments were common to all but one
of the plasmid representatives.
The Cm plasmids from man and pigs (Sets D +
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Table VII. Characteristics of the IncFW R plasmids
Origin Resistance pattern Size (kb) Set
Man SuTp 155 A
Man TcSuTp 164 B
Man TcSmSuTp 170-175 C
Man TcCmSuTpHg 141-158 D
Pigs TcCmSuTpHg 147-162 D'
Pigs SuTpHg 125 E
Pigs TcSuTpHg 131 F
Su = sulphonamide; Tp = trimethoprim; Tc = tetracycline;
Sm = streptomycin; Cm = chloramphenicol; Hg =mercury.
D') shared 14 fragments in common and another
four restriction fragments were present in all but
one of the representatives. Between these two
groups, however, only three restriction fragments
were common—14-6, 8-36 and 4-44 kb. Another
four fragments were shared by some members of
both groups. The R plasmids from pigs without
Cmr (sets E and F) were almost identical in their
restriction fragment patterns. The Tcr plasmids of
set E had one extra restriction fragment of 5-55 kb.
These plasmids shared only two of the three
common restriction fragments (14-6 and 4-44 kb).
Thus the /ncFIV R plasmids with trimethoprim
resistance comprised three major groups. They had
various biotypes of E. coli as the original host, but
differed in size, patterns of resistance and restriction
endonuclease digest patterns. All, however, hybri¬
dised with the type II DHFR probe used and
showed no reaction to the type I DHFR probe.81
The Tpr genes from the epidemiologically related
IncFlV plasmids were cloned into plasmid
pACYC184. The Tpr gene was present on an TscoRI
fragment > 20 kb for plasmids of sets A, B and C,
a 5-28-kb fragment for sets D and D', and an 8-81-
kb fragment for sets E and F.82 Despite the size
variation, the DHFR gene itself was highly con¬
served on all plasmids and map differences in the
flanking regions provided evidence that the most
recent exchange of trimethoprim R plasmids
between pigs and man had occurred relatively
recently and had originated in the animals. These
D and D' R plasmids had identical E. coli hosts,
based on biotyping, indicating that the organism,
together with its R plasmid, had spread from pigs
to man.
Conclusions
The 7«cFIV trimethoprim R plasmids arose in
Perth and exhibited considerable variation in their
struggle to establish themselves. Other work has
shown that they contain several replication regions
and they rearranged their composition, losing and
acquiring resistance determinants, during a rela¬
tively short time span. The extent of variation
within the /ncFIV R plasmids is unusual. Most
studies of R plasmids conferring resistance to a
particular antibiotic and belonging to a particular
incompatibility group have shown a considerable
degree of structural stability of the plasmid itself
for long periods sometimes exceeding a decade.
The variation seen in the case of the IncFlW
trimethoprim R plasmidsmay reflect the difficulties
of establishing in the local community. Within a
few years they had been overtaken by "fitter" IncN
and IncC trimethoprim R plasmids. During their
stay they produced plasmids of sets A, B and C in
man, sets E and F in pigs, and sets D and D' in
both man and pigs. All three groups represent
unique lines of evolutionary development and
probably arose from a prototype fficFIV plasmid.
It is not possible to ascertain whether this original
7/icFIV plasmid arose in pigs or man, but the data
indicate that plasmid exchange between man and
animals is occurring relatively frequently.
The following colleagues provided invaluable assistance in
this study: Dr I. G. Campbell, Mr L. Mulgrave, Dr S. M.
Nikoletti and Ms T. Tija.
Editors' conclusions
The study of trimethoprim resistance has been
greatly facilitated by the advent of improved
technology. The use of specific DNA probes for the
known plasmid-encoded trimethoprim resistance
genes has allowed a much more rapid evaluation of
the relative importance and dissemination of these
different genes. Furthermore, DNA-DNA hybri¬
disation studies have revealed the emergence of a
plethora of new plasmid-encoded resistance genes
with quite distinct biochemical properties. The
advent of rapid automated nucleotide and amino
acid sequencing procedures may soon provide us
with even more efficient methods of studying
possible inter-relationships between these different
genes and understanding the evolution of trimeth¬
oprim resistance on a wider basis. Further collabo¬
ration between molecular biologists and protein
biochemists will undoubtedly continue to provide
exciting and illuminating advances in the study of
trimethoprim resistance in the future.
We thank F. Hoffman La Roche and Co. CIE and the
Wellcome Foundation Ltd for providing financial support for
the Symposium which formed the basis of this review.
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Summary. The type IV plasmid-mediated dihydrofolate reductase (DHFR), from a
clinical strain of Escherichia coli isolated in South India, was prepared from a
transconjugant containing the original clinical plasmid, E. coli J62-2 (pUKl 123), and
from E. coli C600 (pUK1150) containing a 2-6-kb HindUl fragment of pUK1123
cloned into plasmid pBR322. Both preparations were purified by methotrexate affinity
chromatography. Automatic amino-acid sequencing of the N-terminal of the purified
type IV enzyme from both sources gave an identical sequence which was clearly
distinct from other plasmid-mediated trimethoprim-resistant DHFRs. The type IV
DHFR showed most homology with the endogenous, chromosomally-encoded E. coli
enzyme. Amino-acid sequence analysis also showed that the type IV enzyme
preparation from E. coli J62-2 harbouring the original clinical plasmid, pUK1123,
also contained the E. coli DNA-binding protein NS1. Analysis by polyacrylamide gel
electrophoresis suggested that the type IV enzyme, in its native form, consists of a
DHFR of Mr 33 000 coupled to a DNA-binding protein.
Introduction
Trimethoprim [2,4-diamino-5-(3,4,5-trimeth-
oxybenzyl) pyrimidine] prevents the bacterial
NADPH-dependent reduction of dihydrofolate to
tetrahydrofolate by competitively inhibiting the
enzyme dihydrofolate reductase (5,6,7,8-tetrahy-
drofolate; NADP+ oxidoreductase, EC 1.5.1.3)
(DHFR).1 Shortly after its introduction in 1968,
plasmids which encoded resistance to trimethoprim
(Tp) were identified in gram-negative bacteria.2
The mechanism of resistance was subsequently
identified as the production of an additionaJ
trimethoprim-resistant DHFR which enabled the
blocked endogenous chromosomally-encoded en¬
zyme to be bypassed.3
The DHFRs encoded by resistance plasmids (R-
plasmids) in gram-negative bacteria have been
divided into seven major types based on their
biochemical properties." Some of the genes respons¬
ible have also been sequenced.5-10 Initially, plas¬
mid-mediated trimethoprim resistance was
dominated by the spread of two genes encoding
DHFR types I and II. However, since 1982, a
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number of new enzymes have been identified, the
most unusual of these being the type IV DHFR.
Bacteria harbouring plasmids encoding the type
IV plasmid-encoded DHFR were found in South
India in 1984.11 This enzyme confers low-level
resistance on the host bacterium so may be a
potential intermediate between a sensitive enzyme
and the highly-resistant plasmid-mediated DHFR.
This enzyme differs from the six other types
identified in several ways: (1) it is an inducible
enzyme, which is rare for a plasmid-encoded
resistance enzyme in gram-negative bacteria; (2) it
has a large Mr (46 700); and (3) it is only partially
resistant to trimethoprim (ID50 Tp = 0-02 /xm).1 1
Examination of the induction mechanism of the
type IV enzyme and its response to challenge with
trimethoprim has suggested that this resistance
mechanism is more similar to a resistance mecha¬
nism sometimes employed by the bacterial chro¬
mosome, namely the production ofamutant enzyme
which is moderately resistant to trimethoprim and
is hyperproduced, thus swamping the available
drug, with sufficient activity remaining to continue
the bacterial reduction ofdihydrofolate to the active
tetrahydrofolate form.12*13
It is important to establish how the type IV
1
C. J. THOMSON, H-K. YOUNG AND S, G. B. AMYES
enzyme relates to the other plasmid-mediated
DHFRs. We report the use of automatic amino-
acid sequencing to give a rapid partial sequence




The type IV DHFR was prepared for sequence analysis
from two bacterial strains: (1) Escherichia coli J62-2
(pUK1123), an E. coli transconjugant containing the
original clinical trimethoprim R-plasmid from a clinical
strain of E. coli isolated at the Christian Medical College
Hospital, Vellore, South India in 1984;" (2) E. coli C600
(pUKl 150), an E. coli clone containing plasmid pBR322
with a 2-6-kb HindlU fragment of pUK1123 encoding
the type IV DHFR gene.14
Dihydrofolate reductase preparation
DHFR was prepared from 10-L overnight cultures in
Iso-Sensitest Broth (Oxoid) grown at 37°C and shaken
vigorously." Bacteria were harvested by centrifugation
at 6000 g for 15 min and resuspended in buffer A (50 mM
sodium phosphate buffer, pH 7-4, containing 10 mM 2-
mercaptoethanol and 1 m.M EDTA). The bacteria were
disrupted by sonication (2x 30 s, 8 pM\ MSE Soniprep)
and the lysate was cleared by centrifugation at 40 000 g
for 1 h at 4°C. DHFR activity was assayed at 37°C in
40 mM sodium phosphate buffer, pH 6-Q.3
Enzymepurification and sequence analysis
DHFR was precipitated from the crude preparation
by the addition of ammonium sulphate to 50-80%
saturation. The enzyme was resuspended in buffer A and
eluted from a Sephadex G-75 gel filtration column
(2 cm* x 90 cm). The fractions showing peak activity
were pooled and then applied to a column (0-375 cm: x
20 cm) containing methotrexate-agarose. This column
was washed with buffer A until the absorbance at 280 nm
was less than 0-01 OD units and all the unbound protein
had been removed. The DHFR was then eluted with 2 ml
of 0-5 M K;HPOi, containing 4 pM dihydrofolate, fol¬
lowed by 75 ml of 0-1m K;HPOi containing 1 pM
dihydrofolate;13 5-ml fractions were collected. The three
eluted fractions showing peak activity were pooled and
concentrated, with Amicon Centiprep and Centricon
concentrators, to 60 pi. Prior to sequence analysis, each
preparation was checked for purity by reverse-phase
HPLC analysis. The single peak of protein, determined
on the reverse-phase HPLC, was analysed on an Applied
Biosystems 477A protein sequencer.16
Molecular mass (Mr) determination
Molecular mass determination by Sephadex gel filtra¬
tion was performed as described earlier." SDS and
native polyacrylamide gel electrophoresis (PAGE) were
performed on a Pharmacia Phast system according to the
manufacturer's instructions. For SDS gels, protein sam¬
ples were boiled for 3 min in a mixture of SDS and
bromophenol blue. For native gels, samples were simply
dissolved in a solution of bromophenol blue. Protein
bands were visualised by staining with Coomassie Blue.
For SDS gels, a Sigma molecular size marker kit (14 000-
70 000) was used, and for native gels bovine serum
albumin (M, 66 000), ovalbumin (Mr 45 500) and trypsin
inhibitor (Mt 20 100) were employed as standards.
Results
Molecular mass of the type IVDHFR
The type IV DHFR was purified by methotrexate
affinity chromatography from E. coli J62-2
(pUKl 123) and E. coli C600 (pUK1150). In both
cases, the purified protein was analysed by HPLC
and a single protein peak was observed; this was
identified as DHFR.
We have shown previously that a partially-
purified preparation of the type IV DHFR, encoded
by plasmid pUK1123, has a Mr of 46 700 when
measured by Sephadex G-75 gel filtration." We
now examined the methotrexate-agarose purified
enzyme, encoded by plasmid pUK1123, on SDS-
free PAGE. On a homogeneous 20% acrylamide
gel, the enzyme from plasmid pUK1123 co-
migrated with ovalbumin, corresponding to a Mr
of 45 500. Staining of the gel with the non-specific
protein stain Coomassie Blue (fig. 1) confirmed the
high purity obtained by methotrexate-agarose affin¬
ity chromatography.
The Mr of the methotrexate-agarose purified
enzyme from the cloned DHFR gene in piasmid
pUK 1150 was determined in a calibrated Sephadex
G-75 colum and found to be 33 000 (fig. 2). This
lower M^f could have arisen from two causes; (1)
the cloning of the type IV gene into plasmid
pBR322 may have removed some of the sequence
of the gene or it may have put a new stop codon
into the sequence allowing the translation of a
protein of smaller size; or (2) the protein from the
original plasmid pUK.1123 may have been com¬
posed of two non-identical subunits and only one of
the genes had been cloned. If (2) was the case, the
original protein would show different Mr values
when measured by PAGE with SDS.
SDS-PAGEfor Mr determination
The type IV DHFR from the cloned gene in
plasmid pUK1150 was treated with SDS and then
applied to a 10-15% gradient SDS-containing
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Fig. 1. SDS-frse polyacrylamide gel electrophoresis of the
purified type IV DHFR from £. coli J62-2 (pUK1123). Bands
were visualised after staining with Coomassie Blue. A, trypsin
inhibitor; B, ovalbumin; C, bovme serum albumin; D, type IV
DHFR.
polyacrylamide gel. When it was electrophoresed
until the dye front reached the end of the gel, it
migrated as a single protein band of Mf c. 30 000.
This result suggests that the enzyme from the cloned
gene was a monomelic protein. On the other hand,
when the purified DHFR encoded by the clinical
plasmid pUKl 123 was treated in the same manner,
it migrated as one major band and a series of small
bands (fig. 3). The major band had a Mr of 33 000.
The smallest of the minor bands corresponded to
an Mr of c. 10 000. The other minor bands were of
similar intensity and appeared to have Mr values
that were multiples of the smallest band, suggesting
that they might be dimeric and trimeric forms of
the Mr 10 000 protein. If this was the case, it
indicated that the type IV enzyme of Mr c. 46 000,
found on SDS-free PAGE and gel filtration was, in
fact, made up ofmore than one subunit.
N-terminal amino-acid sequence analysis
HPLC was used to establish that the two enzyme
preparations derived from plasmids pUKl 123 and
pUK1150 were pure proteins. The proteins from
the respective HPLC peaks were applied to an
Applied Biosystems AllA protein sequencer and a
clear result was obtained for the first 50 amino acids
of both enzymes (fig. 4). As expected, the DHFR
sequences obtained from E. coli J62-2 (pUK1123)
and E. coli C600 (pUK1150) were identical and
quite distinct from those trimethoprim-resistant
plasmid-mediated DHFRs that have already been
sequenced.5-10 There was, however, one distinct
difference between the enzyme preparation derived
from the clinical plasmid (pUKl 123) and that from
the clone. In the former, the presence of a second
protein was apparent in the sequence analysis
confirming that the native type IV DHFR was
composed of non-identical subunits. The first 19
amino acids were distinguishable and comparison
with known sequences has identified it as an exact
match with the NS1 protein, a DNA-binding
protein in E. coli.I7 The presence of this second
protein in the pUKl 123-derived preparation was
particularly interesting because this DHFR prepa¬
ration had appeared as a single protein on HPLC
and on SDS-free PAGE. In the preparation derived
from the cloned plasmid pUK1150, there was no
evidence at all of any second protein. Furthermore,
the NSl-binding protein has a very distinctive
pattern when measured on SDS-PAGE. It migrates
as not only a monomer of Mr 9250, but also as a
dimer, trimer and tetramer.18 This is the pattern
that was found with the minor bands of the second
protein on SDS-PAGE (fig. 3).
Discussion
Since the introduction of trimethoprim in 1968,
several plasmid-mediated DHFRs have been iden¬
tified that confer resistance to trimethoprim. These
enzymes have, in the past, been largely distin¬
guished by their biochemical properties1 although
the amino-acid sequence of many of them is now
known.5-10 Some of the more recently identified
enzymes are clearly related to earlier plasmid-
mediated DHFRs. For example, amino-acid se¬
quence analysis has revealed that the types la and
V are closely related.10 The unique nature of the
type IV enzyme, however, suggests that it may not
be derived from any of the other plasmid enzymes.
Indeed its sensitivity to trimethoprim and the low
level resistance it confers would suggest that it is a
precursor to the other plasmid-mediated enzymes.
In this investigation, the N-termina! sequence of
the type IV enzyme was determined with the use of
the Applied Biosystems AllA automatic amino-
acid sequencer which allowed rapid sequence
analysis. Two properties of the type IV DHFR
make it particularly suitable for sequencing by this
method; (1) the majority of the active site of all
DHFRs is situated at the N-terminal of the
protein;19-20 and (2) purification of the native
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Fig. 2. DHFR activity or an ammonium sulphate (50-80% saturation)'precipitate from E. coli C600 (pUKl!50) analysed by
Sephadex G-75 gel filtration. Elution ofmarker proteins is also shown—a, ovalbumin; b, chymotrypsinogen; c, cytochrome C.
protein is relatively easy with the use ofmethotrex¬
ate-agarose affinity chromatography, a result of the
methotrexate sensitivity of the type IV enzyme, a
relatively rare property amongst plasmid-encoded
trimethoprim-resistant DHFRs.
Comparison of the first 50 amino acids of the
type IV sequence with those for the other plasmid-
mediated DHFRs sequenced so far (types I-V)5-10
showed the type IV enzyme to be clearly distinct.
However, significant homology occurred with the
E. coli K12 chromosomally-encoded enzyme.
Twenty direct matches were found between the two
enzymes and nine further amino acids were homol-.
ogous with the amino acids at the same position inj
the chromosomal enzyme.21 This high degree of
similarity between the type IV DHFR and the E.
coli chromosomally-encoded enzyme is, perhaps,
not surprising because the type IV enzyme, like the
chromosomally-encoded enzyme, confers only par¬
tial resistance to trimethoprim. Furthermore, stud¬
ies on the induction mechanism of the type IV
enzyme have indicated that its mechanism of
resistance is more similar to the hyper-production
mechanism of resistance mediated by deregulation
of the E. colichromosomally-encoded enzyme rather
than the classical by-pass mechanism mediated by
trimethoprim R-plasmids.:2
One surprising finding was the presence of the
DNA-binding protein NS1 in the purified enzyme
preparation from the original clinical plasmid
(pUKl 123). Analysis of this preparation by HPLC
gave a single peak. As a further check on purity the
preparation was run on native PAGE and stained
with Coomassie Blue, and only a single band was
TYPE IV DIHYDROFOLATE REDUCTASE
Mr (103) misma
A B
ug. 3. SDS-PAGE of the purified type IV DHFR from E. coli
'62-2 (pUK1123). Bands were visualised after staining with
2oomassie Blue. A, Sigma mol. wt markers (Mt 14 000-70 000);
3. type IV DHFR.
obtained at Mr 45 500 confirming its purity. This
corresponds to the Mr of the type IV enzyme when
measured by gel filtration. The results indicate that
the native type IV enzyme is a complex of the two
proteins. SDS-PAGE analysis of this preparation
confirmed the existence of subunits of differing
size. Purified enzyme from the cloned type IV
DHFR from pUKl 150 contained no DNA-binding
protein. The cloned enzyme has a lower Mr and is
monomelic when examined on SDS-PAGE. The
most likely explanation for the lower Mt is the
absence of the complexed DNA-binding protein.
The reason why the type IV enzyme is complexed
with a DNA binding protein is not clear but it may
be related to the induction mechanism, since
proteins which bind to DNA have been implicated
in the control of gene expression.23,2* The absence
of the binding protein in enzyme encoded by the
cloned gene probably results from the lack of the
NS1 gene in the restriction fragment cloned into
pBR322. As pBR322 is a multi-copy vector, the
necessity for induction of the type IV enzyme to
produce trimethoprim resistance has been removed
in the clone,1* thus the selection pressure for the
NS1 protein gene was not present in the cloning
process.
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Ig. 4. N-terminal amino-acid sequences of the type IV plasmid-encoded DHFR and the E. coli K12 chromosomally-encoded
nzyme. The amino acids are identified by standard three-letter abbreviations and are numbered according to the convention of
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thrombocytes, serum creatinine and liver
enzymes were all normal.
During the first two days in hospital the patient
experienced profuse diarrhea and abdominal
pains. From the day 2, she was given oral
norfloxacin, 400 mg twice a day. After two days
of treatment the improvement was remarkable
and she returned home a few days later in good
general condition. The Shigella sonnei strain
was sensitive in vitro to norfloxacin.
A possible explanation for this rare case of
Shigella sonnei sepsis might be the absence of
the primary filtration of the portal blood
through the reticuloendothelial system of the
liver, combined with the absence of the splenic
clearance function. The double protection
afforded by the liver and spleen might be the
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Detection in the UK of Trimethoprim-
Resistant Escherichia coli Encoding
the Type Y Dihydrofolate Reductase
Seven major types of trimethoprim-resistant di¬
hydrofolate reductases (DHFRs) coded for by
plasmids in gram-negative bacteria have now
been described, with several of these major
groups being further divided into related sub¬
types (1). Of the seven major types, the type V
DHFR was originally identified in clinical iso¬
lates of enterobacteria from Sri Lanka (2) and
has not been reported to occur in Europe. We
have previously described a DNA probe suit¬
able for monitoring the spread of plasmids me¬
diating this form of trimethoprim resistance (3).
This probe was used in a retrospective study to
examine 14 trimethoprim R plasmids originally
isolated during the period 1980-82 as part of an
investigation into the distribution of the DHFR
type I gene in the Nottingham area of the UK
(4). The 14 trimethoprim R plasmids selected
(Table 1) were those that had previously been
found not to show any hybridisation with the
DNA probe for the predominant type I gene (4).
Plasmid DNA was isolated on agarose gels and
transferred to nitrocellulose filters as described
previously (3). The DNA probe for the type V
DHFR gene consisted of a Hindi fragment of
plasmid pLK09, approximately 0.5 kb in size (3).
Probes for other known DHFR genes were
those described by Amyes et al. (1). DNA
probes were purified, labelled with biotin-11-
dUTP (Bethesda Research Laboratories, UK),
and then hybridised with the immobilised
plasmid DNA (3, 4). Detection of a positive
hybridisation result was by means of a Blu-
GENE Kit (Bethesda Research Laboratories),
using the conditions and protocols recom¬
mended by the manufacturer.
Eight of the 14 trimethoprim R plasmids gave a
positive hybridisation result with the type V
DHFR gene probe (Table 1). These eight plas¬
mids were also found to give negative hybrid¬
isation results with the available DNA probes
for other DHFR genes (types I, II, III and IV).
Cell-free extracts obtained from cultures carry¬
ing each of the eight plasmids had DHFR-spe-
cific activities varying from 0.39 to 177.4 (Table
1), and it seems that this unusually wide varia¬
tion may be characteristic of plasmid-encoded
type V DHFR enzymes (2). When the properties
of the enzyme encoded by pUN663a (chosen be¬
cause of its high specific activity) were ex¬
amined in more detail, as described by Amyes et
al. (1), they were found to be essentially identi¬
cal to those of the enzyme encoded by the
cloned type V DHFR gene carried by pLK09
(Table 2) and different to those of other previ¬
ously characterised DHFR enzymes (1).
The type V DHFR shows many biochemical
similarities to the original type I DHFR (now
termed type la). However, it does behave differ¬
ently from the type la when separated on a
Sephadex G-50 gel filtration column (5). The
type V enzyme is held back in the column and
gives an apparent molecular weight of 5,000,
possibly due to a greater propensity for hydro¬
phobic amino acids that may retard its progres¬
sion in Sephadex. This is a characteristic of this
enzyme and can be used to distinguish it, al¬
though the true molecular weight when meas¬
ured on native PAGE is approximately the same
as the type la enzyme. It seems probable, there¬
fore, that these two enzymes may share a com¬
mon ancestral gene.











pUN108 1979 Tp -
pUN166 1980 TpTcKmCmSu + 0.58
pUN189 1980 TpSm -
pUN241 1980 TpTcKmCm + 140
pUN283a 1980 TpSu + 1.72
pUN365 1981 TpSu -
pUN394a 1981 TpSu + 039
pUN433 1981 TpSm + 10.46
pUN445a 1981 TpSu + 137
pUN'494 1981 TpTcKmCmSu + 1.71
pUN545 1981 TpAp -
pUN589 1981 TpSmSuTcKm -
pUN663a 1982 TpAp + 177.40
pUN835 1982 TpKmApSmSuTcCm -
*Tp: trimethoprim; Tc: tetracycline; Km: kanamycin; Cm: chloramphenicol; Su: sulphonamides; Sm:
streptomycin; Ap: ampicillin.
bnmol of dihydrofolate reduced/min/mg total protein.
Table 2: Properties of the dihydrofolatc reductases en¬
coded by the prototype type V plasmids pLK09 and pUN-
663a.
pLK09 pUN663a
Activity ratio* 76 98
Trimethoprim 1D50 (pM) 23 20
Methotrexate 1D50 (pM) 35 10
TD50 (min) 3 JO <10
M,b (Da) 5,000 5,000
•Activity of enzyme related to the specific activity of the
Escherichia coli chromosomal enzyme.
bApparent relative molecular weight determined by gel
filtration.
1D50: dose of drug to achieve 50 % inhibition of the en¬
zyme.
TO50: time in min at 45 *C to achieve 50 % inhibition of
the enzyme.
The fact that the type V enzyme has now been
shown to occur in both Sri Lanka and the UK
raises the interesting question as to whether
evolution of the type V gene has occurred inde¬
pendently in two separate locations, or whether
a single evolutionary event has been followed by
wide distribution. Our results demonstrate that
the evolutionary event distinguishing the type V
from the type I DHFR had occurred in the UK
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